Page last updated: 2024-12-05

yohimbine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Yohimbine: A plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of ERECTILE DYSFUNCTION. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

yohimbine : An indole alkaloid with alpha2-adrenoceptor antagonist activity. It is produced by Corynanthe johimbe and Rauwolfia serpentina. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
Corynanthegenus[no description available]RubiaceaeThe Madder plant family of the order Gentianales (formerly Rubiales), subclass Asteridae, class Magnoliopsida includes important medicinal plants that provide QUININE; IPECAC; and COFFEE. They have opposite leaves and interpetiolar stipules.[MeSH]
Corynanthe johimbespecies[no description available]RubiaceaeThe Madder plant family of the order Gentianales (formerly Rubiales), subclass Asteridae, class Magnoliopsida includes important medicinal plants that provide QUININE; IPECAC; and COFFEE. They have opposite leaves and interpetiolar stipules.[MeSH]

Cross-References

ID SourceID
PubMed CID8969
CHEMBL ID15245
CHEBI ID10093
SCHEMBL ID33954
MeSH IDM0023104

Synonyms (118)

Synonym
aphrodyne
BRD-K35586044-001-02-6
BRD-K35586044-003-03-0
actibine
gtpl102
methyl (1s,15r,18s,19r,20s)-18-hydroxy-3,13-diazapentacyclo[11.8.0.0^{2,10}.0^{4,9}.0^{15,20}]henicosa-2(10),4,6,8-tetraene-19-carboxylate
PRESTWICK3_000584
methyl 17alpha-hydroxyyohimban-16alpha-carboxylate
johimbin
CHEBI:10093 ,
17alpha-hydroxyyohimban-16alpha-carboxylic acid methyl ester
(16alpha,17alpha)-17-hydroxyyohimban-16-carboxylic acid methyl ester
IDI1_002213
LOPAC0_001210
BIO2_000458
BIO1_000944
BIO1_000455
BIO2_000938
BIO1_001433
BSPBIO_000428
SMP1_000320
BCBCMAP01_000032
PRESTWICK2_000584
BSPBIO_001236
yohimban-16-.alpha.-carboxylic acid, 17-.alpha.-hydroxy-, methyl ester
(+)-yohimbine
yohimbic acid methyl ester
corynine
yohimban-16-carboxylic acid, 17-hydroxy-, methyl ester, (16alpha,17alpha)- (9ci)
yohimban-16-carboxylic acid, 17-hydroxy-, methyl ester, (16alpha,17alpha)-
yohimban-16alpha-carboxylic acid, 17alpha-hydroxy-, methyl ester (8ci)
aphrodine
yohimbin
17-hydroxyyohimban-16-carboxylic acid methyl ester
quebrachin
trans-quinolizidine yohimbine
quebrachine
yohimbol-16alpha-carboxylic acid, methyl ester (6ci)
aphrosol
C09256
yohimbine
146-48-5
smr000470778
MLS000728591
DB01392
BPBIO1_000472
yohimban-16-alpha-carboxylic acid, 17-alpha-hydroxy-, methyl ester
brn 0097276
einecs 205-672-0
KBIOGR_000576
KBIOSS_000576
KBIO2_000576
KBIO2_005712
KBIO3_001031
KBIO3_001032
KBIO2_003144
PRESTWICK1_000584
SPBIO_002647
PRESTWICK0_000584
NCGC00025018-05
NCGC00025018-06
HMS2089G19
HMS1990N17
NCGC00025018-07
CHEMBL15245 ,
yohimbinum
D08685
yohimbine (dcf)
HMS1362N17
HMS1792N17
bdbm50203564
(1r,2s,4ar,13bs,14as)-2-hydroxy-1,2,3,4,4a,5,7,8,13,13b,14,14a-dodecahydro-indolo[2'',3'':3,4]pyrido[1,2-b]isoquinoline-1-carboxylic acid methyl ester hydrochloride
cid_6169
cid_8969
bdbm50013515
amberlite cg 400
NCGC00013260-01
dtxcid7020130
cas-146-48-5
dtxsid9040130 ,
tox21_110019
CCG-205284
HMS2234C18
thybine
4-25-00-01237 (beilstein handbook reference)
unii-2y49vwd90q
2y49vwd90q ,
ccris 9415
17.alpha.-hydroxy-20-.alpha.-yohimban-16-.beta.-carboxylic acid, methyl ester
yohimbinum [hpus]
yohimbine [mi]
yohimbine [vandf]
yohimbine [who-dd]
AKOS015902024
SCHEMBL33954
tox21_110019_1
NCGC00025018-10
CS-5173
HY-12715
GS-5751
17a-hydroxy-16a-methoxycarbonyl-yohimbane
mfcd00005093
SR-01000075297-5
MRF-0000020
NCGC00025018-11
BLGXFZZNTVWLAY-SCYLSFHTSA-N
103834-06-6
yohimbe hydrochloride
Q412226
yohimbe bark
BRD-K35586044-003-11-3
SDCCGSBI-0051177.P002
NCGC00025018-17
H10057
methyl (1s,15r,18s,19r,20s)-18-hydroxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate
EN300-19731915
methyl (1s,15r,18s,19r,20s)-18-hydroxy-3,13-diazapentacyclo[11.8.0.0^{2,10}.0^{4,9}.0^{15,20}]henicosa-2(10),4(9),5,7-tetraene-19-carboxylate
yohimbehydrochloride

Research Excerpts

Overview

Yohimbine is an alkaloid obtained from the Corynanthe yohimbe tree and other biological sources. It is an alpha 2 adrenergic receptor antagonist, which has been shown to counteract the CNS depressant effects of alpha 2 receptor agonists.

ExcerptReferenceRelevance
"Yohimbine is an indole alkaloid from the leaves and bark of the Pausinystalia johimbe tree that has acquired an enviable reputation in treating erectile dysfunction. "( Severe acute intoxication with yohimbine: Four simultaneous poisoning cases.
Du, L; Gong, W; Han, X; Liu, L; Zhu, J; Zhu, L, 2021
)
2.35
"Yohimbine is an alkaloid that has been encountered on the streets as an aphrodisiac, hallucinogen, dietary supplement and erectile dysfunction drug. "( Case study: two fatal case reports of acute yohimbine intoxication.
Anderson, C; Anderson, D; Harre, N; Wade, N, 2013
)
2.09
"Yohimbine is an alpha-2 adrenoceptor antagonist that has been used in numerous studies as a pharmacological stressor in rodents, monkeys and humans. "( Effect of yohimbine on reinstatement of operant responding in rats is dependent on cue contingency but not food reward history.
Bacharach, SZ; Calu, DJ; Chen, YW; Fiscella, KA; Shaham, Y; Tanda, G, 2015
)
2.26
"Yohimbine is a prototypical alpha2-adrenergic receptor antagonist. "( Yohimbine is a 5-HT1A agonist in rats in doses exceeding 1 mg/kg.
DiMicco, JA; Rusyniak, DE; Zaretskaia, MV; Zaretsky, DV, 2015
)
3.3
"Yohimbine also acts as an agonist of 5-hydroxytryptamine (5-HT) 5-HT1A receptors, which have been shown to be involved in alcohol seeking."( The role of noradrenaline and 5-hydroxytryptamine in yohimbine-induced increases in alcohol-seeking in rats.
Dzung Lê, A; Fletcher, PJ; Funk, D; Harding, S; Juzytsch, W, 2009
)
1.32
"Yohimbine is an alkaloid obtained from the Corynanthe yohimbe tree and other biological sources. "( Acute neurotoxicity after yohimbine ingestion by a body builder.
Campailla, MT; Giampreti, A; Locatelli, C; Lonati, D; Rocchi, L, 2009
)
2.1
"Yohimbine is an alpha(2)-antagonist available in both prescription and herbal supplement products."( Adverse drug events associated with yohimbine-containing products: a retrospective review of the California Poison Control System reported cases.
Haller, C; Kearney, T; Tu, N, 2010
)
1.36
"Yohimbine is an alpha 2 adrenergic receptor antagonist, which has been shown to counteract the CNS depressant effects of alpha 2 receptor agonists in a number of species. "( Pharmacokinetics and pharmacodynamics of three intravenous doses of yohimbine in the horse.
Dimaio Knych, HK; Stanley, SD; Steffey, EP, 2011
)
2.05
"Yohimbine is an alpha 2 adrenergic receptor antagonist used most commonly in veterinary medicine to reverse the effects of the alpha 2 receptor agonists, xylazine and detomidine. "( Pharmacokinetics of yohimbine following intravenous administration to horses.
Deuel, JL; Dimaio Knych, HK; Shepard, RA; Stanley, SD; Steffey, EP, 2011
)
2.14
"Yohimbine is a naturally sourced pharmacological agent, which produces hyperadrenergic physiological effects. "( Yohimbine use for physical enhancement and its potential toxicity.
Cimolai, N; Cimolai, T, 2011
)
3.25
"Yohimbine is a potent and selective alpha2- versus alpha1-adrenoceptor antagonist. "( Yohimbine dimers exhibiting selectivity for the human alpha 2C-adrenoceptor subtype.
Feller, DR; Lalchandani, SG; Lei, L; Liggett, SB; Miller, DD; Moore, BM; Suni, MM; Zheng, W, 2002
)
3.2
"Yohimbine is a selective alpha-2 adrenergic antagonist that has been used in the pharmacologic management of erectile dysfunction (ED). "( Severe Raynaud's phenomenon with yohimbine therapy for erectile dysfunction.
Dewar, C; Iazzetta, J; Johnson, S, 2003
)
2.04
"Yohimbine is a potent and relatively nonselective alpha(2)-adrenergic receptor (AR) antagonist. "( Tethered yohimbine analogs as selective human alpha2C-adrenergic receptor ligands.
Bavadekar, SA; Feller, DR; Ma, G; Miller, DD; Moore, BM; Mustafa, SM, 2006
)
2.19
"Yohimbine is a useful treatment option in orgasmic dysfunction."( Yohimbine in the treatment of orgasmic dysfunction.
Adeniyi, AA; Brindley, GS; Pryor, JP; Ralph, DJ, 2007
)
3.23
"Yohimbine is an alpha-2 adrenoreceptor antagonist that provokes stress- and anxiety-like responses in both humans and laboratory animals. "( The CRF1 receptor antagonist antalarmin attenuates yohimbine-induced increases in operant alcohol self-administration and reinstatement of alcohol seeking in rats.
Funk, D; Harding, S; Juzytsch, W; Lê, AD; Marinelli, PW; Rice, KC; Shaham, Y, 2007
)
2.03
"Yohimbine is an alpha 2-adrenoceptor antagonist that is FDA approved for treatment of impotence. "( Oral yohimbine increases blood pressure and sympathetic nervous outflow in hypertensive patients.
Goldstein, DS; Grossman, E; Holmes, C; Peleg, E; Rosenthal, T, 1993
)
2.24
"Yohimbine is an alkaloid derived mainly from the bark of the African tree, Pausinystalia yohimbe. "( Yohimbine in the treatment of erectile disorder.
Riley, AJ,
)
3.02
"Yohimbine is an alpha2 antagonist, inducing a dose-dependent toxicity."( [Iprindole: a functional link between serotonin and noradrenaline systems?].
Bourin, M; Ganry, H,
)
0.85
"Yohimbine is an alpha 2 adrenoreceptor antagonist occasionally used in the treatment of impotence. "( Benign course after massive ingestion of yohimbine.
Friesen, K; Palatnick, W; Tenenbein, M,
)
1.84
"Yohimbine is an indole alkaloid obtained from the yohimbe tree, a common tree in West Africa. "( Yohimbine-induced cutaneous drug eruption, progressive renal failure, and lupus-like syndrome.
Aronson, P; Sandler, B, 1993
)
3.17
"Yohimbine is an alpha 2-adrenergic antagonist that stimulates norepinephrine (NE) release."( Plasma MHPG response to yohimbine treatment in women with hypoactive sexual desire.
Dunger, B; Feng, YZ; Halaris, A; Maguire, E; Piletz, JE; Segraves, KB,
)
1.16
"Yohimbine is an alpha-2-adrenergic receptor antagonist that activates noradrenergic neurons."( Yohimbine use in a natural setting: effects on posttraumatic stress disorder.
Charney, DS; High, JR; Morgan, CA; Southwick, SM, 1999
)
2.47
"Why? Yohimbine is an old drug."( Yohimbine in erectile dysfunction: the facts.
Morales, A, 2000
)
2.2
"Yohimbine is an effective therapy to treat organic erectile dysfunction in some men with erectile dysfunction."( Yohimbine treatment of organic erectile dysfunction in a dose-escalation trial.
Geisser, ME; Guay, AT; Jacobson, J; Murray, FT; Spark, RF, 2002
)
2.48
"5. Yohimbine is a potent and safe antidote of X not affecting T3 and T4."( The effect of yohimbine on plasma levels of T3, T4 and cortisol in xylazine-immobilized white-tailed deer.
Brown, RD; Bubenik, GA, 1989
)
1.15
"Yohimbine is an alpha-2 blocking agent which also increases cholinergic activity. "( Yohimbine-induced bronchospasm.
Landis, E; Shore, E, 1989
)
3.16
"Yohimbine is a safe treatment for psychogenic impotence that seems to be as effective as sex and marital therapy for restoring satisfactory sexual functioning."( Double-blind trial of yohimbine in treatment of psychogenic impotence.
Condra, M; Fenemore, J; Harris, C; Morales, A; Owen, J; Reid, K; Surridge, DH, 1987
)
1.31
"Yohimbine appeared to be a safe and effective antagonist for xylazine sedation in raptors."( Antagonism of xylazine hydrochloride sedation in raptors by yohimbine hydrochloride.
Baker, B; Freed, D, 1989
)
1.24
"Yohimbine (YOH) is a widely used pharmacological tool employed to produce a selective blockade of alpha 2-adrenergic receptors. "( Evidence for antiserotonergic properties of yohimbine.
Dwoskin, LP; Neal, BS; Sparber, SB, 1988
)
1.98
"Yohimbine is an alpha-adrenoceptor blocker that has been used in the treatment of erectile dysfunction. "( Is yohimbine effective in the treatment of organic impotence? Results of a controlled trial.
Condra, M; Fenemore, J; Harris, C; Morales, A; Owen, JA; Surridge, DH, 1987
)
2.34
"Yohimbine appeared to be a safe and effective antagonist of xylazine-ketamine immobilization in guineafowl and may prove useful in other avian species to produce more rapid recovery from xylazine-ketamine immobilization, xylazine sedation or xylazine overdosage."( Antagonism of xylazine hydrochloride-ketamine hydrochloride immobilization in guineafowl (Numida meleagris) by yohimbine hydrochloride.
Teare, JA, 1987
)
1.21
"Yohimbine is an alpha 2-adrenoreceptor antagonist that acts to enhance sympathetic nervous system discharge and potentiate sympathetically mediated cardiovascular reflex responses. "( Oral yohimbine in human autonomic failure.
Biaggioni, I; Goldberg, MR; Hollister, AS; Onrot, J; Robertson, D; Wiley, RG, 1987
)
2.23
"Yohimbine hydrochloride is an indole alkaloid which blocks alpha 2-adrenergic and dopamine receptors and stimulates serotonergic receptors. "( Effect of yohimbine hydrochloride on serum prolactin concentration in the rat: possible antagonist for fescue toxicosis.
Booth, NH; Jernigan, AD; Robbins, JD; Zahner, JM, 1986
)
2.12

Effects

Yohimbine hydrochloride has been used experimentally to reverse the anesthetic effects of ketamine and xylazine in dogs, cats, cattle and mule deer. There are no reports of its use in nonhuman primates. Yohimbin has had questionable effects in men with organic erectile dysfunction.

ExcerptReferenceRelevance
"Yohimbine, which has a high affinity for Drosophila tyramine receptors, also caused dose-dependent vasorelaxation like tyramine."( Characterization of the vasorelaxant activity of tyramine and other phenylethylamines in rat aorta.
Bouvier, M; Chemtob, S; Deng, XF; Nantel, F; Varma, DR, 1995
)
1.01
"Yohimbine (YOH) has antiproliferative effects against breast cancer and pancreatic cancer; however, its effects on vascular proliferative diseases such as atherosclerosis remain unknown. "( Yohimbine, an α2-Adrenoceptor Antagonist, Suppresses PDGF-BB-Stimulated Vascular Smooth Muscle Cell Proliferation by Downregulating the PLCγ1 Signaling Pathway.
Chiu, CW; Hsieh, CY; Huang, SY; Sheu, JR; Tsai, JH; Yang, CH, 2022
)
3.61
"Yohimbine has been effectively used for decades to treat erectile dysfunction."( Yohimbine hydrochloride inhibits benign prostatic hyperplasia by downregulating steroid 5α-reductase type 2.
An, J; Cao, Y; Li, Y; Lin, S; Ma, X; Wang, S; Xu, L; Yang, M; Yuan, J; Zhang, Y; Zhao, Y, 2021
)
2.79
"Yohimbine has not yet been investigated in the augmentation of exposure therapy for other anxiety disorders."( Yohimbine enhancement of exposure therapy for social anxiety disorder: a randomized controlled trial.
Davis, ML; Handelsman, PR; Hofmann, SG; Julian, K; Otto, MW; Powers, MB; Rosenfield, B; Rosenfield, D; Shiekh, M; Smits, JA; Tuerk, P, 2014
)
2.57
"Yohimbine has been shown to modulate the pharmacological actions of opioid drugs in a way that could be of potential therapeutic interest. "( Yohimbine does not affect opioid receptor activation but prevents adenylate cyclase regulation by morphine in NG108-15 cells.
Alguacil, LF; González-Martín, C; López-Giménez, JF; Polanco, MJ, 2011
)
3.25
"Yohimbine has been widely used as alpha2-adrenergic receptor antagonist in neurophysiological research and in clinical therapy. "( Yohimbine acts as a putative in vivo alpha2A/D-antagonist in the rat prefrontal cortex.
Hernádi, I; Kovács, P, 2006
)
3.22
"Yohimbine, which has a high affinity for Drosophila tyramine receptors, also caused dose-dependent vasorelaxation like tyramine."( Characterization of the vasorelaxant activity of tyramine and other phenylethylamines in rat aorta.
Bouvier, M; Chemtob, S; Deng, XF; Nantel, F; Varma, DR, 1995
)
1.01
"Yohimbine has several other activities, including 5-HT receptor antagonism, at the concentrations at which protection was found."( The effect of alpha 2-adrenoceptor antagonists in isolated globally ischemic rat hearts.
Dzwonczyk, S; Grover, GJ; Sargent, CA, 1994
)
1.01
"Yohimbine has been evaluated in the management of erectile disorder by means of placebo-controlled but often poorly designed trials."( Yohimbine in the treatment of erectile disorder.
Riley, AJ,
)
2.3
"Yohimbine has been proposed for the treatment of neurogenic orthostatic hypotension; however, no controlled trial has been performed in experimental models of orthostatic hypotension or in patients with autonomic failure. "( Effects of yohimbine, an alpha 2-adrenoceptor antagonist, on experimental neurogenic orthostatic hypotension.
Montastruc, JL; Portolan, G; Senard, JM; Tran, MA; Verwaerde, P, 1997
)
2.13
"Yohimbine has had questionable effects in men with organic erectile dysfunction. "( Yohimbine treatment of organic erectile dysfunction in a dose-escalation trial.
Geisser, ME; Guay, AT; Jacobson, J; Murray, FT; Spark, RF, 2002
)
3.2
"Yohimbine, which has been shown to induce anxiety both in animals and in man, was used for comparison."( Anxiogenic activity of quinine--an experimental study in rodents.
Bhattacharya, SK; Mitra, SK, 1992
)
1
"Yohimbine, which has activity both at alpha 2-adrenoreceptors and benzodiazepine receptors in the CNS, had an anxiogenic action (1.25-2.5 mg/kg) in the social interaction test in rats. "( Are the anxiogenic effects of yohimbine mediated by its action at benzodiazepine receptors?
Chopin, P; File, SE; Pellow, S, 1985
)
2
"Yohimbine has approximately one-hundredth the potency of prazosin for blocking adrenergic inhibition of [3H]acetylcholine overflow."( Acetylcholine release from rat atria can be regulated through an alpha 1-adrenergic receptor.
Brown, JH; Goldstein, D; Wetzel, GT, 1985
)
0.99
"Yohimbine has been observed to cause a selective increase of cerebral norepinephrine."( Noradrenergic cerebral stimulation of sensorineural impaired subjects: yohimbine effects on speech intelligibility and the auditory brain response.
Binggeli, R; Gott, PS; Hughes, EC; Weinstein, RC, 1988
)
1.23
"Yohimbine has opposite effects."( Interactions between the effects of yohimbine, clonidine and [Ca]o on the electrical response of the mouse vas deferens.
Blakeley, AG; Mathie, A; Petersen, SA, 1986
)
1.27
"Yohimbine hydrochloride has been used experimentally to reverse the anesthetic effects of ketamine and xylazine in dogs, cats, cattle and mule deer, but there are no reports of its use in nonhuman primates. "( Failure of yohimbine to reverse ketamine anesthesia in rhesus monkeys.
Line, S; Lynch, S, 1985
)
2.1

Actions

Yohimbine can inhibit TNF-α, IL-1β and IL-6 overproduction and relieve the severity of pulmonary inflammation induced by endotoxin. It can cause tonic seizures and mortality in rats given 70 mg/kg s.c.

ExcerptReferenceRelevance
"Yohimbine displays marked affinity at human (h)alpha(2A)-, halpha(2B)- and halpha(2C)-ARs, significant affinity for h5-HT(1A), h5-HT(1B), h5-HT(1D), and hD(2) receptors and weak affinity for hD(3) receptors."( Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic tr
Audinot, V; Boutin, JA; Cogé, F; Cussac, D; Dekeyne, A; Galizzi, JP; Gobert, A; Lejeune, F; Millan, MJ; Newman-Tancredi, A; Nicolas, JP; Rivet, JM, 2000
)
1.31
"Yohimbine could inhibit the neuroprotective effect of Dex."( Dexmedetomidine attenuates perioperative neurocognitive disorders by suppressing hippocampal neuroinflammation and HMGB1/RAGE/NF-κB signaling pathway.
Chu, T; Liu, C; Wang, J; Xin, Y; Xu, A, 2022
)
1.44
"Yohimbine-associated increase in plasma MHPG correlated with increased impulsive response rates."( Norepinephrine and impulsivity: effects of acute yohimbine.
Cox, B; Lane, SD; Lijffijt, M; Moeller, FG; Steinberg, JL; Swann, AC, 2013
)
1.37
"Yohimbine can inhibit TNF-α, IL-1β and IL-6 overproduction and relieve the severity of pulmonary inflammation induced by endotoxin, which is maybe mediated by blockade of α2A AR on inflammatory cells."( Yohimbine protects against endotoxin-induced acute lung injury by blockade of alpha 2A adrenergic receptor in rats.
A, LT; Chen, L; Lin, Y; Yang, YL; Yao, WZ; Zhu, X, 2011
)
3.25
"Yohimbine was able to blunt the effects of clonidine, verifying that both drugs are acting through the same receptor population."( Transiently overexpressed alpha2-adrenoceptors and their control of DNA synthesis in the developing brain.
Cousins, MM; Kreider, ML; Seidler, FJ; Slotkin, TA; Tate, CA, 2004
)
1.04
"Yohimbine led to an increase in the amplitude of the error-related negativity in conjunction with a significant reduction of action errors."( Noradrenergic stimulation enhances human action monitoring.
Barbanoj, MJ; Morte, A; Münte, TF; Riba, J; Rodríguez-Fornells, A, 2005
)
1.05
"Yohimbine's ability to cause tonic seizures and mortality in rats given 70 mg/kg s.c."( Potentiation by yohimbine of pentylenetetrazol-induced seizures in rats: role of alpha 2 adrenergic receptors.
Lazarova, M; Samanin, R, 1983
)
1.33
"Yohimbine did not enhance the antagonistic effects of 4-AP."( Reversal of pentobarbital anesthesia with 4-aminopyridine and yohimbine in cats pretreated with acepromazine and xylazine.
Booth, NH; Clark, JD; Hatch, RC; Kitzman, JV; Zahner, JM, 1984
)
1.23
"But yohimbine itself produce no effect on pain threshold and the concentration of beta-endorphin."( [The inhibition of yohimbine injected intrathecally on electroacupuncture-induced analgesia and release of beta-endorphin from rat brain].
Chen, M; Huang, X; Zhuang, W, 1996
)
1.1
"Yohimbine blocked the increase caused by medetomidine but not by atipamezole."( Melatonin release from rat pineals in vitro is stimulated by both the alpha(2)-adrenoceptor agonist medetomidine and the antagonist atipamezole.
Alila-Johansson, A; Bäck, N; Laakso, ML; Mustanoja, SM, 1999
)
1.02
"Yohimbine-induced increase in noradrenaline release was significantly more marked after selegiline."( Changes in vascular alpha 1- and alpha 2-adrenoceptor responsiveness by selegiline treatment.
Berlan, M; Montastruc, JL; Pelat, M; Senard, JM; Tran, MA; Verwaerde, P, 2001
)
1.03

Treatment

Yohimbine is a safe treatment for psychogenic impotence that seems to be as effective as sex and marital therapy for restoring satisfactory sexual functioning.

ExcerptReferenceRelevance
"Yohimbine treatment facilitated extinction in 129S1, but neither extended extinction training nor d-cycloserine treatment improved 129S1 extinction."( Impaired fear extinction learning and cortico-amygdala circuit abnormalities in a common genetic mouse strain.
Bussey, TJ; Hefner, K; Holmes, A; Juhasz, J; Karlsson, RM; Norcross, M; Saksida, LM; Singewald, N; Whittle, N, 2008
)
1.07
"Yohimbine pretreatment also suppressed agmatine induced restoration of blood pressure; however, the survival rate was found to be 17% for 3 min."( Effects of agmatine on the survival rate in rats bled to hemorrhage.
Ekinci, O; Gill, F; Gören, MZ; Pelit, T; Terzioğlu, B, 2011
)
1.09
"Yohimbine treatments that markedly increase copulatory behavior of male hamsters in long days were completely ineffective in facilitating MSB when injected after gonadal regression induced by 16 wks of short day lengths and after complete gonadal recrudescence after 32 wks of short days; apomorphine was similarly ineffective."( Winter day lengths counteract stimulatory effects of apomorphine and yohimbine on sexual behavior of male Syrian hamsters.
Jarjisian, SG; Piekarski, DJ; Zucker, I, 2012
)
1.33
"Yohimbine pre-treatment decreased the amnestic effects of dexamethasone or dexamethasone plus clonidine."( The role of alpha-adrenoceptors in the amnestic effect of intracerebroventricular dexamethasone.
Hadi, M; Homayoun, H; Khavandgar, S; Postami, P; Shafaghi, B; Zarrindast, MR, 2002
)
1.04
"Yohimbine pretreatment attenuated the effect of clonidine."( Adrenoceptor mechanisms underlying imipramine-induced memory deficits in rats.
Ghiasvand, M; Homayoun, H; Khavandgar, S; Rostami, P; Shafaghi, B; Zarrindast, MR, 2003
)
1.04
"Yohimbine treatment facilitated extinction of both cue and context fear with massed protocols."( Adrenergic transmission facilitates extinction of conditional fear in mice.
Barad, M; Blouin, AM; Cain, CK,
)
0.85
"Yohimbine pretreatment in the absence of cocaine-associated cues or cues by themselves reliably reinstated responding on the previously cocaine-paired lever (3-4 times higher than extinction levels)."( Potentiation of cue-induced reinstatement of cocaine-seeking in rats by the anxiogenic drug yohimbine.
Feltenstein, MW; See, RE, 2006
)
1.28
"Yohimbine is a useful treatment option in orgasmic dysfunction."( Yohimbine in the treatment of orgasmic dysfunction.
Adeniyi, AA; Brindley, GS; Pryor, JP; Ralph, DJ, 2007
)
3.23
"Yohimbine pretreatment did not affect the first T(c) rise, which continued unchanged for 6 h; the second rise, however, was absent, and PGE(2) levels did not increase."( Preoptic norepinephrine mediates the febrile response of guinea pigs to lipopolysaccharide.
Blatteis, CM; Feleder, C; Perlik, V, 2007
)
1.06
"In yohimbine-treated rats, DMI potentiated significantly (p less than 0.001) both pressor and NE responses to stimulation."( Effect of desipramine on the effects of alpha-adrenoceptor inhibitors on pressor responses and release of norepinephrine into plasma of pithed rats.
Bayorh, MA; Kopin, IJ; Zukowska-Grojec, Z,
)
0.65
"Yohimbine pretreatment (0.1 mg/kg i.v.) was more effective in antagonizing clonidine than morphine."( Morphine-like effects of clonidine on the EEG, slow wave sleep and behavior in the dog.
Gupta, VN; Pickworth, WB; Sharpe, LG, 1982
)
0.99
"Both yohimbine pretreatment and CNS monoamine depletion (with reserpine 5 mg/kg i.p."( Studies on the mechanism of amphetamine mydriasis in the cat.
Koss, MC, 1980
)
0.72
"Yohimbine pretreatment prevented both the increase in juxtamucosal pH gradient depth and the protective effect of nicotine."( Topical nicotine protects rat gastric mucosa against ASA-induced damage. A role for mucosal fluid secretion in cytoprotection.
Fallone, CA; Morris, GP, 1995
)
1.01
"In yohimbine-pretreated (2 mg/kg i.v.) animals, diaspirin crosslinked hemoglobin did not produce any change in heart rate, stroke volume, cardiac output, and total peripheral resistance, but a slight increase in blood pressure was observed compared with baseline values obtained after the administration of yohimbine."( Yohimbine modulates diaspirin crosslinked hemoglobin-induced systemic hemodynamics and regional circulatory effects.
Gulati, A; Sharma, AC, 1995
)
2.25
"In yohimbine treated animals the enhancement of aggression was reduced already at 1 mg/kg."( Alpha 2-adrenoceptor blockade, pituitary-adrenal hormones, and agonistic interactions in rats.
Barna, I; Haller, J; Kovács, JL, 1994
)
0.8
"In yohimbine-pretreated rabbits, the reduction of cAMP level in the photocoagulated iris-ciliary body was absent."( In vivo cAMP level in rabbit iris-ciliary body after topical epinephrine treatment.
Gallar, J; Liu, JH, 1996
)
0.81
"Yohimbine pretreatment resulted in a rightward shift of the dose-response curves (DMET > CLON > UK)."( Pharmacological evidence for different alpha 2-adrenergic receptor sites mediating analgesia and sedation in the rat.
Buerkle, H; Yaksh, TL, 1998
)
1.02
"In yohimbine-treated dogfish, papaverine treatment elicited marked decreases in PCA, RS, and Q, and increases in plasma Ang II and catecholamines."( Cardiovascular control via angiotensin II and circulating catecholamines in the spiny dogfish, Squalus acanthias.
Bernier, NJ; Gilmour, KM; Perry, SF; Takei, Y, 1999
)
0.82
"Yohimbine treatment (1 mg/kg) increased gastric volume by half (p < 0.05), whereas bethanechol (3 microg/kg) decreased it by 35% (p < 0.05)."( A plethysmometric method for gastric compliance studies in anesthetized rats.
Gondim, FA; Graca, JR; Leal, PR; Rola, FH; Santos, AA,
)
0.85
"in yohimbine-treated monkeys) significantly improved the reserpine- or yohimbine-induced memory impairments."( Effect of huperzine A on working memory in reserpine- or yohimbine-treated monkeys.
Cai, JX; Ou, LY; Tang, XC, 2001
)
1.07
"Yohimbine pretreatment (0.5 mg/kg, i.v.) antagonized the effects of clonidine but not chlorpromazine in both preparations."( Effects of clonidine and chlorpromazine on a sympathetic-cholinergic reflex.
Bernthal, PJ; Koss, MC, 1979
)
0.98
"Yohimbine pretreatment (0.5 mg/kg, i.v.) antagonized the effects of clonidine but did not alter the effectiveness of clorpromazine in inhibiting these responses."( Effect of clonidine and chlorpromazine on centrally evoked electrodermal responses and their interaction with yohimbine.
Koss, MC, 1977
)
1.19
"The yohimbine treatment had a significant (p less than 0.05) effect on the frequency of headslap display (the main behavioral pattern of reproductive activity) in all treated animals but did not result in a significant increase in copulation frequency."( Effect of yohimbine on the reproductive behavior of the male Nile crocodile Crocodylus niloticus.
Morpurgo, B; Robinzon, B; Rozenboim, I, 1992
)
1.17
"Yohimbine treatments alone at 0.5, 1 and 2 mg/kg, i.p."( Stimulation of food intake in rats by the alpha 2-adrenoceptor agonists xylazine and detomidine.
Ayoub, RS; Majeed, NH; Mohammad, FK, 1991
)
1
"Yohimbine treatment inhibited isolation-induced attack in mice but had no effect on defense. "( Effects of yohimbine on isolation-induced aggression, social attraction, and conspecific odor preference in mice.
Behrens, M; Gibson, BM; Kemble, ED; Rawleigh, JM, 1991
)
2.11
"In yohimbine treated ferrets, an increase in mean heart rate measurement was noted 5 minutes after the intramuscular administration of yohimbine, and followed, over the next 15 minutes, by a progressive increase in mean heart rate."( Effects of yohimbine on bradycardia and duration of recumbency in ketamine/xylazine anesthetized ferrets.
Berman, NG; Fox, JG; Sylvina, TJ, 1990
)
1.18
"In a yohimbine-treated group, a 10% bleeding reduced duodenal blood flow by 28% and arterial [HCO3-] by 7% without influencing duodenal HCO3- secretion."( Effects of hypovolemia on blood flow, arterial [HCO3-], and HCO3- output in the rat duodenum.
Fändriks, L; Holm, L; Jansson, T; Jönson, C, 1990
)
0.73
"Yohimbine pretreatment attenuated the effects of subsequent treatment with either clonidine or chlordimeform."( An alpha 2-adrenergic mode of action of chlordimeform on rat visual function.
Boyes, WK; Moser, VC, 1988
)
1
"Yohimbine-treated rats were more likely to copulate than control rats during both acquisition and extinction of lithium chloride-induced associative inhibition of copulatory behavior."( Differential effects of yohimbine and naloxone on copulatory behaviors of male rats.
Blythe, BL; Koch, PC; Peters, RH, 1988
)
1.3
"Yohimbine pretreatment did not significantly alter spontaneous NE overflow but did significantly increase total NE overflow, NE overflow/stimulus and fractional NE overflow at all PNS frequencies used in both WKY and SHR preparations."( Effects of propranolol and yohimbine on periarterial nerve stimulation-induced release of endogenous norepinephrine from the mesenteric vasculature of Wistar Kyoto and spontaneously hypertensive rats.
Cline, WH; Yamamoto, R, 1988
)
1.29
"Yohimbine pretreatment reduced cocaine-induced latent lethality by 50%, but did not alter the time to lethality."( Antagonism of cocaine-induced hepatotoxicity by the alpha adrenergic antagonists phentolamine and yohimbine.
Harbison, RD; James, RC; Roberts, SM; Schiefer, MA, 1987
)
1.21
"Yohimbine is a safe treatment for psychogenic impotence that seems to be as effective as sex and marital therapy for restoring satisfactory sexual functioning."( Double-blind trial of yohimbine in treatment of psychogenic impotence.
Condra, M; Fenemore, J; Harris, C; Morales, A; Owen, J; Reid, K; Surridge, DH, 1987
)
1.31
"Yohimbine pretreatment did not significantly affect the systemic blood pressure response to baroreceptor unloading, but abolished the effect on intestinal vascular resistance and PD."( Baroreflex control of jejunal blood flow and fluid transport in cats; effects of yohimbine, an alpha 2-adrenergic antagonist.
Butcher, P; Hemlin, M; Sjövall, H, 1988
)
1.22
"Yohimbine pretreatment significantly enhanced the cardiovascular actions of cocaine and this enhancement was most pronounced in the presence of atropine."( Cardiovascular effects of cocaine: enhancement by yohimbine and atropine.
Wilkerson, RD, 1989
)
1.25
"Yohimbine pretreatment had no effect on acquisition of freezing behavior to the light, nor on bar pressing during testing in the absence of the light, in either experiment."( Long-term effects of yohimbine on behavioral sensitivity to a stressor.
Davidson, TL; Lucki, I, 1987
)
1.31
"In yohimbine-treated castrated rats, a decrease in the blood pressure was observed in males and a slight increase was observed in females after l-adrenaline administration."( [Sexual dimorphism in the pressor response to l-adrenaline in rats].
Fujii, T; Tomori, M, 1986
)
0.78
"Treatment with yohimbine or JP-1302 clearly ameliorated kidney function and cell apoptosis."( Inhibition of α2C-adrenoceptors ameliorates cisplatin-induced acute renal failure in rats.
Miura, T; Nishinaka, T; Shimokawa, T; Takama, M; Terada, T; Tsutsui, H; Yamagata, M; Yukimura, T, 2018
)
0.82
"pretreatment with yohimbine. And the immobilization stress-induced blood glucose level was not inhibited by i.c.v."( Involvement of α(2)-adrenergic receptor in the regulation of the blood glucose level induced by immobilization stress.
Kang, YJ; Park, SH; Sharma, N; Sim, YB; Suh, HW, 2015
)
0.74
"pretreatment with yohimbine. Furthermore, plasma insulin level was attenuated by clonidine, and yohimbine pretreatment reversed partially, but significantly, clonidine-induced down-regulation of the plasma insulin level."( Activation of spinal α2 adrenergic receptors induces hyperglycemia in mouse though activating sympathetic outflow.
Jung, JS; Kim, SS; Lim, SM; Park, SH; Sim, YB; Suh, HW, 2014
)
0.73
"pretreatment with yohimbine, an α2-adrenoceptor antagonist, or tropisetron, a 5-HT3 antagonist, significantly blocked caulerpine-induced antinociception."( Assessment of mechanisms involved in antinociception produced by the alkaloid caulerpine.
Alexandre-Moreira, MS; Barbosa-Filho, JM; Cavalcante-Silva, LH; da Silva, TM; de Araújo-Júnior, JX; de Miranda, GE; Falcão, MA; Noël, F; Santos, BV; Sousa, JC; Viana, MD; Vieira, AC, 2014
)
0.73
"Pretreatment with yohimbine consistently increased responding across repeated injections."( Baclofen blocks yohimbine-induced increases in ethanol-reinforced responding in rats.
Bielak, JT; Nickel, MM; Williams, KL, 2016
)
1.1
"Treatment with yohimbine reversed the antinociceptive effect of ortho-eugenol, suggesting involvement of the adrenergic system."( Ortho-eugenol exhibits anti-nociceptive and anti-inflammatory activities.
Almeida, RN; Aragão Neto, Hde C; Barbosa Filho, JM; Caldas Filho, MR; Fonsêca, DV; Golzio, AM; Leite, FC; Melo, CG; Piuvezam, MR; Pordeus, LC; Salgado, PR, 2016
)
0.77
"Pretreatment with yohimbine or propranolol significantly inhibited the increase in the MBF."( Interactions between β-adrenergic vasodilation and cervical sympathetic nerves are mediated by α
Ishii, H; Sato, T, 2017
)
0.78
"Pretreatment with yohimbine (2mg/kg, i.p.) enhanced the shaking induced by a low dose of icilin (0.5mg/kg)."( Icilin-evoked behavioral stimulation is attenuated by alpha₂-adrenoceptor activation.
Cowan, A; Hirsch, DD; Kim, J; Lisek, R; Rawls, SM; Raymondi, N; Rosenthal, A, 2011
)
0.69
"Pre-treatment with yohimbine, an alpha 2-adrenergic receptor antagonist, notably reversed the antinociceptive activity induced by octacosanol in the abdominal constriction test."( Antinociceptive and anti-inflammatory effects of octacosanol from the leaves of Sabicea grisea var. grisea in mice.
Barreto, E; Brito, FA; Conserva, LM; De Souza Ferro, JN; Lemos, RPL; Oliveira, AM, 2012
)
0.7
"Treatment with yohimbine or sildenafil significantly increased the sexual arousal and potency and corrected the effects induced by stress on the mating behavior of male rats."( Potential effects of yohimbine and sildenafil on erectile dysfunction in rats.
Abd El-Latif, HA; Eid, NI; Saad, MA; Sayed, HM, 2013
)
1.05
"Pretreatment with yohimbine (alpha2-adrenoceptor antagonist with low affinity for Ii-imidazoline receptors) and efaroxan (Ii-imidazoline receptor antagonist with low affinity for alpha2-adrenoceptors) abolished the effect of moxonidine."( Effect of moxonidine on contractile activity of isolated large intestine in mice: role of alpha2-adrenoceptors and Ii-imidazoline receptors.
Korobov, NV; Kozaeva, LP; Medvedev, OS, 2004
)
0.65
"Pretreatment with yohimbine (2 mg kg(-1), i.p., 30 min before each morphine injection) provided protection against morphine-induced GFAP upregulation."( The alpha2-adrenoceptor antagonist yohimbine reduces glial fibrillary acidic protein upregulation induced by chronic morphine administration.
Alguacil, LF; Díez-Fernández, C; Garrido, E; Pérez-García, C,
)
0.73
"Pre-treatment with yohimbine reduced the duration of motor block from 101.5 (83-115) to 76.5 (68-86) min (P < 0.05) or from 114.5 (103-156) to 90 (83-93) min (P < 0.05) when DEX was administered by the intrathecal or intraperitoneal routes."( Dexmedetomidine prolongs spinal anaesthesia induced by levobupivacaine 0.5% in guinea-pigs.
Calasans-Maia, JA; Sudo, RT; Zapata-Sudo, G, 2005
)
0.65
"Treatment with yohimbine (0.1 mg/ kg, i.p.) to male dogs, at 0.5, 1, 3, or 5 h before the testing, produced a significant stimulatory effects on the ejaculatory response elicited by manual penile stimulation; the amount of ejaculated semen was increased and the onset of ejaculation was shortened following each treatment."( Long-lasting effects of yohimbine on the ejaculatory function in male dogs.
Amano, T; Ebiko, M; Kimura, Y; Sakurada, S; Yonezawa, A; Yoshizumii, M, 2005
)
0.98
"Pre-treatment with yohimbine (320 nmol) into the lateral ventricle did not change the renal vasodilation produced by moxonidine (20 nmol) into the lateral ventricle."( Involvement of central alpha1- and alpha2-adrenoceptors on cardiovascular responses to moxonidine.
Colombari, E; Menani, JV; Moreira, TS; Takakura, AC, 2007
)
0.66
"Treatment with yohimbine, an alpha 2-adrenergic blocker, prior to the injection of a subdiabetogenic dose of streptozotocin (STZ) produced hyperglycemia and hypoinsulinemia in mice 7 days later. "( Adrenergic receptors and the onset of streptozotocin-induced diabetes in mice.
Kato, R; Muraki, T; Nakadate, T; Nakaki, T, 1981
)
0.62
"Pretreatment with yohimbine completely blocked the effect of NE on ADH release, and brought about a slight rise in blood pressure and heart rate."( The role of central alpha 1- and alpha 2-adrenoceptors in the regulation of vasopressin release and the cardiovascular system.
Iitake, K; Kimura, T; Matsui, K; Ota, K; Shoji, M; Yoshinaga, K, 1984
)
0.59
"Pretreatment with yohimbine hydrochloride (0.5 mg/kg i.v.) shifted the dose-response curve for all of the compounds tested to the right."( Analysis of pupillary dilation produced by analogs of clonidine.
Koss, MC, 1981
)
0.59
"Treatment with yohimbine (0.5 mg/kg i.v.), before amphetamine administration, blocked the amphetamine-induced reduction of parasympathetic nerve activity and partially antagonized the pupillary dilation."( Studies on the mechanism of amphetamine mydriasis in the cat.
Koss, MC, 1980
)
0.6
"Pretreatment with yohimbine prevented the clonidine-induced in SS binding."( Alpha-2 adrenoceptors modulate the somatostatinergic system and G protein levels in the rat hippocampus.
Arilla, E; Guijarro, LG; López-Sañudo, S; Prieto, JC; Puebla, L, 1995
)
0.61
"Pretreatment with yohimbine (1-10 microM) caused a concentration-dependent increase in reperfusion left ventricular developed pressure and a reduction in end diastolic pressure and lactate dehydrogenase release."( The effect of alpha 2-adrenoceptor antagonists in isolated globally ischemic rat hearts.
Dzwonczyk, S; Grover, GJ; Sargent, CA, 1994
)
0.61
"Pretreatment with yohimbine, the alpha2-adrenoceptor antagonist (8 microg; 5 microl; i.c.v.) blocked the cardiovascular responses to a subsequent i.c.v."( Cardiovascular effects of central administration of clonidine in conscious cats.
Ally, A, 1997
)
0.62
"pretreatment of yohimbine or prazosin prevented the inhibitory or facilitatory responses released by NE, respectively."( Locus coeruleus modulates thalamic nociceptive responses via adrenoceptors.
Dafny, N; Guo, YQ; Qiao, JT; Zhang, C, 1998
)
0.63
"pretreatment with yohimbine, the alpha2-adrenoceptor and 5-HT1A receptor antagonist, blocked the cardiovascular responses to a subsequent i.v."( Cardiovascular effects of intravenous administration of clonidine in conscious cats.
Ally, A, 1998
)
0.62
"Posttreatment with yohimbine and methysergide showed a significantly greater increase in the number of flinches in phase 2."( Formalin-induced nociception activates a monoaminergic descending inhibitory system.
Kawamata, M; Kawamata, T; Namiki, A; Omote, K, 1998
)
0.62
"Pretreatment with yohimbine completely blocked the decreased reactivity to hypercapnia."( Intrathecal dexmedetomidine attenuates hypercapnic but not hypoxic cerebral vasodilation in anesthetized rabbits.
Dohi, S; Iida, H; Iida, M; Takenaka, M, 2000
)
0.63
"Pretreatment with yohimbine (alpha(2)-adrenoceptor) or prazosin (alpha(1)-adrenoceptor) 15 min prior to naloxone administration attenuated some of the behavioural signs of morphine withdrawal."( Changes in catecholaminergic pathways innervating the rat heart ventricle during morphine dependence. Involvement Of alpha(1)- and alpha(2)-adrenoceptors.
Laorden, ML; Milanés, MV, 2000
)
0.63
"Pretreatment with yohimbine completely blocked the antinociception provided by the three opioid agonists in the mouse tail-immersion test."( Effects of yohimbine on the antinociceptive and place conditioning effects of opioid agonists in rodents.
Alguacil, LF; Morales, L; Perez-Garcia, C, 2001
)
1.02
"pretreatment with yohimbine (30 microg) had no effect on improgan antinociception."( A role for spinal, but not supraspinal, alpha(2) adrenergic receptors in the actions of improgan, a powerful, non-opioid analgesic.
Hough, LB; Leurs, R; Menge, WM; Nalwalk, JW; Svokos, K; Timmerman, H, 2001
)
0.63
"pretreatment with yohimbine and prazosin."( Adrenergic mechanisms in antinociceptive effects of non steroidal anti-inflammatory drugs in acute thermal nociception in mice.
Miranda, HF; Pinardi, G; Sierralta, F, 2002
)
0.64
"Pretreatment with yohimbine (1 mg x kg-1 i.v.) significantly increased delta BP in response to PNS by about 20% without any change in basal HR being observed."( Alpha- and beta-adrenoceptor-mediated effects on nerve stimulation-evoked release of neuropeptide Y (NPY)-like immunoreactivity in the pithed guinea pig.
Dahlöf, C; Dahlöf, P; Lundberg, JM; Tarizzo, VI, 1991
)
0.6
"Treatment with yohimbine had no effect on any variable in comparison with the control group."( Yohimbine does not affect fat distribution in men.
Sax, L, 1991
)
2.06
"Pretreatment with yohimbine (1.25 to 10 mg/kg, ip) had no significant effect on apomorphine stereotypy in rats and apomorphine induced cage climbing behaviour in mice."( Effects of yohimbine on dopamine dependent behaviours in rats and mice.
Balsara, JJ; Bapat, TR; Bende, MM; Chandorkar, AG, 1990
)
0.99
"pretreatment with yohimbine (YO) (alpha 2-antagonist), did not influence the effect of PHE."( Effects of systemic and intracerebroventricular phenylephrine and clonidine on corticosterone secretion in rats.
Bugajski, J; Gadek-Michalska, A; Połczyńska-Konior, G; Turoń, M, 1990
)
0.6
"Pretreatment with yohimbine or phenoxybenzamine, alpha-adrenergic blockers, or picrotoxin, a gamma-aminobutyric acid (GABA) antagonist, blunted the plasma GH increase induced by intracerebroventricular injection of galanin."( Possible mechanisms involved in growth hormone secretion induced by galanin in the rat.
Hattori, N; Imura, H; Kato, Y; Koshiyama, H; Murakami, Y; Shimatsu, A; Yanaihara, N, 1989
)
0.6
"Pretreatment with yohimbine could also abolish the effects of clonidine."( [Inhibitory action of intracerebroventricular injections of norepinephrine and clonidine on ventricular extrasystoles induced by stimulating hypothalamus in rabbits].
Li, DX; Shen, GS, 1989
)
0.6
"Pretreatment with yohimbine did not block the effect of morphine on the CV system nor alter the stimulatory effect of morphine on the secretion of corticosterone."( Role of alpha-adrenergic mechanism in effects of morphine on the hypothalamo-pituitary-adrenocortical and cardiovascular systems in the rat.
Cascio, CS; Dallman, MF; Darlington, DN; Shinsako, J; Suemaru, S, 1989
)
0.6
"Pretreatment with yohimbine suppressed the marked pressor responses of subsequent NE or Dyn A (60 nmoles/kg) administration whereas prazosin antagonized the rise in MAP of only the lower doses of dynorphin as well as NE."( Opiate and alpha receptor antagonists block the pressor responses of conscious rats given intravenous dynorphin.
Gregor, L; Saunders, WS; Thornhill, JA,
)
0.45
"Treatment with yohimbine (10(-9) and 10(-8) M) potentiated the response to nerve stimulation dose-dependently in the dog arteries, but rather attenuated the response of the primate arteries."( Prejunctional alpha adrenoceptor and angiotensin receptor function in isolated human, monkey and dog arteries.
Inoue, S; Okunishi, H; Toda, N, 1988
)
0.61
"Pretreatment with yohimbine (0.5 mg/kg) was used to create a strong beta 1-stimulus by raising the intra-synaptic NA level through blockade of the inhibitory alpha 2-adrenoceptors."( Characterization of presynaptic beta-adrenoceptors facilitating endogenous noradrenaline release in the portal vein of permanently cannulated, freely moving rats.
Bos, EA; Knot, HJ; Remie, R; Zaagsma, J, 1988
)
0.6
"Pretreatment with yohimbine (1.5 mg/kg, IP) reversed the protective effect of clonidine, indicating the involvement of alpha 2 receptors in the action of clonidine."( Reversal by alpha-2 agonists of diazepam withdrawal hyperactivity in rats.
Kulkarni, SK; Kunchandy, J, 1986
)
0.59
"Pretreatment with yohimbine completely prevented the clonidine-induced suppression of ejaculation, while clonidine attenuated the facilitatory effects of yohimbine, suggesting a competitive interaction."( Evidence for the modulation of sexual behavior by alpha-adrenoceptors in male rats.
Clark, JT; Davidson, JM; Smith, ER, 1985
)
0.59
"pretreatment with yohimbine. Yohimbine failed to prevent motion sickness but did occasion an unexplained variability in the incidence of vomiting."( Xylazine emesis, yohimbine and motion sickness susceptibility in the cat.
Crampton, GH; Lucot, JB, 1986
)
0.93
"Treatment with yohimbine had the opposite effects on ethanol sensitivity, K+ affinity, K+ interactions with ethanol and ATP, and thermodynamic parameters for cation activation or conformational change."( Brain Na+,K+-ATPase: alteration of ligand affinities and conformation by chronic ethanol and noradrenergic stimulation in vivo.
Swann, AC, 1986
)
0.61
"Treatment with yohimbine prevented xylazine-induced hypoinsulinemia and hyperglycemia."( Effect of yohimbine on xylazine-induced hypoinsulinemia and hyperglycemia in mares.
Benson, GJ; Greene, SA; Thurmon, JC; Tranquilli, WJ, 1987
)
1.02
"Pretreatment with yohimbine (5 mg/kg s.c.), before administration of WHR 1049, decreased the myoelectric activity inhibition by two-thirds (but did not completely block it)."( WHR 1049, a potent metabolite of lidamidine, has antidiarrheal and antimotility effects on the small intestine in rats.
Bixler, GB; Eaker, EY; Mathias, JR, 1988
)
0.6
"Pretreatment with yohimbine (10(-6) M) and propranolol (7 X 10(-6) M) had no significant effects."( Effects of delta-aminolaevulinic acid on contractile activity in the isolated small intestine of the rabbit. Role of adrenergic receptors.
Cutler, MG; McLaughlin, M; McNeil, E; Moore, MR, 1985
)
0.59
"Treatment with yohimbine, a alpha-2-adrenergic blocking agent, resulted in resolution of clinical signs attributed to xylazine intoxication."( Yohimbine for treatment of xylazine overdosing in a cat.
Jensen, WA, 1985
)
2.05

Toxicity

Yohimbine failed to antagonize lipid peroxidation caused by in vitro incubation of cocaine with hepatic microsomes. Only 7% of patients rated tolerability fair or poor, and most adverse experiences were mild.

ExcerptReferenceRelevance
" LD50 values of three of these compounds were assessed after intraperitoneal administration with a special emphasis on interactions with drugs increasing catecholaminergic neurotransmission."( Acute toxicity of three new selective COMT inhibitors in mice with special emphasis on interactions with drugs increasing catecholaminergic neurotransmission.
Männistö, PT; Törnwall, M, 1991
)
0.28
" This effect does not appear to result from an inhibition of the toxic metabolite(s) of cocaine, as a 10-fold molar excess of yohimbine failed to antagonize lipid peroxidation caused by in vitro incubation of cocaine with hepatic microsomes."( Antagonism of cocaine-induced hepatotoxicity by the alpha adrenergic antagonists phentolamine and yohimbine.
Harbison, RD; James, RC; Roberts, SM; Schiefer, MA, 1987
)
0.7
" The LD50 value for adrenaline in control animals was 11."( Adrenaline toxicity in mice: sensitization of alpha 1 adrenoreceptors by nitroglycerin.
Axelsson, KL; Rydell, EL, 1984
)
0.27
"), a selective alpha-2 agonist, enhanced the toxic effects of digoxin by decreasing both the arrhythmogenic and lethal dose of digoxin."( Central alpha receptors and their role in digoxin cardiotoxicity.
Plunkett, LM; Tackett, RL, 1983
)
0.27
" Therefore, administering alpha 2 adrenergic agonists together with NMDA antagonists may be a valuable strategy for preventing adverse side effects of NMDA antagonists and making these agents safer for various neurotherapeutic purposes."( alpha 2 adrenergic agonists prevent MK-801 neurotoxicity.
Duhan, NL; Farber, NB; Foster, J; Olney, JW, 1995
)
0.29
"To evaluate the toxic effects of amitraz in dogs and their reversal by various doses of atipamezole."( Toxicity and kinetics of amitraz in dogs.
Berny, PJ; Buronrosse, F; Cadoré, JL; Hugnet, C; Lorgue, G; Pineau, X, 1996
)
0.29
" Yohimbine was well-tolerated: Only 7% of patients rated tolerability fair or poor, and most adverse experiences were mild."( Double-blind, placebo-controlled safety and efficacy trial with yohimbine hydrochloride in the treatment of nonorganic erectile dysfunction.
Brandl, P; Gierend, M; Kockott, G; Schadrack, J; Schmitz, JR; Vogt, HJ; Wiegand, MH, 1997
)
1.45
" Partial α2-adrenoceptor agonists might offer the potential for effective and safe treatment of obesity."( A Comparison of the Anorectic Effect and Safety of the Alpha2-Adrenoceptor Ligands Guanfacine and Yohimbine in Rats with Diet-Induced Obesity.
Bednarski, M; Dudek, M; Głuch-Lutwin, M; Kazek, G; Knutelska, J; Mordyl, B; Nowiński, L; Pytka, K; Sapa, J; Zygmunt, M, 2015
)
0.63

Pharmacokinetics

The pharmacokinetic parameters and the time course of the effect after acute oral. administration of yohimbine on salivary secretion in patients treated with tricyclic antidepressants were investigated. The harmonic mean effective half-life (+/- pseudo standard deviation) was 46.

ExcerptReferenceRelevance
" Therefore, a comparative study on the pharmacokinetic and pharmacodynamic properties of DHE was performed in beagle dogs."( Dihydroergotamine: pharmacokinetics, pharmacodynamics, and mechanism of venoconstrictor action in beagle dogs.
Müller-Schweinitzer, E; Rosenthaler, J, 1987
)
0.27
" The harmonic mean effective half-life (+/- pseudo standard deviation) of yohimbine was 46."( Comparative pharmacokinetics of yohimbine in steers, horses and dogs.
Akbari, A; Booth, NH; Hatch, RC; Jernigan, AD; Wilson, RC, 1988
)
0.79
"1 mg/kg of xylazine from 2 manufacturers and the pharmacokinetic parameters calculated from the disposition curves."( Pharmacokinetics of xylazine in ponies: influence of yohimbine.
Dyer, DC; Hsu, WH; Lloyd, WE, 1987
)
0.52
"The pharmacokinetic parameters and the time course of the effect after acute oral administration of yohimbine on salivary secretion in patients treated with tricyclic antidepressants were investigated."( Pharmacokinetic study of yohimbine and its pharmacodynamic effects on salivary secretion in patients treated with tricyclic antidepressants.
Bagheri, H; Berlan, M; Houin, G; Montastruc, JL; Picault, P; Schmitt, L, 1994
)
0.81

Compound-Compound Interactions

The study investigated the effects of berberine in combination with yohimbine (BY) on neutrophil tissue infiltration and multiple organ damage during sepsis. The study further elucidated the involved mechanisms.

ExcerptReferenceRelevance
" Clonidine, given alone, had no effect; however, when administered with morphine it blocked the analgesic effect of morphine."( Effects of clonidine and yohimbine, alone and in combination with morphine, on supraspinal analgesia.
Izenwasser, S; Kornetsky, C, 1990
)
0.58
"15 mg/kg) were administered subcutaneously in the rat in combination with KET (50 mg/kg), in the presence or not of YOH (2 mg/kg)."( Corneal toxicity of xylazine and clonidine, in combination with ketamine, in the rat.
Bordi, F; Casini, ML; Corubolo, C; Fehér, J; Fumagalli, E; Guidolin, D; Leone, MG; Mattioli, F; Romanelli, L; Saso, L; Tita, B,
)
0.13
"To determine the anesthetic dose and cardiopulmonary effects of xylazine hydrochloride when used alone or in combination with ketamine hydrochloride and evaluate the efficacy of yohimbine hydrochloride to reverse anesthetic effects in captive Axis deer."( Anesthesia induced by administration of xylazine hydrochloride alone or in combination with ketamine hydrochloride and reversal by administration of yohimbine hydrochloride in captive Axis deer (Axis axis).
Reddy, AP; Shivaji, S; Sontakke, SD; Umapathy, G, 2007
)
0.73
" In the present study, we investigated the effects of berberine in combination with yohimbine (BY) on neutrophil tissue infiltration and multiple organ damage during sepsis, and further elucidated the involved mechanisms."( Berberine in combination with yohimbine attenuates sepsis-induced neutrophil tissue infiltration and multiorgan dysfunction partly via IL-10-mediated inhibition of CCR2 expression in neutrophils.
Li, H; Lu, D; Lv, X; Tang, X; Wang, F; Wang, H; Wang, Y; Yang, D, 2016
)
0.95

Bioavailability

ExcerptReferenceRelevance
" The method was used in bioavailability study of YO following oral and intravenous administration in humans."( Determination of yohimbine and its two hydroxylated metabolites in humans by high-performance liquid chromatography and mass spectral analysis.
Chevanne, F; Döe De Maindreville, M; Le Corre, P; Le Verge, R; Levy, J; Royer, D, 1992
)
0.62
" The reversal of clonidine-induced mydriasis in the rat was used to assess bioavailability and indicated that 1b was a potent alpha 2-adrenoceptor antagonist in vivo."( Structure-affinity relationships of 12-sulfonyl derivatives of 5,8,8a,9,10,11,12,12a,13,13a-decahydro-6H-isoquino[2,1-g][1 ,6] naphthyridines at alpha-adrenoceptors.
Berger, J; Brown, CM; Clague, RU; Clark, RD; Kilpatrick, AT; MacKinnon, AC; Nelson, JT; Repke, DB; Spedding, M, 1991
)
0.28
" The low oral bioavailability of SK&F 104078 did not appear to be due to high first-pass oxidative metabolism, since pretreatment of SHR with the suicide substrate inhibitor of cytochrome P-450, 1-aminobenzotriazole (ABT), did not result in increased oral efficacy."( Cardiovascular effects of SK&F 104078, a novel alpha-adrenoceptor antagonist, in normotensive and hypertensive rats.
Gombar, CT; Gutzait, L; Hieble, JP; Sulpizio, AC, 1990
)
0.28
" The oral bioavailability showed great variability, ranging from 7% to 87% (mean value was 33%)."( Yohimbine bioavailability in humans.
Grunhaus, LJ; Guthrie, SK; Hariharan, M, 1990
)
1.72
" In addition, L-654,284 had better (5-6 times) oral bioavailability than RX 781094 or WY 26703."( L-654,284 a new potent and selective alpha 2-adrenoceptor antagonist.
Baldwin, JJ; Clineschmidt, BV; Huff, JR; Lotti, VJ; Martin, GE; Pettibone, DJ; Randall, WC; Vacca, J, 1986
)
0.27
"The aim of the study was to test the hypothesis that the sympathetic nerves to the jejunum enhance net fluid absorption rate by inhibiting an electrogenic flux of anions into the lumen."( Electrogenic and electroneutral components of the sympathetic effect on fluid absorption in the rat jejunum.
Butcher, P; Hemlin, M; Sjövall, H, 1987
)
0.27
"The aim of the study was to test the hypothesis that baroreceptor unloading increases jejunal fluid absorption rate via an alpha 2-adrenergic effect on electrogenic active transport."( Baroreflex control of jejunal blood flow and fluid transport in cats; effects of yohimbine, an alpha 2-adrenergic antagonist.
Butcher, P; Hemlin, M; Sjövall, H, 1988
)
0.5
" Significant intersubject variability in the pharmacokinetic parameters of yohimbine was observed, with some individuals exhibiting greatly increased oral bioavailability of yohimbine."( Effects of yohimbine on autonomic measures are determined by individual values for area under the concentration-time curve.
Grasing, K; Kulkarni, GD; Maines, P; Rosen, RC; Seibold, JR; Sturgill, MG; Thomas, TJ; Trout, JR, 1996
)
0.91
") oral absolute bioavailability of YO was 22."( Biopharmaceutics and metabolism of yohimbine in humans.
Chevanne, F; Dollo, G; Le Corre, P; Le Verge, R, 1999
)
0.58
"The monoamine theory of depression proposes decreased bioavailability of monoamines, such as norepinephrine (NE), as the underlying cause of depression."( An antidepressant mechanism of desipramine is to decrease tumor necrosis factor-alpha production culminating in increases in noradrenergic neurotransmission.
Ignatowski, TA; Reynolds, JL; Spengler, RN; Sud, R, 2005
)
0.33
" Local BH(4) supplementation augments reflex and tyramine-induced VC in aged skin, suggesting that reduced BH(4) bioavailability may contribute to attenuated VC during whole-body cooling."( Local tetrahydrobiopterin administration augments cutaneous vasoconstriction in aged humans.
Holowatz, LA; Kenney, WL; Lang, JA, 2009
)
0.35
", ip) indicate that the liver is the primary site of biotransformation of the compound, suggesting that both 22a and its metabolite(s) are active, compensating probably low bioavailability of the parent molecule."( Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.
Bednarski, M; Gunia-Krzyżak, A; Marona, H; Nitek, W; Pękala, E; Powroźnik, B; Słoczyńska, K; Walczak, M; Waszkielewicz, AM; Żesławska, E, 2016
)
0.43
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

The alpha-sympatholytic drug yohimbine (1 mg/kg) displaced both dose-response curves to the right, but the effect was greatest for guanfacine. In rat mesenteric artery, the pA2 value for yohimbine against clonidine was not statistically different from values obtained with the other agonists.

ExcerptRelevanceReference
" 2 The alpha-adrenoceptor blockers thus caused a shift to the right and an increase of the maximum height of log dose-response curves of alpha-adrenoceptor stimulants."( Dual effect of alpha-adrenoceptor antagonists in rat isolated vas deferens.
Jurkiewicz, A; Jurkiewicz, NH, 1976
)
0.26
" Presynaptic alpha-adrenoceptor antagonist activity was assessed by studying the effects of increasing concentrations of the antagonists on cumulative clonidine dose-response curves on the stimulated vas deferens."( Selectivity of blocking agents for pre-and postsynaptic alpha-adrenoceptors.
Doxey, JC; Smith, CF; Walker, JM, 1977
)
0.26
" The dose-response curve for dopamine was not affected by the antagonists pimozide (10(-6) M), yohimbine (10(-5) M) pindolol (3 x 10(-8) M) and phentolamine (10(-6) M) when these agents were given separately."( No evidence for involvement of dopaminergic receptors in the positive inotropic action of dopamine on the isolated rabbit papillary muscle.
Brodde, OE; Motomura, S; Schümann, HJ, 1978
)
0.48
" The alpha-sympatholytic drug yohimbine (1 mg/kg) displaced both dose-response curves to the right, but the effect was greatest for guanfacine."( Possible subdivision of postsynaptic alpha-adrenoceptors mediating pressor responses in the pithed rat.
Kwa, HY; Timmermans, PB; van Zwieten, PA, 1979
)
0.55
" The patients who were kept on their individually adjusted oral digitoxin maintenance dosage received the three preparations in a randomised order."( [Gycoside serum concentrations under maintenance therapy with Lanicor, Card-Lamuran, MF708d, and Lanitop (author's transl)].
Glocke, M; Olcay, A; Teufel, W; Weiss, W, 1975
)
0.25
" For all bones the first dose-response curve was produced under control conditions."( The effect of hypothermic ischemia on the alpha-adrenergic mechanisms of the canine tibia vascular bed.
Davis, TR; Vanhoutte, PM; Wood, MB, 1992
)
0.28
" The alpha 2-blocking agent yohimbine shifted the dose-response curve of the contractile response to the alpha 2-agonist, clonidine, in a dose-dependent manner, 10(-7) M causing a 10 fold shift."( The contribution of alpha-adrenoceptors to neurally-mediated contractions of the rabbit urethral smooth muscle.
Brading, AF; Chen, HI, 1992
)
0.58
" Head-up tilts in these rats did not produce orthostatic hypotension when performed either prior to or after acute dosing of prazosin (0."( Orthostatic hypotension occurs following alpha 2-adrenoceptor blockade in chronic prazosin-pretreated conscious spontaneously hypertensive rats.
Brune, ME; DeBernardis, JF; Lee, JY; Warner, RB, 1992
)
0.28
" Pretreatment with the alpha 2 antagonist rauwolscine caused a 1 to 2 log unit right shift in the dose-response curve of UK in the CNM."( Pharmacological evidence for heterogeneity of ocular alpha 2 adrenoceptors.
Crosson, CE; DeVries, GW; Heath, AR; Potter, DE, 1992
)
0.28
" We have used dose-response curves to quantitate the potentiation of adenosine 5'-diphosphate (ADP)-induced aggregation and thromboxane (TXA2) generation by 5-hydroxytryptamine (5-HT) and adrenaline in human citrated platelet-rich plasma."( Potentiation of ADP-induced aggregation in human platelet-rich plasma by 5-hydroxytryptamine and adrenaline.
Bochner, F; Duncan, EM; Lloyd, JV; Rodgers, SE; Vanags, DM, 1992
)
0.28
" Further investigations need to be done to establish the most appropriate dosage rates for these preparations in ostriches."( Ostrich (Struthio camelus) immobilisation using carfentanil and xylazine and reversal with yohimbine and naltrexone.
Malan, JH; Quandt, SK; Raath, JP, 1992
)
0.5
" Yohimbine scores correlated closely with baseline levels; there was no dose-response relationship."( Dose-response effects of oral yohimbine in unrestrained primates.
Bassoff, T; Coplan, JD; Friedman, S; Rosenblum, LA, 1991
)
1.48
" (d) Yohimbine, but not prazosin, suppressed the noradrenaline dose-response curve for prostaglandin production."( Noradrenaline-induced prostaglandin production by sympathetic postganglionic neurons is mediated by alpha 2-adrenergic receptors.
Goldyne, ME; Gonzales, R; Levine, JD; Sherbourne, CD, 1991
)
0.8
" Since the behavioural effects of B-HT 920 vary according to the dosage employed, discussion centres on what receptors might conceivably underly these effects and on their preclinical relevance."( Effects of B-HT 920 in the tail-suspension test.
Cassinadri, M; Ferrari, F; Tampieri, A; Tartoni, PL, 1991
)
0.28
" The dorsal hand vein technique was used because it permits complete dose-response studies of venous constriction without confounding reflex alterations."( In vivo studies on alpha-adrenergic receptor subtypes in human veins.
Blöchl-Daum, B; Eichler, HG; Korn, A; Schmidt, E; Wolzt, M, 1991
)
0.28
" A norepinephrine dose-response curve was obtained by using incremental single bolus doses."( Antagonist drugs and bone vascular smooth muscle.
Dean, MT; Vanhoutte, PM; Wood, MB, 1992
)
0.28
" This study also indicates that the effects of yohimbine on male genital responses vary with its dosage used."( Biphasic effects of yohimbine on the ejaculatory response in the dog.
Ando, R; Kawamura, S; Kimura, Y; Nobunaga, T; Tadano, T; Yonezawa, A, 1991
)
0.86
" Dose-response lines in response to the two agonists, expressed as percent maximal contraction, did not differ among the groups."( Muscarinic-receptor functioning in tracheas from normal and ovalbumin-sensitive guinea pigs.
Biggs, DF; Yang, ZJ, 1991
)
0.28
" The enhanced attenuation of responses to noxious colorectal distension produced by the coadministration of these drugs is evidenced by significant leftward shifts in the dose-response curves as compared to those of each drug alone and by isobolographic analysis."( Intrathecal coadministration of clonidine with serotonin receptor agonists produces supra-additive visceral antinociception in the rat.
Danzebrink, RM; Gebhart, GF, 1991
)
0.28
"The dose-response effects of hexamethonium, prazosin and rauwolscine - a ganglionic blocker, alpha 1- and alpha 2-adrenoceptor antagonists, respectively - on mean arterial pressure (MAP) and mean circulatory filling pressure (MCFP), an index of body venous tone, were examined in conscious and unrestrained rats."( Effects of alpha 1- and alpha 2-adrenoceptor antagonists on venous tone in conscious rats.
D'Oyley, HM; Pang, CC, 1990
)
0.28
" When YOH was used as an anesthetic antagonist at dosage of 20 mg/kg, 20% mortality was observed and was attributable to acute respiratory arrest."( Antagonism of ketamine-xylazine anesthesia in rats by administration of yohimbine, tolazoline, or 4-aminopyridine.
Komulainen, A; Olson, ME, 1991
)
0.51
" Although yohimbine is rapidly absorbed when given orally, the bioavailability is quite variable and considerable individualization of dosing may be necessary when the drug is used orally for clinical indications."( Yohimbine bioavailability in humans.
Grunhaus, LJ; Guthrie, SK; Hariharan, M, 1990
)
2.12
" In 5- and 10-day-old animals, prenalterol treatment produced minimal stimulation of PRA and the dose-response curve was essentially flat."( Effects of sympathetic activation on plasma renin activity in the developing rat.
Johnson, AK; Kirby, RF, 1990
)
0.28
" Chloroethylclonidine (1-5 X 10(-5) M) shifted noradrenaline dose-response curve to the right approximately 5000-fold without depressing the maximum."( Chloroethylclonidine unmasks a non-alpha-adrenoceptor noradrenaline binding site in the rat aorta.
Bevan, JA; Oriowo, MA, 1990
)
0.28
" Pretreatment with the same dose of yohimbine or idazoxan shifted the rilmenidine dose-response curves for its hypotensive and bradycardic effects to the right."( Evidence for the involvement of imidazoline receptors in the central hypotensive effect of rilmenidine in the rabbit.
Belcourt, A; Bousquet, P; Bricca, G; Dontenwill, M; Feldman, J; Tibiriça, E, 1990
)
0.55
" Cumulative dose-response curves of the alpha 1-agonists l-phenylephrine or cirazoline applied luminally in rat tail arteries and in side branches of canine femoral arteries were identical to those obtained by adventitial application in the intact arteries, and were not modified by removal of the endothelium (eliminating acetylcholine-induced dilations)."( Endothelium-mediated dilations contribute to the polarity of the arterial wall in vasomotion induced by alpha 2-adrenergic agonists.
Busse, R; Holtz, J; Kuon, E; Matsuda, H,
)
0.13
"In pithed rats two recently-introduced beta-blockers, nipradilol and arotinolol, as well as labetalol shifted the pressor dose-response curve for phenylephrine to the right."( Alpha-blockade and vasodilatation induced by nipradilol, arotinolol and labetalol in pithed rats.
Chin, WP; Imai, S; Nakagawa, Y; Nakahara, H, 1985
)
0.27
" At 6 h post DE, there were no differences between the dose-response curves obtained from aortic rings with or without endothelium."( Effect of endothelium removal on stimulatory and inhibitory modulation of rat aortic prostacyclin synthesis.
Dandona, P; Jeremy, JY, 1989
)
0.28
" Dose-response curves for phenylephrine and norepinephrine were constructed by plotting the change in mean arterial pressure following a bolus dose of the agent against the dose of the pressor agent used."( Ethanol exhibits alpha receptor blocking-like properties in anesthetized rats.
Abdel-Rahman, AA; Russ, RD; Wooles, WR, 1989
)
0.28
"25 mg, in 8 normal subjects before and after treatment with the selective alpha-2 adrenoceptor antagonist, yohimbine, at a maximal dosage of 60 mg daily."( Yohimbine and aldosterone responsiveness to angiotensin II or corticotrophin in normal subjects.
Beretta-Piccoli, C; Kressebuch, H; Lucchini, E, 1989
)
1.93
" Dose-response curves to 5-bromo-6-(2-imidazoline-2-yl-amino)quinoxaline (UK 14,304) an alpha-2 adrenergic agonist, were generated in the absence and presence of three concentrations of various antagonists."( Alpha-2A and alpha-2B adrenergic receptor subtypes: attenuation of cyclic AMP production in cell lines containing only one receptor subtype.
Bylund, DB; Ray-Prenger, C, 1989
)
0.28
" Furthermore, the vasodilator responses in patients with heart failure were similar to the normal subjects in terms of the percent increase in forearm blood flow, the dose-response relation, and the fractional response to hyperemia and phentolamine; thus, alpha 2-receptor-mediated vasoconstriction is neither enhanced nor down-regulated in heart failure."( Alpha 2-receptor-mediated vasoconstriction in patients with congestive heart failure.
Cohn, JN; Heifetz, SM; Kubo, SH; Rector, TS, 1989
)
0.28
" Yohimbine caused about a 30 fold shift to the right in the dose-response curve whereas idazoxan almost completely abolished the mydriatic response to (+)-Amp."( Mechanism of dexamphetamine-induced mydriasis in the anaesthetized rat.
Hey, JA; Ito, T; Koss, MC, 1989
)
1.19
" Dose-response curves were generated for epinephrine, and were then repeated in the presence of either prazosin (alpha 1 antagonist), yohimbine (alpha 2 antagonist) or SK&F-86466 (alpha 2 antagonist)."( An in vivo evaluation of alpha adrenergic receptors in canine prostate.
Chernesky, CE; Chou, TC; Felsen, D; Marion, DN; Somers, WJ; Vaughan, ED, 1989
)
0.48
" Using a dosage of 3-5 mg/kg there is a marked negative effect on the cardio-vascular system."( [The antagonism of ketamine/xylazine anesthesia ("Hellabrunn mixture") in wild zoo ruminants].
Erhardt, W; Hafner, S; Halm, S; von Hegel, G; Wiesner, H, 1989
)
0.28
" Dose-response curves (DRCs) were obtained in the absence and cumulative presence of propranolol (PROP; beta-antagonist), corynanthine (CORY; alpha 1-antagonist) and idazoxan (IDX; alpha 2-antagonist) to estimate effective dosages (ED) required for 15 and 75% peak reductions in renal blood flow."( Unmasking sensitive alpha 2-adrenoceptor-mediated renal vasoconstriction in conscious rats.
Colindres, RE; Strandhoy, JW; Wolff, DW, 1989
)
0.28
" IBI at 10(-6) M shifted the dose-response curve of phenylephrine to the right with reduction in maxima."( Paradoxical effects of isothiocyanate analog of tolazoline on rat aorta and human platelets.
Feller, DR; Hamada, A; Miller, DD; Patil, PN; Shams, G; Venkataraman, BV, 1989
)
0.28
" In particular, a 3-bromo-5-isoxazolecarbonyl derivative, selected for further in vivo investigation, was provided with as high antihypertensive action as prazosin in spontaneously hypertensive rats (SHR) coupled to a shallow dose-response curve by oral route."( New isoxazole derivatives provided with antihypertensive activity.
Carenzi, A; Chiarino, D; Napoletano, M; Reggiani, A; Sala, A; Sala, R, 1989
)
0.28
" The inactivation of a small receptor fraction shifted the dose-response curves for isoprenaline and clonidine to the right but did not alter the maximum effect of the agonists (responsiveness)."( Adrenoceptor occupancy in isolated human fat cells and its relationship with lipolysis rate.
Arner, P; Engfeldt, P; Hellmér, J; Ostman, J; Wennlund, A, 1988
)
0.27
" Clonidine treatment produced a dosage related increase in amplitude of both components similar to that produced by chlordimeform (W."( An alpha 2-adrenergic mode of action of chlordimeform on rat visual function.
Boyes, WK; Moser, VC, 1988
)
0.27
" However, dose-response curves for SHR characteristically displayed a depression of the maximum response as compared with those for WKY."( Renal alpha 1-adrenergic receptor response coupling in spontaneously hypertensive rats.
Jeffries, WB; Pettinger, WA; Yang, E, 1988
)
0.27
" The inhibition, which was dose and time dependent, was characterized by progressive shift to the right in the norepinephrine dose-response curve."( Alkylation of alpha-1 receptors with a chemically reactive analog of prazosin reveals low affinity sites for norepinephrine in rabbit aorta.
Babich, M; Butler, BT; Kusiak, JW; Le, HT; Piascik, MT; Pitha, J, 1988
)
0.27
" In the presence of Ang II, the NE dose-response curve shifted to the left twofold and the maximal response was not changed."( Angiotensin II amplification of alpha-adrenergic vasoconstriction: role of receptor reserve.
Purdy, RE; Weber, MA, 1988
)
0.27
" Furthermore, the hormone caused a dose-dependent maximum 10-fold shift to the right of the dose-response curve for isoprenaline-induced lipolysis without changing the amplitude of the curve."( Effects of insulin on adrenoceptor binding and the rate of catecholamine-induced lipolysis in isolated human fat cells.
Arner, P; Engfeldt, P; Hellmér, J; Wahrenberg, H, 1988
)
0.27
" The dose-response relationship between renal alpha-2 adrenoceptor stimulation (clonidine) and water and electrolyte excretion was evaluated in anesthetized rats."( Dose selective dissociation of water and solute excretion after renal alpha-2 adrenoceptor stimulation.
Blandford, DE; Smyth, DD, 1988
)
0.27
"The effect of nifedipine on pressor dose-response curves to phenylephrine, alpha-methylnoradrenaline and angiotensin II was determined in anaesthetized cats pretreated with propranolol and atropine."( Lack of differential inhibition by nifedipine of pressor responses induced by alpha 1- and alpha 2-adrenoceptor agonists and by angiotensin II in anaesthetized cats.
Alabaster, VA; Solca, AM, 1985
)
0.27
" Phentolamine effected a partial dose-related inhibition of flow reductions; however, prazosin and yohimbine, given separately or in combination, failed to produce any significant effect despite an alpha-blocking action equivalent to or greater than that of phentolamine (alpha-agonist dose-response studies)."( Influence of alpha-adrenergic blockade on platelet-mediated thrombosis in stenosed canine coronary arteries.
Bolli, R; Brandon, TA; Mace, ML; Weibaecher, DG, 1985
)
0.49
" Methoxamine produced a dose-related increase in uterine activity, prazosin produced a rightward displacement of the dose-response curve of methoxamine reaching the same maximal effect."( Effect of methoxamine on spontaneous motility of the isolated rat uterus.
Esplugues, J; Estañ, L; Morales-Olivas, FJ; Rubio, E, 1985
)
0.27
" Prior saline infusion reduced the hypertensive response to the two higher doses of clonidine by 65 and 70%, and displaced the slope of the dose-response curve downwards, but mannitol had no such effect."( Sodium chloride-induced partial inhibition in vivo of alpha 2-adrenoceptor agonist function.
Biollaz, B; Biollaz, J; Gavras, H; Gavras, I; Kohlmann, O, 1985
)
0.27
" According to published data and past experience, the dosage of xylazine used would be expected to provide 115, 120, and 100 minutes of immobilization in captive moose, mule deer, and white-tailed deer, respectively."( Use of yohimbine and 4-aminopyridine to antagonize xylazine-induced immobilization in North American Cervidae.
Olsen, CD; Renecker, LA, 1985
)
0.72
" The thrombin dose-response relationship was complex and did not have a classic sigmoidal shape, whether the endothelium was functional or not."( Alpha adrenoceptor antagonists selectively reduce thrombin-stimulated contraction in rabbit arteries.
Bevan, JA; Garland, CJ, 1986
)
0.27
" Reserpinization shifted the (-)-norephedrine dose-response curve slightly to the right, indicating that only a minor portion of its activity is due to the release of stored endogenous catecholamines."( Adrenergic receptor subtype activation by (+)-, (-)- and (+/-)-norephedrine in the pithed rat.
Maher, TJ; Moya-Huff, FA, 1987
)
0.27
" Dose-response curves for pressor responses to alpha 2-adrenoceptor agonists were located to the left of those for alpha 1-adrenoceptor agonists."( Evidence for central alpha 2-adrenoceptor-mediated hypertension in freely moving, normotensive rats.
Kawasaki, H; Takasaki, K, 1987
)
0.27
" The responsiveness of central alpha 2-adrenergic receptors was determined by comparing among groups the dose-response curves for the effects of cumulative intracerebroventricular injections of guanabenz (5, 25, and 125 micrograms) on changes in mean arterial pressure, renal sympathetic nerve activity, and urinary sodium excretion."( Sodium responsiveness of central alpha 2-adrenergic receptors in spontaneously hypertensive rats.
DiBona, GF; Jones, S; Koepke, JP, 1988
)
0.27
"1 mg/kg) and of yohimbine (1 mg/kg) on the dose-response curves for cirazoline in the pithed rat, and for phenylephrine in the anaesthetized dog were compared, after various doses of phenoxybenzamine."( Loss of selectivity of so-called selective alpha 1-adrenoceptor agonists after phenoxybenzamine.
Gonçalves, J; Guimarães, S; Nunes, JP; Paiva, MQ, 1988
)
0.62
" Coronary flow resistance increased in a dose-response fashion with a maximum increase of 22."( The differential effects of alpha 2-adrenergic stimulation on the myocardium and coronary vessels in the isolated rat heart.
Fouad-Tarazi, FM; Hirakata, H, 1988
)
0.27
" Further studies demonstrated a rightward shift in the dose-response curves for the inhibition by norepinephrine of cyclic AMP accumulation following pretreatment with increasing phenoxybenzamine concentration."( Alpha 2-adrenergic receptor-mediated regulation of adenylate cyclase in the intact human platelet. Evidence for a receptor reserve.
Ehrlich, YH; Ellis, J; Lenox, RH; Van Riper, D, 1985
)
0.27
" Depletion of CNS monoamines by more than 95% with reserpine (5 mg/kg) and alpha-methyl-para-tyrosine (2 X 300 mg/kg) failed to alter the dose-response relation to clonidine."( Studies on the mechanism of clonidine-induced mydriasis in the rat.
Gherezghiher, T; Hey, JA; Koss, MC, 1985
)
0.27
"In rat isolated perfused tail arteries, dose-response curves were established for the vasopressor effects of phenylephrine (alpha 1-adrenoceptor agonist), clonidine (alpha 1- and alpha 2-adrenoceptor agonist), clonidine in the presence of 10(-7) mol/l prazosin (alpha 2-agonist), and BHT-920 (alpha 2-agonist)."( Investigations into the nature of alpha 2-adrenoceptors in rat tail arteries.
Armsworth, SJ; Chapman, KL; Marwood, JF; Stokes, GS,
)
0.13
"Inhibition of platelet aggregation was observed after 4 days of oral dosing with the calcium antagonists, verapamil (160 mg) or nisoldipine (20 mg) but not following acute dosing."( Effects of verapamil and nisoldipine on human platelets: in vivo and in vitro studies.
Elliott, HL; Jones, CR; Pasanisi, F; Reid, JL, 1985
)
0.27
" 6-hydroxydopamine (2 X 250 micrograms) there was a small increase in alpha 1-adrenoceptor binding sites but a parallel shift to the left in the noradrenaline [3H]inositol phosphate accumulation dose-response curve."( Alpha 1-adrenoceptor-mediated inositol phospholipid hydrolysis in rat cerebral cortex: relationship between receptor occupancy and response and effects of denervation.
Brown, E; Kendall, DA; Nahorski, SR, 1985
)
0.27
" Standardized dose-response curves demonstrated that the injured tissue was increasingly sensitive over time to norepinephrine and that this was more marked at physiologic levels of norepinephrine."( Increased vascular contraction and sensitivity to norepinephrine after endothelial denudation is inhibited by prazosin.
Cole, CW; Hagen, PO; McCann, RL; Mikat, EM; O'Malley, MK; Radic, ZS, 1986
)
0.27
" B-HT 933 did not affect the cumulative dose-response curves of the vas deferens and of MP-LM to noradrenaline (NA) and acetylcholine (Ach) respectively."( Mechanism of action of B-HT 933 (azepexole) in rat vas deferens and guinea-pig ileum.
Brugger, AJ; Vargas, ML, 1985
)
0.27
" The differences observed in the dose-response curves of adenylate cyclase activity to isoproterenol or noradrenaline were prevented in the presence of clonidine (a alpha 2-agonist) or yohimbine (alpha 2-antagonist) respectively."( Occurrence of alpha 2-adrenergic effects on adenylate cyclase activity and (3H)-clonidine specific binding in brown adipose tissue from foetal rats.
Benito, M; Domínguez, MJ; Elliott, K; Fernández, M, 1986
)
0.46
") and prazosin (5 mg orally) induced significant shifts to the right in the blood pressure dose-response curve of norepinephrine."( A clinical approach for the identification of peripheral pre- and post-synaptic alpha-adrenergic receptors.
Magometschnigg, D; Schütz, W, 1986
)
0.27
"1% respectively; the dose-response curve for NE inhibitory action is described."( Quantitative evaluation of alpha- and beta-adrenoceptor modulation of [3H]choline release in guinea pig superior cervical ganglia.
Belluzzi, O; Bonifazzi, C; Perri, V; Travagli, RA, 1987
)
0.27
" Urotensin I diminished the maximum increase in perfusion pressure and shifted the log dose-response curves to the right for all three agonists."( Differential antagonism of alpha-1 and alpha-2 adrenoceptor-mediated pressor responses by urotensin I, a selective mesenteric vasodilator peptide.
Bolt, GR; Itoh, H; Lederis, K; MacCannell, KL, 1987
)
0.27
" Isolated rings (circular preparations) obtained from rat thoracic aortae responded to increasing concentrations of NE with dose-dependent tonic enhancement, not significantly affected by the presence of indomethacin (10(-6)M); whereas, preincubation with phentolamine (10(-6)M), yohimbine (10(-7)M) or prazosin (10(-8)M), shifted significantly to the right points of the positive inotropic dose-response curve for NE."( Possible prostacyclin involvement on disparate tonic responses to "in vitro" norepinephrine in circular and in longitudinal preparations from rat thoracic aorta.
Chaud, M; Franchi, AM; Gimeno, AL; Gimeno, MA, 1987
)
0.45
" For each agent tested in this study, dose-response curves were established."( Micturition in the unanesthetized rat: spinal vs. peripheral pharmacology of the adrenergic system.
Durant, PA; Lucas, PC; Yaksh, TL, 1988
)
0.27
" Yohimbine, but not naloxone, antagonized the antinociceptive effects of clonidine, whereas both yohimbine and naloxone altered the dose-response function for the effects of clonidine on blood pressure."( Intrathecal morphine and clonidine: antinociceptive tolerance and cross-tolerance and effects on blood pressure.
Gebhart, GF; Solomon, RE, 1988
)
1.19
" EEG recordings, psychometric and psychophysiological tests as well as evaluation of pulse, blood pressure and side effects were carried out at 0, 2, 4, 6 and 8 h after the administration of one single dose on day 1 (acute effect), at the 0 h on day 21 (subacute effect) as well as at the 2, 4, 6, and 8 h after one additional superimposed dosage on day 21 (superimposed effect)."( Double-blind, placebo-controlled quantitative EEG and psychometric studies in elderlies on vigilance-promoting effects of an almitrine/raubasine combination (Duxil).
Anderer, P; Grünberger, J; Linzmayer, L; Saletu, B, 1988
)
0.27
" Dose-response experiments indicate that norepinephrine is approximately 10,000 times more potent on a molar basis than carbachol in stimulating antral gastrin release."( Comparison of adrenergic and cholinergic receptor-mediated stimulation of gastrin release from rat antral fragments.
Harty, RF; Maico, DG; McGuigan, JE,
)
0.13
" When this preparation was incubated with morphine for 1 h tolerance developed to the inhibitory effect, since dose-response curves were shifted to the right."( Yohimbine reduces morphine tolerance in guinea-pig ileum.
Alamo, C; Alguacil, LF; Cuenca, E; Santos, C, 1987
)
1.72
" The dose-response curve for morphine (i."( Central and systemic morphine-induced antinociception in mice: contribution of descending serotonergic and noradrenergic pathways.
Wigdor, S; Wilcox, GL, 1987
)
0.27
" The dose-response curve of detomidine was shifted to the right in a parallel manner by the selective alpha 2-antagonist idazoxan."( Effect of detomidine on the release and turnover of noradrenaline in rat brain.
Kaisila, M; MacDonald, E; Virtanen, R, 1986
)
0.27
" Yohimbine injection at postpentobarbital dosing minute 50 reversed the resumed xylazine-induced bradycardia and relieved other signs of respiratory depression associated with xylazine-pentobarbital anesthesia."( Xylazine-pentobarbital anesthesia in dogs and its antagonism by yohimbine.
Hsu, WH, 1985
)
1.42
" Dose-response curves were constructed correlating decreases in renal blood flow with doses of phenylephrine, clonidine, and guanabenz injected as boluses into renal arteries of anesthetized dogs."( Renal alpha 1- and alpha 2-adrenoceptor mediated vasoconstriction in dogs: comparison of phenylephrine, clonidine, and guanabenz.
Buckalew, VM; Strandhoy, JW; Wolff, DW, 1984
)
0.27
" Dose-response curves for the alpha1-adrenoceptor-mediated vasoconstrictor effects of cirazoline were shifted in a rightward direction with no depression of the maximum response by lower does of phenoxybenzamine (0."( Existence of spare alpha 1-adrenoreceptors, but not alpha 2-adrenoreceptors, for respective vasopressor effects of cirazoline and B-HT 933 in the pithed rat.
Ruffolo, RR; Yaden, EL,
)
0.13
" Adrenaline's ability to induce platelet aggregation measured as the concentration required to achieve half maximal aggregation assessed from dose-response curves showed similar interindividual variation."( Human platelet alpha 2-adrenoceptors: relationship between radioligand binding studies and adrenaline-induced aggregation in normal individuals.
Barnett, DB; Pearson, D; Swart, SS; Wood, JK, 1984
)
0.27
" The presynaptic alpha-adrenoceptor antagonist activity of the drugs was quantitatively determined by studying the effect of increasing concentrations on the clonidine dose-response curve in the electrically stimulated vas deferens."( Effects of raubasine stereoisomers on pre- and postsynaptic alpha-adrenoceptors in the rat vas deferens.
Demichel, P; Roquebert, J, 1984
)
0.27
", n = 8) caused dose-dependent shifts to the right of the dose-response curve of intraarterial norepinephrine (NE) infusions."( Sympathetic vasoconstriction sensitive to alpha 2-adrenergic receptor blockade. No evidence for preferential innervation of alpha 1-adrenergic receptors in the canine femoral bed.
Bassenge, E; Elsner, D; Holtz, J; Saeed, M; Sommer, O,
)
0.13
" Then prazosin or yohimbine were administered intra-arterially and dose-response curves repeated."( Renal alpha 1- and alpha 2-adrenoceptor mediated vasoconstriction in dogs.
Buckalew, VM; Strandhoy, JW; Wolff, DW, 1984
)
0.6
" 3 Presynaptic alpha-adrenoceptor antagonist activity was assessed by studying the effect of increasing antagonist concentrations on cumulative clonidine dose-response curves on the stimulated vas deferens."( Pre- and postsynaptic alpha-adrenoceptor blocking activity of raubasine in the rat vas deferens.
Demichel, P; Gomond, P; Roquebert, J, 1981
)
0.26
" Cumulative dose-response curves with noradrenaline as the agonist, were made using isolated thoracic aorta and vas deferens of rat kept in a Krebs solution."( [Antinoradrenergic activity of raubasine on isolated thoracic aorta and vas deferens of rat (author's transl)].
Demichel, P; Gomond, P; Roquebert, J,
)
0.13
" The dose-response curve to guanfacine for increase in blood pressure was shifted in a parallel fashion to the right by 1 mg/kg of yohimbine, an alpha 2-antagonist and by 1 mg/kg of phentolamine, a nonselective alpha 1- and alpha 2-antagonist."( [Effects of guanfacine on pre- and postsynaptic alpha-adrenoceptors studied in comparison with those of clonidine].
Chin, W; Imai, S; Nakagawa, Y, 1982
)
0.47
"Twenty-four crossbred steers (4 groups of 6 steers each) were injected IM with a standard dosage range of xylazine hydrochloride (0."( Antagonism of xylazine sedation by 4-aminopyridine and yohimbine in cattle.
Booth, NH; Hatch, RC; Kitzman, JV; Wallner, B, 1982
)
0.51
"0 mg/kg) resulted in a 3-10-fold shift to the right in the clonidine dose-response curve."( Effects of clonidine on operant behavior and electric shock titration in the squirrel monkey: effects of alpha 2-adrenoreceptor antagonism.
McKearney, JW, 1983
)
0.27
"beta-Blocked pithed rats were used to obtained dose-response curves (blood-pressure increase) for 13 various alpha-adrenoceptor agonists of clinical and theoretical interest, in the absence and in the presence of the selective antagonists rauwolscine (alpha 2) and prazosin (alpha 1)."( alpha 1/alpha 2 Selectivity ratio in a series of agonists and their relation to pre/postsynaptic activity ratios.
Kobinger, W; Pichler, L, 1983
)
0.27
" These alpha 2-agonists also inhibited the uptake of 45Ca evoked by carbachol with similar dose-response curve to inhibition of catecholamine secretion."( Inhibition by alpha 2-adrenoceptor agonists of the secretion of catecholamines from isolated adrenal medullary cells.
Izumi, F; Kobayashi, H; Sakurai, S; Wada, A; Yanagihara, N, 1983
)
0.27
" The dose-response relationships for the effects of alpha 2-adrenoceptor antagonists on retinal TH activity were similar to those for the effects on brain noradrenergic neurons, where alpha 2-adrenoceptors have been shown to be involved in the autoregulation of neuronal activity."( Alpha 2-adrenergic receptors influence tyrosine hydroxylase activity in retinal dopamine neurons.
Iuvone, PM; Rauch, AL, 1983
)
0.27
" In all these data indicate that in the dog: 1) CLON induces GH release via activation of alpha 2-adrenergic receptors; 2) these receptors are likely located on presynaptic sites [experiments with reserpine (1), DU-18288, mianserin, dose-response curve with CLON 2-32/micrograms/kg iv]; 3) the adrenergic receptors involved in GH release exhibit supersensitivity upon (YOH-induced) chronic pharmacologic denervation."( Presynaptic alpha 2 -adrenergic stimulation leads to growth hormone release in the dog.
Cella, SG; Mantegazza, P; Morgese, M; Müller, EE; Picotti, GB, 1984
)
0.27
" Rauwolscine, RX 781094 and RS 21361 caused rightward parallel displacements of the log dose-response curve to the increase in diastolic pressure of methoxamine (alpha-1 agonist) and B-HT 920 (alpha-2 agonist) as well as to the B-HT 920-induced reduction in stimulation-evoked tachycardia."( A study of the selectivity and potency of rauwolscine, RX 781094 and RS 21361 as antagonists of alpha-1 and alpha-2 adrenoceptors.
Qian, JQ; Ruffolo, RR; Timmermans, PB; van Zwieten, PA, 1984
)
0.27
"6 mg/kg) shifted the norepinephrine pressor dose-response curve to the right but were ineffective in alpha 2-blocked animals."( Interference of calcium entry blockade in vivo with pressor responses to alpha-adrenergic stimulation: effects of two unrelated blockers on responses to both exogenous and endogenously released norepinephrine.
Pedrinelli, R; Tarazi, RC, 1984
)
0.27
" Shifts in the (-)-noradrenaline dose-response curve produced by BE2254 and prazosin were parallel and there was no significant effect on the observed maximal response."( Competitive antagonism of alpha 1-adrenoceptor mediated pressor responses in the rat mesenteric artery.
Coupar, IM; McPherson, GA; Taylor, DA, 1984
)
0.27
" In response to infusions of the relatively selective alpha 2-adrenoceptor agonist alpha-methylnorepinephrine, the pressor dose-response curve shifted to the right with idazoxan."( The alpha adrenoceptor antagonist properties of idazoxan in normal subjects.
Elliott, HL; Jones, CR; Lawrie, CB; Reid, JL; Vincent, J, 1984
)
0.27
" The dose-response curve for alpha-methylnorepinephrine in the presence of prazosin, using Hofstee's plots, revealed alpha 1- and alpha 2-adrenoceptors, respective proportions being 80."( Postjunctional alpha-adrenoceptors. Alpha 1 and alpha 2 subtypes in rat vasculature in vitro and in vivo.
Decker, N; Ehrhardt, JD; Leclerc, G; Schwartz, J, 1984
)
0.27
" Prazosin (10(-8) M-10(-6) M, alpha 1-adrenoceptor antagonist) produced a rightward shift of the phenylephrine and clonidine dose-response curve in both the trigone and urethra."( Alpha 1- and alpha 2-adrenoceptors in the smooth muscle of isolated rabbit urinary bladder and urethra.
Satake, N; Shibata, S; Ueda, S, 1984
)
0.27
" At that dosage level, Duxil may therefore be considered an active treatment of hypoxia associated with old age."( [Effects of 5023 SE on PaO2 at rest in elderly patients with cerebral impairment. A double-blind cross-over trial versus placebo].
Memin, Y, 1983
)
0.27
" For MES testing, mice were injected with either reserpine, yohimbine, propranolol, haloperidol or metergoline prior to dosing with TET."( Pharmacological and biochemical evaluation of triethyltin's anticonvulsant effects.
Fox, DA,
)
0.37
" In the presence of YOH, the ISO dose-response curve therefore completely disappears."( Lipolysis in rat adipose tissue in vitro and its alpha 2 adrenergic control.
Horný, I; Kadrabová, M; Mühlbachová, E; Zámostný, V, 1983
)
0.27
" Higher concentrations of yohimbine (above 2 microM) and phentolamine (above 20 microM) failed to produce a further shift in the dose-response curves of these agonists."( Pharmacological evidence for high affinity and low affinity a2-adrenoceptor binding sites in rat vas deferens.
Mottram, DR, 1983
)
0.57
" Preincubation of rat aortic strips with both derivatives produced non-parallel rightward shifts in the dose-response curves of noradrenaline and significantly depressed the maximum response in a manner characteristic of irreversible receptor antagonists."( Study of two alkylating derivatives: the p-isothiocyanato- and the p-methylisothiocyanato-clonidine.
Decker, N; Leclerc, G; Quennedey, MC; Rouot, B; Schwartz, J, 1983
)
0.27
" Prazosin caused a parallel shift to the right of the dose-response curve to phenylephrine, and not to clonidine in the vessels."( [Characteristics of alpha adrenoceptors of lymphatics and their physiological significance].
Azuma, T; Ohhashi, T, 1983
)
0.27
" In rat mesenteric artery, the pA2 value for yohimbine against clonidine was not statistically different from values obtained with the other agonists; however, in the presence of prazosin the dose-response curve to clonidine was biphasic, suggesting that the action of clonidine is mediated through two distinct sites to which prazosin has different affinities."( Pharmacological characterization of the postsynaptic alpha adrenoceptors in vascular smooth muscle from canine and rat mesenteric vascular beds.
Agrawal, DK; Daniel, EE; Triggle, CR, 1984
)
0.53
" Our data indicate that yohimbine produces a significant reversal of xylazine-induced rumen hypomotility at dosage levels that are without effect on sedation induced by this drug."( Influence of yohimbine on xylazine-induced depression of central nervous, gastrointestinal and cardiovascular function in the calf.
Guard, CL; Schwark, WS, 1984
)
0.94
" The pooled mean dosage level of pentobarbital required for anesthesia was 12."( Meperidine-acepromazine-pentobarbital anesthesia in cats: reversal by 4-aminopyridine and yohimbine.
Booth, NH; Hatch, RC; Zahner, JM, 1984
)
0.49
"Groups of fasted atropinized crossbred dogs of both sexes were injected IM with a standard dosage of a xylazine-acepromazine combination (2."( Acepromazine-xylazine combination in dogs: antagonism with 4-aminopyridine and yohimbine.
Booth, NH; Brown, J; Cronin, MF; Hatch, RC, 1983
)
0.49
" Required dosage of pentobarbital, arousal and walk times (measured from injection of antagonists), respiratory rate, and heart rate were measured."( Comparison of five preanesthetic medicaments in pentobarbital-anesthetized dogs: antagonism by 4-aminopyridine, yohimbine, and naloxone.
Booth, NH; Clark, JD; Hatch, RC; Kitzman, JV, 1983
)
0.48
"0 mg/kg) shifted the clonidine dose-response curves to the right, suggesting competitive antagonism."( An analysis of the effects of systemically administered clonidine on the food and water intake of rats.
Sanger, DJ, 1983
)
0.27
" Intravenous injection of xylazine (1 to 10 mg/kg) induced a dose-dependent CNS depression that was prevented by a low dosage of yohimbine (0."( Effect of yohimbine on xylazine-induced central nervous system depression in dogs.
Hsu, WH, 1983
)
0.87
" Responses to both 5-HT and noradrenaline were monitored isometrically on spiral strips from saphenous arteries and femoral veins removed 24 and 72 h after the last oral dosage of DHE."( Ex vivo studies after oral treatment of the beagle with dihydroergotamine.
Müller-Schweinitzer, E; Rosenthaler, J, 1983
)
0.27
") shifted the dose-response curve for all of the compounds tested to the right."( Analysis of pupillary dilation produced by analogs of clonidine.
Koss, MC, 1981
)
0.26
" Of the subject ratings, next day ratings obtained on the day after dosing resulted in significant correlations whereas same day ratings obtained while subjects were under the influence of triazolam did not."( Reinforcing effects of triazolam in sedative abusers: correlation of drug liking and self-administration measures.
Henningfield, JE; Jaffe, JH; Klein, S; Meisch, RA; Roache, JD; Sampson, A, 1995
)
0.29
"The dose-response curves for a number of alpha-adrenergic drugs were investigated to estimate a possible role of the alpha 2/alpha 1 selectivity of these drugs on the incidence of cortical high voltage spindles (HVS), reflecting level of vigilance."( Some unusual effects of alpha 2-adrenergic drugs on cortical high voltage spindles in rats.
Haapalinna, A; Riekkinen, P; Sirviö, J; Yavich, L, 1994
)
0.29
" Next, we determined norepinephrine dose-response relations before and after prazosin, yohimbine, and benextramine."( Effects of maturation on alpha-adrenergic receptor affinity and occupancy in small cerebral arteries.
Elliott, SR; Pearce, WJ, 1994
)
0.51
" The selective alpha 2-adrenergic antagonist rauwolscine produced rightward shifts of EPI dose-response curves and decreased the basal level of [35-S]GTP gamma S binding across the same range of concentrations."( Determinants of alpha 2-adrenergic receptor activation of G proteins: evidence for a precoupled receptor/G protein state.
Deth, RC; Duzic, E; Lanier, SM; Tian, WN, 1994
)
0.29
" Reversal with yohimbine hydrochloride using a mean dosage of 83 mg/animal resulted in a mean (SD) recovery time of 22."( Postpartum immobilization of adult female moose using xylazine, ketamine and yohimbine hydrochlorides.
Addison, EM; Garner, DL, 1994
)
0.87
" The potentiating action of L-NNA on noradrenaline-induced contractions could also be observed in the presence of yohimbine or rauwolscine, although dose-response curves were shifted to the right."( Involvement of alpha-adrenoceptors in the endothelium-dependent depression of noradrenaline-induced contraction in rat aorta.
Kaneko, K; Sunano, S, 1993
)
0.5
"A standardbred mare was dosed with 40 mg yohimbine intravenously."( A liquid chromatographic procedure for the analysis of yohimbine in equine serum and urine.
Chui, YC; Reimer, G; Suarez, A,
)
0.64
" Animals also received four injections of nicotine to determine whether repetitive dosing leads to progressive reduction of the norepinephrine response."( Detection by in vivo microdialysis of nicotine-induced norepinephrine secretion from the hypothalamic paraventricular nucleus of freely moving rats: dose-dependency and desensitization.
Matta, SG; Sharp, BM, 1993
)
0.29
" Coadministration of clonidine with LSD produced a leftward shift of the dose-response relationship of LSD without a significant change in the slope of the dose-response line."( Complex stimulus properties of LSD: a drug discrimination study with alpha 2-adrenoceptor agonists and antagonists.
Marona-Lewicka, D; Nichols, DE, 1995
)
0.29
" Recovery time varied with weight and dosage of yohimbine."( Immobilization of Rocky Mountain elk with Telazol and xylazine hydrochloride, and antagonism by yohimbine hydrochloride.
Brundige, GC; Hustead, DR; Jenks, JA; Millspaugh, JJ; Tyner, CL, 1995
)
0.76
" The dosage based on experimental studies."( [Clinical investigations of an i.m. combination anesthesia with fentanylclimazolam/xylazine and postoperative i.v. antagonism with naloxone/sarmazenil/yohimbine in guinea pigs].
Brill, T; Erhardt, W; Henke, J; Lendl, C; Matis, U; Otto, K; Roberts, U, 1996
)
0.49
"1-fold leftward shift in the dose-response curve."( Intrathecal Tyr-W-MIF-1 produces potent, naloxone-reversible analgesia modulated by alpha 2-adrenoceptors.
Gergen, KA; Kastin, AJ; Paul, D; Zadina, JE, 1996
)
0.29
" These results are different from those previously obtained in rats, which show bell-shaped dose-response curves in response to alpha 2 adrenoceptor blockers (small doses increased, while large doses decreased aggression)."( The effect of alpha 2 adrenoceptor blockers on aggressive behavior in mice: implications for the actions of adrenoceptor agents.
Haller, J; Kovács, JL; Makara, GB, 1996
)
0.29
" The parallelism of the dose-response curves indicates activation of a common receptor subtype."( alpha-Adrenoceptor and opioid receptor modulation of clonidine-induced antinociception.
Miranda, HF; Naquira, D; Pinardi, G; Sierralta, F, 1996
)
0.29
" Rauwolscine (10 microM) enhanced epinephrine effects, shifting the dose-response curve for epinephrine to the left (EC50 = 120 nM); however, beta-antagonists inhibited epinephrine-induced cAMP accumulation."( Effect of epinephrine on cAMP accumulation in cultured rat inner medullary collecting duct cells.
Jeffries, WB; Umemura, S; Yasuda, G, 1997
)
0.3
" Yohimbine was administered orally in a dosage of 30 mg a day (two 5 mg tablets three times daily) for eight weeks."( Double-blind, placebo-controlled safety and efficacy trial with yohimbine hydrochloride in the treatment of nonorganic erectile dysfunction.
Brandl, P; Gierend, M; Kockott, G; Schadrack, J; Schmitz, JR; Vogt, HJ; Wiegand, MH, 1997
)
1.45
" The antagonists could be divided in two classes: those that displayed surmountable inhibition (right-shift of the agonist dose-response curve), and those that displayed different degrees of insurmountable inhibition (depression of the maximum signal and a possible right-shift of the agonist dose-response curve)."( Different apparent modes of inhibition of alpha2A-adrenoceptor by alpha2-adrenoceptor antagonists.
Akerman, KE; Cockcroft, V; Huifang, G; Jansson, CC; Kukkonen, JP; Savola, JM; Wurster, S, 1997
)
0.3
" The appropriate and usual dosage (2 tablets per day) and the good tolerance of the compound have been confirmed in a French multicentric study in 5,361 outpatients."( Clinical efficacy of almitrine-raubasine. An overview.
Allain, H; Bentué-Ferrer, D, 1998
)
0.3
" In contrast, the alpha2-adrenergic receptor antagonist 10(-7) M yohimbine and the alpha1-adrenergic receptor antagonist 10(-9) and 10(-8) M prazosin caused a significant shift in the dose-response curve."( Alpha1A-adrenergic receptors mediate vasoconstriction of the isolated spiral modiolar artery in vitro.
Dang, H; Gruber, DD; Scofield, MA; Shimozono, M; Wangemann, P, 1998
)
0.54
" Yohimbine pretreatment resulted in a rightward shift of the dose-response curves (DMET > CLON > UK)."( Pharmacological evidence for different alpha 2-adrenergic receptor sites mediating analgesia and sedation in the rat.
Buerkle, H; Yaksh, TL, 1998
)
1.21
" Currently, dose-response investigations are not available, alternative routes of administration (i."( Yohimbine in erectile dysfunction: the facts.
Morales, A, 2000
)
1.75
" The presence of YSL-3S or yohimbine caused a parallel, rightward the dose-response curve of clonidine in a dose-dependent manner, indicating an antagonistic action at the presynaptic alpha2-adrenoceptors."( Pharmacological characterization of (10bS)-1,2,3,5,6,10b-hexahydropyrrolo[2,1-a]isoquinoline oxalate (YSL-3S) as a new alpha2-adrenoceptor antagonist.
Chung, SH; Jin, C; Lee, JY; Lee, YS; Min, BJ; Yook, J, 2000
)
0.6
" Dose-response curves were obtained for the antinociceptive effect of diclofenac, phenylephrine, clonidine, desipramine, prazosin, and yohimbine administered both systemically and intrathecally, and ED(50)s were calculated."( An isobolographic analysis of the adrenergic modulation of diclofenac antinociception.
Miranda, HF; Pinardi, G; Sierralta, F, 2001
)
0.51
" Currently, dose-response investigations are not available, alternative routes of administration (i."( Yohimbine in erectile dysfunction: would an orphan drug ever be properly assessed?
Morales, A, 2001
)
1.75
") caused dose-dependent rightward shift in the pressor dose-response curve induced by B-HT 920."( alpha(2)-adrenoceptor antagonist properties of OPC-28326, a novel selective peripheral vasodilator.
Hashimoto, A; Imaizumi, T; Kambe, T; Kishi, M; Mori, T; Nakazawa, T; Orito, K, 2001
)
0.31
" The effect of huperzine A on memory impairments exhibited an inverted U-shaped dose-response pattern."( Effect of huperzine A on working memory in reserpine- or yohimbine-treated monkeys.
Cai, JX; Ou, LY; Tang, XC, 2001
)
0.56
" In fetal, but not adult, MCA, UK-14304 induced a significant decrease in pD(2) for the phenylephrine dose-response relation."( Pre- and postjunctional alpha(2)-adrenergic receptors in fetal and adult ovine cerebral arteries.
Bishai, JM; Buchholz, JN; Gheorghe, CP; Longo, LD; Meulenaar, R; Nijland, R; Penninga, L; Zhang, L; Zhao, Y, 2002
)
0.31
" AGN192403, a selective ligand at I1-R, had no influence on the dose-response curve of moxonidine (log EC50: -6."( Presynaptic effects of moxonidine in isolated buffer perfused rat hearts: role of imidazoline-1 receptors and alpha2-adrenoceptors.
Burgdorf, C; Engelhardt, A; Kurz, T; Richardt, G; Schäfer, U, 2002
)
0.31
" Administration of both non-selective and selective alpha-adrenoceptor agonists in doses of 1-40 microg noradrenaline kg(-1) body weight (BW), 1-100 microg clonidine kg(-1) BW, or 100-800 mg methoxamine kg(-1) BW enhanced contractions of the proximal cauda epididymidis in a dose-response manner."( Mediation of contraction in rat cauda epididymidis by alpha-adrenoceptors.
Chaturapanich, G; Maythaarttaphong, S; Pholpramool, C; Verawatnapakul, V, 2002
)
0.31
" The mean dosage (0."( Tiletamine-zolazepam, ketamine, and xylazine anesthesia of captive cheetah (Acinonyx jubatus).
Bonar, CJ; Evans, SE; Lewandowski, AH, 2002
)
0.31
" twice, 30 min before each dosing of dopamine."( Dopamine-induced protection against indomethacin-evoked intestinal lesions in rats--role of anti-intestinal motility mediated by D2 receptors.
Kato, S; Matsumoto, M; Miyazawa, T; Takeuchi, K, 2003
)
0.32
" Morphine exhibited a bell-shaped dose-response curve in Lewis rats, these animals being more sensitive than F344 at 1 and 5 mg/kg but less sensitive at 10 mg/kg."( The contribution of alpha2-adrenoceptor and opioid receptor mechanisms to antinociception differs in Lewis and Fischer 344 rats.
Alguacil, LF; Herradón, G; Morales, L; Pérez-García, C, 2003
)
0.32
" Dose-response curves were established for the noradrenaline-induced (10(-12) to 10(-7) mol/kg) increase of diastolic blood pressure in pithed rats treated with tubocurarine, propranolol, and atropine."( Reduction of vascular noradrenaline sensitivity by AT1 antagonists depends on functional sympathetic innervation.
Dendorfer, A; Dominiak, P; Raasch, W; Ziegler, A, 2004
)
0.32
" Dose-response curves for the inhibitory effect of clonidine showed subsensitivity of alpha2-adrenergic autoreceptors in protein-deprived rats, a phenomenon reversed by fluoxetine treatment."( Locus coeruleus activity in perinatally protein-deprived rats: effects of fluoxetine administration.
Cuadra, GR; Orsingher, OA; Ramírez, OA; Sodero, AO; Valdomero, A, 2004
)
0.32
" A fixed ratio of 1 mg CAR:10 mg XYL intramuscularly was used, increasing or decreasing the dosage until the optimal dosage (defined by an induction time < 3 min and PaCO(2)< 60 mmHg) was reached for each animal."( Determination and evaluation of an optimal dosage of carfentanil and xylazine for the immobilization of white-tailed deer (Odocoileus virginianus).
Miller, KV; Osborn, DA; Ramsay, EC; Schumacher, J; Storms, TN; Zagaya, N, 2005
)
0.33
" In the abdominal constriction test, LXM-10 had a significant dose-response effect, and the maximal inhibition ratio was 79."( Antinociceptive effects of the novel spirocyclopiperazinium salt compound LXM-10 in mice.
Li, CL; Li, RT; Sun, Q; Ye, J; Yue, CQ, 2007
)
0.34
" At 10(-7) M of ST-91, the antagonism was characterized by a rightward shift of isoproterenol dose-response curve (A50=6."( alpha2B-adrenoceptor agonist ST-91 antagonizes beta2-adrenoceptor-mediated relaxation in rat mesenteric artery rings.
Gyires, K; Kató, E; Lipták, L; Mátyus, P; Rónai, AZ; Shujaa, N, 2008
)
0.35
" The dose-response effect as studied by platelet aggregometry showed that the required molar concentration to block the interactive effect in the case of YH was less than that of MRS2179."( Platelet responsiveness to yohimbine hydrochloride and MRS2179 in the context of the interaction between collagen and epinephrine in acute coronary syndrome.
Chakrabarti, P; Chaudhuri, U; Dasgupta, AK; Deb, S; Guha, P; Guha, S; Lahiri, P; Roy, S; Sardar, P,
)
0.43
") enhanced the ascending (3 mgxkg(-1)) and descending (30 mgxkg(-1)) portions of buprenorphine's dose-response curve, but only spinal, not supraspinal, nociceptin (10 nmolxL(-1)) enhanced buprenorphine anti-nociception."( Identification of an additional supraspinal component to the analgesic mechanism of action of buprenorphine.
Ding, Z; Raffa, RB, 2009
)
0.35
" Dose-response curves of tapentadol (intravenous) were determined in combination with vehicle or a fixed dose (intraperitoneal) of the mu-opioid receptor antagonist naloxone (1mg/kg), the alpha2-adrenoceptor antagonist yohimbine (2."( Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain.
Christoph, T; Jahnel, U; Schröder, W; Tzschentke, TM; Vry, JD, 2010
)
0.55
" These data do not support the initial findings of exposure-enhancing effects of YOH in this dosage in clinical populations."( Does yohimbine hydrochloride facilitate fear extinction in virtual reality treatment of fear of flying? A randomized placebo-controlled trial.
Emmelkamp, PM; Meyerbroeker, K; Powers, MB; van Stegeren, A, 2012
)
0.89
" There is level 5 evidence (expert opinion) that combination therapy of PDE5 inhibitors + L-arginine or daily dosing of tadalafil + short-acting PDE5 inhibitors pro re nata may rescue PDE5 inhibitor monotherapy failures."( SOP conservative (medical and mechanical) treatment of erectile dysfunction.
Brock, G; Burnett, A; Ghanem, H; Giuliano, F; Glina, S; Hellstrom, W; Martin-Morales, A; Porst, H; Salonia, A; Sharlip, I, 2013
)
0.39
"083 mg/infusion) of cocaine, but the sensitivity to cocaine reinforcement, assessed using a dose-response analysis, was not altered in isolated rats."( Disrupted social development enhances the motivation for cocaine in rats.
Baarendse, PJ; Limpens, JH; Vanderschuren, LJ, 2014
)
0.4
" Our findings suggest that recurrent YOH administration may prove a useful and reliable model for simulating recurrent stress/anxiety, and that enhancements to the paradigm such as higher or more frequent dosing of YOH could yield stronger or more extensive behavioral effects."( Effect of recurrent yohimbine on immediate and post-hoc behaviors, stress hormones, and energy homeostatic parameters.
Figlewicz, DP; Hill, SR; Jay, JL; Sipols, AJ; West, CH; Zavosh, AS, 2014
)
0.73
" SP600125 (a c-Jun NH2-terminal kinase [JNK] inhibitor) dose-response curves were generated in aortas that were pre-contracted with DMT or phorbol 12,13-dibutyrate (PDBu), a protein kinase C (PKC) activator."( Dexmedetomidine-induced contraction involves phosphorylation of caldesmon by JNK in endothelium-denuded rat aortas.
Baik, J; Cho, H; Choi, MJ; Kim, W; Lee, HK; Nam, IK; Ok, SH; Sohn, JT; Yu, J, 2014
)
0.4
" Les chats dans les autres groupes reçurent de la xylazine par voie intramusculaire à un dosage de 2 mg/kg de poids corporel (PC), et de la saline (comme témoin); 160 μg/kg PC de prazosin; ou 40, 160, ou 480 μg/kg PC d’atipamezole ou de yohimbine par voie intraveineuse 0,5 h plus tard."( Antagonistic effects of atipamezole, yohimbine, and prazosin on xylazine-induced diuresis in clinically normal cats.
Hikasa, Y; Miki, Y; Murahata, Y, 2014
)
0.86
" Although atipamezole and yohimbine dosing guidelines are available for mice, no controlled comparison has been performed to guide the lab animal community in the selection of one over the other."( Comparison of Atipamezole with Yohimbine for Antagonism of Xylazine in Mice Anesthetized with Ketamine and Xylazine.
Janssen, CF; Kracinovsky, KB; Maiello, P; Newsome, JT; Wright, MJ, 2017
)
1.04
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (2 Product(s))

Product Categories

Product CategoryProducts
Active Lifestyle & Fitness2

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved
Nutrex Research LIPO-6® Black -- 60 CapsulesNutrex ResearchActive Lifestyle & FitnessCaffeine Anhydrous, Rauwolscine, Yohimbine2024-11-29 10:47:42
Nutrex Research LIPO-6® Black Hers -- 60 CapsulesNutrex ResearchActive Lifestyle & FitnessCaffeine Anhydrous, Folic Acid, Glycerin, Rauwolscine, Vitamin B12, Yohimbine2024-11-29 10:47:42

Roles (3)

RoleDescription
alpha-adrenergic antagonistAn agent that binds to but does not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous alpha-adrenergic agonists. alpha-Adrenergic antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma.
serotonergic antagonistDrugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or serotonergic agonists.
dopamine receptor D2 antagonistAn antagonist that binds to and deactivates the dopamine receptor D2, the main receptor for all antipsychotic drugs.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
methyl 17-hydroxy-20xi-yohimban-16-carboxylate
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (59)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ClpPBacillus subtilisPotency14.12541.995322.673039.8107AID651965
RAR-related orphan receptor gammaMus musculus (house mouse)Potency8.41270.006038.004119,952.5996AID1159521
Fumarate hydrataseHomo sapiens (human)Potency5.62340.00308.794948.0869AID1347053
TDP1 proteinHomo sapiens (human)Potency9.44110.000811.382244.6684AID686978
regulator of G-protein signaling 4Homo sapiens (human)Potency2.11720.531815.435837.6858AID504845
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency25.63880.001530.607315,848.9004AID1224848; AID1224849; AID1259403
cytochrome P450 2D6Homo sapiens (human)Potency1.73770.00108.379861.1304AID1645840
polyproteinZika virusPotency5.62340.00308.794948.0869AID1347053
arylsulfatase AHomo sapiens (human)Potency2.39341.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency21.19230.035520.977089.1251AID504332
aryl hydrocarbon receptorHomo sapiens (human)Potency17.05050.000723.06741,258.9301AID743085; AID743122
Histone H2A.xCricetulus griseus (Chinese hamster)Potency21.97410.039147.5451146.8240AID1224845
D(1A) dopamine receptorHomo sapiens (human)Potency10.34600.02245.944922.3872AID488982; AID488983
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency22.38720.01789.637444.6684AID588834
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency25.94480.000323.4451159.6830AID743065; AID743067
importin subunit beta-1 isoform 1Homo sapiens (human)Potency112.20205.804836.130665.1308AID540263
serine/threonine-protein kinase mTOR isoform 1Homo sapiens (human)Potency14.68920.00378.618923.2809AID2668
snurportin-1Homo sapiens (human)Potency112.20205.804836.130665.1308AID540263
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency35.48130.425612.059128.1838AID504891
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency31.62280.251215.843239.8107AID504327
Ataxin-2Homo sapiens (human)Potency22.38720.011912.222168.7989AID588378
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Estrogen receptor betaMus musculus (house mouse)Ki0.08400.06500.07770.0840AID221207
Bile salt export pumpHomo sapiens (human)IC50 (µMol)254.00000.11007.190310.0000AID1449628
Alpha-2A adrenergic receptorHomo sapiens (human)IC50 (µMol)0.03530.00001.44217.3470AID255287; AID36188; AID625201; AID751697; AID751901; AID752262
Alpha-2A adrenergic receptorHomo sapiens (human)Ki0.01290.00010.807410.0000AID1581731; AID238495; AID35916; AID35935; AID35945; AID35949; AID36040; AID36181; AID36341; AID36342; AID36343; AID36344; AID36345; AID36346; AID36498; AID36515; AID625201; AID751697; AID751901
Cytochrome P450 2D6Homo sapiens (human)IC50 (µMol)1.02000.00002.015110.0000AID240619; AID625249
Cytochrome P450 2D6Homo sapiens (human)Ki0.35000.00011.19868.0000AID150607; AID238250
DNA topoisomerase 1Homo sapiens (human)IC50 (µMol)30.00000.02101.862610.0000AID402038
D(2) dopamine receptorHomo sapiens (human)IC50 (µMol)2.06000.00000.74728.0000AID625253
D(2) dopamine receptorHomo sapiens (human)Ki0.68700.00000.651810.0000AID625253
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)1.30000.00021.874210.0000AID167198
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)Ki0.38860.00010.949010.0000AID35412; AID36004; AID36010
Alpha-2B adrenergic receptorHomo sapiens (human)IC50 (µMol)0.04280.00001.23808.1590AID255287; AID36188; AID625202; AID751901; AID752262
Alpha-2B adrenergic receptorHomo sapiens (human)Ki0.01460.00020.725710.0000AID1063790; AID1581732; AID238496; AID35916; AID36040; AID36181; AID36220; AID36226; AID36341; AID36342; AID36343; AID36344; AID36345; AID36346; AID36498; AID36515; AID625202; AID751901
Alpha-1A adrenergic receptorBos taurus (cattle)Ki0.00360.00000.50723.7020AID35916
Alpha-2C adrenergic receptorHomo sapiens (human)IC50 (µMol)0.04660.00001.47257.8980AID255287; AID36188; AID625203; AID751901; AID752262
Alpha-2C adrenergic receptorHomo sapiens (human)Ki0.01300.00030.483410.0000AID1152690; AID1196335; AID1581733; AID239677; AID35916; AID36040; AID36181; AID36341; AID36342; AID36343; AID36344; AID36345; AID36346; AID36403; AID36498; AID36515; AID625203; AID751901
Alpha-2A adrenergic receptorSus scrofa (pig)Ki0.00440.00441.37514.1000AID36503
DRattus norvegicus (Norway rat)Ki2.00000.00010.610010.0000AID63016
D(3) dopamine receptorRattus norvegicus (Norway rat)Ki2.14330.00010.25675.8000AID63016; AID65625
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)IC50 (µMol)0.12600.00031.38338.4000AID625190
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)Ki0.04030.00010.739610.0000AID37243; AID625190
Alpha-2B adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.06820.00031.09147.7625AID1336304; AID167201; AID36781; AID566240
Alpha-2B adrenergic receptorRattus norvegicus (Norway rat)Ki0.05610.00000.929610.0000AID221207; AID35187; AID35328; AID35504; AID35624; AID36010; AID36374; AID37240; AID37241; AID37242; AID37243; AID37244; AID37246; AID37381; AID37382
Estrogen receptorMus musculus (house mouse)Ki0.08400.06500.07770.0840AID221207
Alpha-2C adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.06820.00031.09147.7625AID1336304; AID167201; AID36781; AID566240
Alpha-2C adrenergic receptorRattus norvegicus (Norway rat)Ki0.05930.00000.970810.0000AID221207; AID35187; AID35328; AID35504; AID35624; AID36010; AID37240; AID37241; AID37242; AID37243; AID37244; AID37246; AID37381; AID37382
Alpha-2A adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.06820.00031.06917.7625AID1336304; AID167201; AID36781; AID566240
Alpha-2A adrenergic receptorRattus norvegicus (Norway rat)Ki0.05930.00000.937510.0000AID221207; AID35187; AID35328; AID35504; AID35624; AID36010; AID37240; AID37241; AID37242; AID37243; AID37244; AID37246; AID37381; AID37382
Alpha-1D adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)1.30000.00021.270410.0000AID167198
Alpha-1D adrenergic receptorRattus norvegicus (Norway rat)Ki0.22030.00000.575110.0000AID35412; AID35603; AID36004; AID36010
Alpha-1D adrenergic receptorHomo sapiens (human)IC50 (µMol)1.01300.00020.75688.8970AID625200
Alpha-1D adrenergic receptorHomo sapiens (human)Ki0.26290.00000.360910.0000AID35314; AID35328; AID625200
D(1B) dopamine receptorRattus norvegicus (Norway rat)Ki2.00000.00020.24622.0000AID63016
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)IC50 (µMol)0.12600.00051.48357.8000AID625190
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)Ki0.07200.00031.29679.2440AID625190
M-phase inducer phosphatase 1Homo sapiens (human)IC50 (µMol)22.30000.02204.20249.4000AID691261
Alpha-2B adrenergic receptorMus musculus (house mouse)Ki0.02810.00020.10912.1500AID36353; AID36367; AID36368
D(4) dopamine receptorRattus norvegicus (Norway rat)Ki2.00000.00020.18872.0000AID63016
Alpha-1A adrenergic receptorHomo sapiens (human)Ki1.05700.00000.272610.0000AID36600
Alpha-1B adrenergic receptorHomo sapiens (human)Ki0.32480.00000.471310.0000AID37183; AID37213; AID37335
5-hydroxytryptamine receptor 2BHomo sapiens (human)IC50 (µMol)0.07400.00011.18738.9125AID625217
5-hydroxytryptamine receptor 2BHomo sapiens (human)Ki0.04700.00030.769310.0000AID625217
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)1.30000.00001.819410.0000AID167198
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)Ki0.38860.00000.965010.0000AID35412; AID36004; AID36010
5-hydroxytryptamine receptor 6Homo sapiens (human)IC50 (µMol)1.68900.00170.83815.4200AID625221
5-hydroxytryptamine receptor 6Homo sapiens (human)Ki0.78400.00020.522910.0000AID625221
D(2) dopamine receptorRattus norvegicus (Norway rat)Ki2.00000.00000.437510.0000AID63016
Alpha-2C adrenergic receptorMus musculus (house mouse)Ki0.02810.00020.10912.1500AID36353; AID36367; AID36368
Alpha-2A adrenergic receptorMus musculus (house mouse)Ki0.02810.00020.10912.1500AID36353; AID36367; AID36368
Lysosomal alpha-glucosidaseRattus norvegicus (Norway rat)Ki0.00870.00871.09573.5000AID37243
Lysosomal alpha-glucosidaseBos taurus (cattle)Ki0.00870.00870.00870.0087AID37243
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
POsterior SegregationCaenorhabditis elegansEC50 (µMol)300.00002.201047.1808186.6810AID1964
Alpha-2A adrenergic receptorHomo sapiens (human)EC50 (µMol)0.00850.00080.37336.7100AID380498
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)Kd0.55430.00020.52667.5858AID196984; AID35849; AID35866; AID35872; AID36173
Alpha-2B adrenergic receptorRattus norvegicus (Norway rat)Kd0.06340.00020.62779.3325AID196985; AID35363; AID35476
Alpha-2C adrenergic receptorRattus norvegicus (Norway rat)Kd0.06340.00020.62779.3325AID196985; AID35363; AID35476
Alpha-2A adrenergic receptorRattus norvegicus (Norway rat)Kd0.06340.00020.62779.3325AID196985; AID35363; AID35476
Alpha-1D adrenergic receptorRattus norvegicus (Norway rat)Kd0.55430.00020.89627.5858AID196984; AID35849; AID35866; AID35872; AID36173
Sodium-dependent noradrenaline transporter Homo sapiens (human)EC50 (µMol)103.48600.082031.0243168.9080AID1960
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)Kd0.55430.00020.51397.5858AID196984; AID35849; AID35866; AID35872; AID36173
Zinc finger protein mex-5Caenorhabditis elegansEC50 (µMol)103.48600.082033.5679168.9080AID1960
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (279)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
positive regulation of cytokine productionAlpha-2A adrenergic receptorHomo sapiens (human)
DNA replicationAlpha-2A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
Ras protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
Rho protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell population proliferationAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2A adrenergic receptorHomo sapiens (human)
actin cytoskeleton organizationAlpha-2A adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell migrationAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
cellular response to hormone stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2A adrenergic receptorHomo sapiens (human)
vasodilationAlpha-2A adrenergic receptorHomo sapiens (human)
glucose homeostasisAlpha-2A adrenergic receptorHomo sapiens (human)
fear responseAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of potassium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAP kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion-dependent exocytosisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2A adrenergic receptorHomo sapiens (human)
intestinal absorptionAlpha-2A adrenergic receptorHomo sapiens (human)
thermoceptionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of lipid catabolic processAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of membrane protein ectodomain proteolysisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretion involved in cellular response to glucose stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of uterine smooth muscle contractionAlpha-2A adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
phospholipase C-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of wound healingAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transmembrane transporter activityAlpha-2A adrenergic receptorHomo sapiens (human)
xenobiotic metabolic processCytochrome P450 2D6Homo sapiens (human)
steroid metabolic processCytochrome P450 2D6Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2D6Homo sapiens (human)
estrogen metabolic processCytochrome P450 2D6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid catabolic processCytochrome P450 2D6Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2D6Homo sapiens (human)
isoquinoline alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2D6Homo sapiens (human)
retinol metabolic processCytochrome P450 2D6Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2D6Homo sapiens (human)
negative regulation of bindingCytochrome P450 2D6Homo sapiens (human)
oxidative demethylationCytochrome P450 2D6Homo sapiens (human)
negative regulation of cellular organofluorine metabolic processCytochrome P450 2D6Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 2D6Homo sapiens (human)
DNA topological changeDNA topoisomerase 1Homo sapiens (human)
chromatin remodelingDNA topoisomerase 1Homo sapiens (human)
circadian rhythmDNA topoisomerase 1Homo sapiens (human)
response to xenobiotic stimulusDNA topoisomerase 1Homo sapiens (human)
programmed cell deathDNA topoisomerase 1Homo sapiens (human)
phosphorylationDNA topoisomerase 1Homo sapiens (human)
peptidyl-serine phosphorylationDNA topoisomerase 1Homo sapiens (human)
circadian regulation of gene expressionDNA topoisomerase 1Homo sapiens (human)
embryonic cleavageDNA topoisomerase 1Homo sapiens (human)
chromosome segregationDNA topoisomerase 1Homo sapiens (human)
DNA replicationDNA topoisomerase 1Homo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
temperature homeostasisD(2) dopamine receptorHomo sapiens (human)
response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein phosphorylationD(2) dopamine receptorHomo sapiens (human)
response to amphetamineD(2) dopamine receptorHomo sapiens (human)
nervous system process involved in regulation of systemic arterial blood pressureD(2) dopamine receptorHomo sapiens (human)
regulation of heart rateD(2) dopamine receptorHomo sapiens (human)
regulation of sodium ion transportD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(2) dopamine receptorHomo sapiens (human)
positive regulation of neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
positive regulation of receptor internalizationD(2) dopamine receptorHomo sapiens (human)
autophagyD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
neuron-neuron synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
axonogenesisD(2) dopamine receptorHomo sapiens (human)
synapse assemblyD(2) dopamine receptorHomo sapiens (human)
sensory perception of smellD(2) dopamine receptorHomo sapiens (human)
long-term memoryD(2) dopamine receptorHomo sapiens (human)
grooming behaviorD(2) dopamine receptorHomo sapiens (human)
locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
adult walking behaviorD(2) dopamine receptorHomo sapiens (human)
protein localizationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell population proliferationD(2) dopamine receptorHomo sapiens (human)
associative learningD(2) dopamine receptorHomo sapiens (human)
visual learningD(2) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(2) dopamine receptorHomo sapiens (human)
response to light stimulusD(2) dopamine receptorHomo sapiens (human)
response to toxic substanceD(2) dopamine receptorHomo sapiens (human)
response to iron ionD(2) dopamine receptorHomo sapiens (human)
response to inactivityD(2) dopamine receptorHomo sapiens (human)
Wnt signaling pathwayD(2) dopamine receptorHomo sapiens (human)
striatum developmentD(2) dopamine receptorHomo sapiens (human)
orbitofrontal cortex developmentD(2) dopamine receptorHomo sapiens (human)
cerebral cortex GABAergic interneuron migrationD(2) dopamine receptorHomo sapiens (human)
adenohypophysis developmentD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell migrationD(2) dopamine receptorHomo sapiens (human)
peristalsisD(2) dopamine receptorHomo sapiens (human)
auditory behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of synaptic transmission, GABAergicD(2) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(2) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
response to histamineD(2) dopamine receptorHomo sapiens (human)
response to nicotineD(2) dopamine receptorHomo sapiens (human)
positive regulation of urine volumeD(2) dopamine receptorHomo sapiens (human)
positive regulation of renal sodium excretionD(2) dopamine receptorHomo sapiens (human)
positive regulation of multicellular organism growthD(2) dopamine receptorHomo sapiens (human)
response to cocaineD(2) dopamine receptorHomo sapiens (human)
negative regulation of circadian sleep/wake cycle, sleepD(2) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(2) dopamine receptorHomo sapiens (human)
drinking behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(2) dopamine receptorHomo sapiens (human)
response to morphineD(2) dopamine receptorHomo sapiens (human)
pigmentationD(2) dopamine receptorHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
positive regulation of G protein-coupled receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(2) dopamine receptorHomo sapiens (human)
negative regulation of innate immune responseD(2) dopamine receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IID(2) dopamine receptorHomo sapiens (human)
negative regulation of insulin secretionD(2) dopamine receptorHomo sapiens (human)
acid secretionD(2) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(2) dopamine receptorHomo sapiens (human)
behavioral response to ethanolD(2) dopamine receptorHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityD(2) dopamine receptorHomo sapiens (human)
response to axon injuryD(2) dopamine receptorHomo sapiens (human)
branching morphogenesis of a nerveD(2) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(2) dopamine receptorHomo sapiens (human)
epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(2) dopamine receptorHomo sapiens (human)
release of sequestered calcium ion into cytosolD(2) dopamine receptorHomo sapiens (human)
dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
positive regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of synapse structural plasticityD(2) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(2) dopamine receptorHomo sapiens (human)
excitatory postsynaptic potentialD(2) dopamine receptorHomo sapiens (human)
positive regulation of growth hormone secretionD(2) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeD(2) dopamine receptorHomo sapiens (human)
regulation of locomotion involved in locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
negative regulation of cellular response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
positive regulation of glial cell-derived neurotrophic factor productionD(2) dopamine receptorHomo sapiens (human)
positive regulation of long-term synaptic potentiationD(2) dopamine receptorHomo sapiens (human)
hyaloid vascular plexus regressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of neuron migrationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(2) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(2) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
angiogenesisAlpha-2B adrenergic receptorHomo sapiens (human)
regulation of vascular associated smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2B adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2B adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of blood pressureAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of uterine smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-1A adrenergic receptorBos taurus (cattle)
positive regulation of MAPK cascadeAlpha-1A adrenergic receptorBos taurus (cattle)
regulation of cardiac muscle contractionAlpha-1A adrenergic receptorBos taurus (cattle)
regulation of smooth muscle contractionAlpha-2C adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2C adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2C adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2C adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2C adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2C adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2C adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2C adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2C adrenergic receptorHomo sapiens (human)
monoamine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent noradrenaline transporter Homo sapiens (human)
chemical synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent noradrenaline transporter Homo sapiens (human)
response to painSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent noradrenaline transporter Homo sapiens (human)
neuron cellular homeostasisSodium-dependent noradrenaline transporter Homo sapiens (human)
amino acid transportSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent noradrenaline transporter Homo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of cell population proliferationAlpha-1D adrenergic receptorHomo sapiens (human)
neuron-glial cell signalingAlpha-1D adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-1D adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of vasoconstrictionAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-1D adrenergic receptorHomo sapiens (human)
regulation of cyclin-dependent protein serine/threonine kinase activityM-phase inducer phosphatase 1Homo sapiens (human)
G1/S transition of mitotic cell cycleM-phase inducer phosphatase 1Homo sapiens (human)
G2/M transition of mitotic cell cycleM-phase inducer phosphatase 1Homo sapiens (human)
cell population proliferationM-phase inducer phosphatase 1Homo sapiens (human)
response to radiationM-phase inducer phosphatase 1Homo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycleM-phase inducer phosphatase 1Homo sapiens (human)
cellular response to UVM-phase inducer phosphatase 1Homo sapiens (human)
positive regulation of DNA replicationM-phase inducer phosphatase 1Homo sapiens (human)
cell divisionM-phase inducer phosphatase 1Homo sapiens (human)
positive regulation of G2/MI transition of meiotic cell cycleM-phase inducer phosphatase 1Homo sapiens (human)
MAPK cascadeAlpha-1A adrenergic receptorHomo sapiens (human)
negative regulation of heart rate involved in baroreceptor response to increased systemic arterial blood pressureAlpha-1A adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressureAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of heart rate by epinephrine-norepinephrineAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of the force of heart contraction by epinephrine-norepinephrineAlpha-1A adrenergic receptorHomo sapiens (human)
apoptotic processAlpha-1A adrenergic receptorHomo sapiens (human)
smooth muscle contractionAlpha-1A adrenergic receptorHomo sapiens (human)
signal transductionAlpha-1A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-1A adrenergic receptorHomo sapiens (human)
activation of phospholipase C activityAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAlpha-1A adrenergic receptorHomo sapiens (human)
adult heart developmentAlpha-1A adrenergic receptorHomo sapiens (human)
negative regulation of cell population proliferationAlpha-1A adrenergic receptorHomo sapiens (human)
response to xenobiotic stimulusAlpha-1A adrenergic receptorHomo sapiens (human)
response to hormoneAlpha-1A adrenergic receptorHomo sapiens (human)
negative regulation of autophagyAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of cardiac muscle hypertrophyAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicAlpha-1A adrenergic receptorHomo sapiens (human)
intracellular signal transductionAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of action potentialAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of vasoconstrictionAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of smooth muscle contractionAlpha-1A adrenergic receptorHomo sapiens (human)
calcium ion transport into cytosolAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of cardiac muscle contractionAlpha-1A adrenergic receptorHomo sapiens (human)
cell growth involved in cardiac muscle cell developmentAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of protein kinase C signalingAlpha-1A adrenergic receptorHomo sapiens (human)
pilomotor reflexAlpha-1A adrenergic receptorHomo sapiens (human)
neuron-glial cell signalingAlpha-1A adrenergic receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayAlpha-1A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-1A adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-1A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-1B adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAlpha-1B adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-1B adrenergic receptorHomo sapiens (human)
intracellular signal transductionAlpha-1B adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-1B adrenergic receptorHomo sapiens (human)
regulation of cardiac muscle contractionAlpha-1B adrenergic receptorHomo sapiens (human)
neuron-glial cell signalingAlpha-1B adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-1B adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-1B adrenergic receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayAlpha-1B adrenergic receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAlpha-1B adrenergic receptorHomo sapiens (human)
neural crest cell migration5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cytokine production5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of endothelial cell proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor internalization5-hydroxytryptamine receptor 2BHomo sapiens (human)
heart morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
cardiac muscle hypertrophy5-hydroxytryptamine receptor 2BHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
neural crest cell differentiation5-hydroxytryptamine receptor 2BHomo sapiens (human)
intestine smooth muscle contraction5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphorylation5-hydroxytryptamine receptor 2BHomo sapiens (human)
calcium-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 2BHomo sapiens (human)
negative regulation of apoptotic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of MAP kinase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
embryonic morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of nitric-oxide synthase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell division5-hydroxytryptamine receptor 2BHomo sapiens (human)
ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cellular response to temperature stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2BHomo sapiens (human)
cerebral cortex cell migration5-hydroxytryptamine receptor 6Homo sapiens (human)
positive regulation of TOR signaling5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 6Homo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 6Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 6Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
maltose metabolic processLysosomal alpha-glucosidaseBos taurus (cattle)
regulation of the force of heart contractionLysosomal alpha-glucosidaseBos taurus (cattle)
diaphragm contractionLysosomal alpha-glucosidaseBos taurus (cattle)
heart morphogenesisLysosomal alpha-glucosidaseBos taurus (cattle)
glycogen catabolic processLysosomal alpha-glucosidaseBos taurus (cattle)
locomotory behaviorLysosomal alpha-glucosidaseBos taurus (cattle)
tissue developmentLysosomal alpha-glucosidaseBos taurus (cattle)
aorta developmentLysosomal alpha-glucosidaseBos taurus (cattle)
vacuolar sequesteringLysosomal alpha-glucosidaseBos taurus (cattle)
muscle cell cellular homeostasisLysosomal alpha-glucosidaseBos taurus (cattle)
neuromuscular process controlling postureLysosomal alpha-glucosidaseBos taurus (cattle)
neuromuscular process controlling balanceLysosomal alpha-glucosidaseBos taurus (cattle)
cardiac muscle contractionLysosomal alpha-glucosidaseBos taurus (cattle)
glycophagyLysosomal alpha-glucosidaseBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (70)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein kinase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-1B adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-2C adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
thioesterase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
heterotrimeric G-protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
norepinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2A adrenergic receptorHomo sapiens (human)
monooxygenase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activityCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2D6Homo sapiens (human)
heme bindingCytochrome P450 2D6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingDNA topoisomerase 1Homo sapiens (human)
DNA bindingDNA topoisomerase 1Homo sapiens (human)
chromatin bindingDNA topoisomerase 1Homo sapiens (human)
double-stranded DNA bindingDNA topoisomerase 1Homo sapiens (human)
single-stranded DNA bindingDNA topoisomerase 1Homo sapiens (human)
RNA bindingDNA topoisomerase 1Homo sapiens (human)
DNA topoisomerase type I (single strand cut, ATP-independent) activityDNA topoisomerase 1Homo sapiens (human)
protein serine/threonine kinase activityDNA topoisomerase 1Homo sapiens (human)
protein bindingDNA topoisomerase 1Homo sapiens (human)
ATP bindingDNA topoisomerase 1Homo sapiens (human)
DNA binding, bendingDNA topoisomerase 1Homo sapiens (human)
protein domain specific bindingDNA topoisomerase 1Homo sapiens (human)
supercoiled DNA bindingDNA topoisomerase 1Homo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(2) dopamine receptorHomo sapiens (human)
G-protein alpha-subunit bindingD(2) dopamine receptorHomo sapiens (human)
protein bindingD(2) dopamine receptorHomo sapiens (human)
heterotrimeric G-protein bindingD(2) dopamine receptorHomo sapiens (human)
dopamine bindingD(2) dopamine receptorHomo sapiens (human)
ionotropic glutamate receptor bindingD(2) dopamine receptorHomo sapiens (human)
identical protein bindingD(2) dopamine receptorHomo sapiens (human)
heterocyclic compound bindingD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(2) dopamine receptorHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2B adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2B adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2B adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-1A adrenergic receptorBos taurus (cattle)
alpha2-adrenergic receptor activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2C adrenergic receptorHomo sapiens (human)
alpha-2A adrenergic receptor bindingAlpha-2C adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2C adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2C adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2C adrenergic receptorHomo sapiens (human)
actin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
protein bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
alpha-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
metal ion bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
beta-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
protein bindingAlpha-1D adrenergic receptorHomo sapiens (human)
identical protein bindingAlpha-1D adrenergic receptorHomo sapiens (human)
alpha1-adrenergic receptor activityAlpha-1D adrenergic receptorHomo sapiens (human)
phosphoprotein phosphatase activityM-phase inducer phosphatase 1Homo sapiens (human)
protein tyrosine phosphatase activityM-phase inducer phosphatase 1Homo sapiens (human)
protein bindingM-phase inducer phosphatase 1Homo sapiens (human)
protein kinase bindingM-phase inducer phosphatase 1Homo sapiens (human)
protein-folding chaperone bindingM-phase inducer phosphatase 1Homo sapiens (human)
alpha1-adrenergic receptor activityAlpha-1A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-1A adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-1A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-1B adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-1B adrenergic receptorHomo sapiens (human)
alpha1-adrenergic receptor activityAlpha-1B adrenergic receptorHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
G-protein alpha-subunit binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
GTPase activator activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
histamine receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
protein binding5-hydroxytryptamine receptor 6Homo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
alpha-1,4-glucosidase activityLysosomal alpha-glucosidaseBos taurus (cattle)
carbohydrate bindingLysosomal alpha-glucosidaseBos taurus (cattle)
maltose alpha-glucosidase activityLysosomal alpha-glucosidaseBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (61)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
cytoplasmAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
basolateral plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
neuronal cell bodyAlpha-2A adrenergic receptorHomo sapiens (human)
axon terminusAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic active zone membraneAlpha-2A adrenergic receptorHomo sapiens (human)
dopaminergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
postsynaptic density membraneAlpha-2A adrenergic receptorHomo sapiens (human)
glutamatergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
GABA-ergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
receptor complexAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
mitochondrionCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulumCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2D6Homo sapiens (human)
cytoplasmCytochrome P450 2D6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2D6Homo sapiens (human)
nuclear chromosomeDNA topoisomerase 1Homo sapiens (human)
P-bodyDNA topoisomerase 1Homo sapiens (human)
fibrillar centerDNA topoisomerase 1Homo sapiens (human)
male germ cell nucleusDNA topoisomerase 1Homo sapiens (human)
nucleusDNA topoisomerase 1Homo sapiens (human)
nucleoplasmDNA topoisomerase 1Homo sapiens (human)
nucleolusDNA topoisomerase 1Homo sapiens (human)
perikaryonDNA topoisomerase 1Homo sapiens (human)
protein-DNA complexDNA topoisomerase 1Homo sapiens (human)
nucleolusDNA topoisomerase 1Homo sapiens (human)
Golgi membraneD(2) dopamine receptorHomo sapiens (human)
acrosomal vesicleD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
ciliumD(2) dopamine receptorHomo sapiens (human)
lateral plasma membraneD(2) dopamine receptorHomo sapiens (human)
endocytic vesicleD(2) dopamine receptorHomo sapiens (human)
axonD(2) dopamine receptorHomo sapiens (human)
dendriteD(2) dopamine receptorHomo sapiens (human)
synaptic vesicle membraneD(2) dopamine receptorHomo sapiens (human)
sperm flagellumD(2) dopamine receptorHomo sapiens (human)
dendritic spineD(2) dopamine receptorHomo sapiens (human)
perikaryonD(2) dopamine receptorHomo sapiens (human)
axon terminusD(2) dopamine receptorHomo sapiens (human)
postsynaptic membraneD(2) dopamine receptorHomo sapiens (human)
ciliary membraneD(2) dopamine receptorHomo sapiens (human)
non-motile ciliumD(2) dopamine receptorHomo sapiens (human)
dopaminergic synapseD(2) dopamine receptorHomo sapiens (human)
GABA-ergic synapseD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor complexD(2) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(2) dopamine receptorHomo sapiens (human)
presynaptic membraneD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
cytosolAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
cell surfaceAlpha-2B adrenergic receptorHomo sapiens (human)
intracellular membrane-bounded organelleAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
nucleusAlpha-1A adrenergic receptorBos taurus (cattle)
cytoplasmAlpha-1A adrenergic receptorBos taurus (cattle)
plasma membraneAlpha-1A adrenergic receptorBos taurus (cattle)
caveolaAlpha-1A adrenergic receptorBos taurus (cattle)
nuclear membraneAlpha-1A adrenergic receptorBos taurus (cattle)
cytoplasmAlpha-2C adrenergic receptorHomo sapiens (human)
endosomeAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
cell surfaceSodium-dependent noradrenaline transporter Homo sapiens (human)
membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
presynaptic membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
axonSodium-dependent noradrenaline transporter Homo sapiens (human)
plasma membraneAlpha-1D adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1D adrenergic receptorHomo sapiens (human)
nucleoplasmM-phase inducer phosphatase 1Homo sapiens (human)
cytosolM-phase inducer phosphatase 1Homo sapiens (human)
nucleusM-phase inducer phosphatase 1Homo sapiens (human)
cytoplasmM-phase inducer phosphatase 1Homo sapiens (human)
nucleusAlpha-1A adrenergic receptorHomo sapiens (human)
nucleoplasmAlpha-1A adrenergic receptorHomo sapiens (human)
cytoplasmAlpha-1A adrenergic receptorHomo sapiens (human)
cytosolAlpha-1A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1A adrenergic receptorHomo sapiens (human)
caveolaAlpha-1A adrenergic receptorHomo sapiens (human)
nuclear membraneAlpha-1A adrenergic receptorHomo sapiens (human)
intracellular membrane-bounded organelleAlpha-1A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1A adrenergic receptorHomo sapiens (human)
nucleusAlpha-1B adrenergic receptorHomo sapiens (human)
cytoplasmAlpha-1B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1B adrenergic receptorHomo sapiens (human)
caveolaAlpha-1B adrenergic receptorHomo sapiens (human)
nuclear membraneAlpha-1B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1B adrenergic receptorHomo sapiens (human)
nucleoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
cytoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2BHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 6Homo sapiens (human)
cilium5-hydroxytryptamine receptor 6Homo sapiens (human)
synapse5-hydroxytryptamine receptor 6Homo sapiens (human)
dendrite5-hydroxytryptamine receptor 6Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 6Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
lysosomal membraneLysosomal alpha-glucosidaseBos taurus (cattle)
autolysosome lumenLysosomal alpha-glucosidaseBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (406)

Assay IDTitleYearJournalArticle
AID624229Antagonists at Rat 5-Hydroxytryptamine receptor 5-HT1F1993Proceedings of the National Academy of Sciences of the United States of America, Mar-15, Volume: 90, Issue:6
Molecular cloning and functional expression of 5-HT1E-like rat and human 5-hydroxytryptamine receptor genes.
AID1346058Human alpha2B-adrenoceptor (Adrenoceptors)1994European journal of pharmacology, Jan-24, Volume: 252, Issue:1
Further characterization of human alpha 2-adrenoceptor subtypes: [3H]RX821002 binding and definition of additional selective drugs.
AID624231Antagonists at Human 5-Hydroxytryptamine receptor 5-HT1D1992Proceedings of the National Academy of Sciences of the United States of America, Apr-15, Volume: 89, Issue:8
Human serotonin 1D receptor is encoded by a subfamily of two distinct genes: 5-HT1D alpha and 5-HT1D beta.
AID1346049Human alpha2A-adrenoceptor (Adrenoceptors)1992Molecular pharmacology, Jul, Volume: 42, Issue:1
Pharmacological characteristics of alpha 2-adrenergic receptors: comparison of pharmacologically defined subtypes with subtypes identified by molecular cloning.
AID1346058Human alpha2B-adrenoceptor (Adrenoceptors)1994The Journal of pharmacology and experimental therapeutics, Dec, Volume: 271, Issue:3
The novel alpha-2 adrenergic radioligand [3H]-MK912 is alpha-2C selective among human alpha-2A, alpha-2B and alpha-2C adrenoceptors.
AID1346264Human 5-HT1B receptor (5-Hydroxytryptamine receptors)2000Synapse (New York, N.Y.), Feb, Volume: 35, Issue:2
Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic tr
AID624231Antagonists at Human 5-Hydroxytryptamine receptor 5-HT1D1996Molecular pharmacology, Dec, Volume: 50, Issue:6
Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamin
AID1346302Mouse 5-HT1B receptor (5-Hydroxytryptamine receptors)1992Proceedings of the National Academy of Sciences of the United States of America, Apr-01, Volume: 89, Issue:7
Mouse 5HT1B serotonin receptor: cloning, functional expression, and localization in motor control centers.
AID1346159Human alpha2C-adrenoceptor (Adrenoceptors)1994The Journal of pharmacology and experimental therapeutics, Dec, Volume: 271, Issue:3
The novel alpha-2 adrenergic radioligand [3H]-MK912 is alpha-2C selective among human alpha-2A, alpha-2B and alpha-2C adrenoceptors.
AID1346867Human 5-HT2B receptor (5-Hydroxytryptamine receptors)1994Molecular pharmacology, Aug, Volume: 46, Issue:2
Molecular cloning, functional expression, and mRNA tissue distribution of the human 5-hydroxytryptamine2B receptor.
AID1346159Human alpha2C-adrenoceptor (Adrenoceptors)1994European journal of pharmacology, Jan-24, Volume: 252, Issue:1
Further characterization of human alpha 2-adrenoceptor subtypes: [3H]RX821002 binding and definition of additional selective drugs.
AID624228Antagonists at Rat 5-Hydroxytryptamine receptor 5-HT2B1993Molecular pharmacology, Mar, Volume: 43, Issue:3
Pharmacological characteristics of the newly cloned rat 5-hydroxytryptamine2F receptor.
AID1346528Human 5-HT1D receptor (5-Hydroxytryptamine receptors)1991Molecular pharmacology, Aug, Volume: 40, Issue:2
Primary structure and functional characterization of a human 5-HT1D-type serotonin receptor.
AID1346739Human 5-HT1F receptor (5-Hydroxytryptamine receptors)1993Proceedings of the National Academy of Sciences of the United States of America, Jan-15, Volume: 90, Issue:2
Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase.
AID624226Antagonists at Human 5-Hydroxytryptamine receptor 5-HT1F1993Proceedings of the National Academy of Sciences of the United States of America, Jan-15, Volume: 90, Issue:2
Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase.
AID1345291Human 5-HT7 receptor (5-Hydroxytryptamine receptors)1993The Journal of biological chemistry, Nov-05, Volume: 268, Issue:31
Cloning of a novel human serotonin receptor (5-HT7) positively linked to adenylate cyclase.
AID1346903Rat 5-HT2B receptor (5-Hydroxytryptamine receptors)1993Molecular pharmacology, Mar, Volume: 43, Issue:3
Pharmacological characteristics of the newly cloned rat 5-hydroxytryptamine2F receptor.
AID1346049Human alpha2A-adrenoceptor (Adrenoceptors)1994European journal of pharmacology, Jan-24, Volume: 252, Issue:1
Further characterization of human alpha 2-adrenoceptor subtypes: [3H]RX821002 binding and definition of additional selective drugs.
AID1346159Human alpha2C-adrenoceptor (Adrenoceptors)1992Molecular pharmacology, Jul, Volume: 42, Issue:1
Pharmacological characteristics of alpha 2-adrenergic receptors: comparison of pharmacologically defined subtypes with subtypes identified by molecular cloning.
AID1346603Human 5-ht1e receptor (5-Hydroxytryptamine receptors)1993Proceedings of the National Academy of Sciences of the United States of America, Jan-15, Volume: 90, Issue:2
Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase.
AID1345615Human 5-HT1A receptor (5-Hydroxytryptamine receptors)2000Synapse (New York, N.Y.), Feb, Volume: 35, Issue:2
Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic tr
AID1345061Mouse 5-HT5A receptor (5-Hydroxytryptamine receptors)1993Molecular pharmacology, Mar, Volume: 43, Issue:3
Mouse 5-hydroxytryptamine5A and 5-hydroxytryptamine5B receptors define a new family of serotonin receptors: cloning, functional expression, and chromosomal localization.
AID1346528Human 5-HT1D receptor (5-Hydroxytryptamine receptors)1992Proceedings of the National Academy of Sciences of the United States of America, Apr-15, Volume: 89, Issue:8
Human serotonin 1D receptor is encoded by a subfamily of two distinct genes: 5-HT1D alpha and 5-HT1D beta.
AID624231Antagonists at Human 5-Hydroxytryptamine receptor 5-HT1D1991Molecular pharmacology, Aug, Volume: 40, Issue:2
Primary structure and functional characterization of a human 5-HT1D-type serotonin receptor.
AID624215Antagonists at Human 5-Hydroxytryptamine receptor 5-HT1A2000Synapse (New York, N.Y.), Feb, Volume: 35, Issue:2
Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic tr
AID1346264Human 5-HT1B receptor (5-Hydroxytryptamine receptors)1992Proceedings of the National Academy of Sciences of the United States of America, Apr-15, Volume: 89, Issue:8
Human serotonin 1D receptor is encoded by a subfamily of two distinct genes: 5-HT1D alpha and 5-HT1D beta.
AID1345068Human 5-HT5A receptor (5-Hydroxytryptamine receptors)1994FEBS letters, Dec-05, Volume: 355, Issue:3
Cloning and characterisation of the human 5-HT5A serotonin receptor.
AID624218Antagonists at Human 5-Hydroxytryptamine receptor 5-HT2B1994Molecular pharmacology, Aug, Volume: 46, Issue:2
Molecular cloning, functional expression, and mRNA tissue distribution of the human 5-hydroxytryptamine2B receptor.
AID1346058Human alpha2B-adrenoceptor (Adrenoceptors)1992Molecular pharmacology, Jul, Volume: 42, Issue:1
Pharmacological characteristics of alpha 2-adrenergic receptors: comparison of pharmacologically defined subtypes with subtypes identified by molecular cloning.
AID624218Antagonists at Human 5-Hydroxytryptamine receptor 5-HT2B1998Naunyn-Schmiedeberg's archives of pharmacology, Jan, Volume: 357, Issue:1
[3H]Rauwolscine: an antagonist radioligand for the cloned human 5-hydroxytryptamine2b (5-HT2B) receptor.
AID1346867Human 5-HT2B receptor (5-Hydroxytryptamine receptors)1999British journal of pharmacology, Jul, Volume: 127, Issue:5
RS-127445: a selective, high affinity, orally bioavailable 5-HT2B receptor antagonist.
AID624231Antagonists at Human 5-Hydroxytryptamine receptor 5-HT1D2000Synapse (New York, N.Y.), Feb, Volume: 35, Issue:2
Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic tr
AID1346783Rat 5-HT1F receptor (5-Hydroxytryptamine receptors)1993Proceedings of the National Academy of Sciences of the United States of America, Mar-15, Volume: 90, Issue:6
Molecular cloning and functional expression of 5-HT1E-like rat and human 5-hydroxytryptamine receptor genes.
AID1345061Mouse 5-HT5A receptor (5-Hydroxytryptamine receptors)1995FEBS letters, Dec-27, Volume: 377, Issue:3
Expression of functional mouse 5-HT5A serotonin receptor in the methylotrophic yeast Pichia pastoris: pharmacological characterization and localization.
AID624232Antagonists at Human 5-Hydroxytryptamine receptor 5-ht1e1993Proceedings of the National Academy of Sciences of the United States of America, Jan-15, Volume: 90, Issue:2
Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase.
AID1346528Human 5-HT1D receptor (5-Hydroxytryptamine receptors)2000Synapse (New York, N.Y.), Feb, Volume: 35, Issue:2
Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic tr
AID1346049Human alpha2A-adrenoceptor (Adrenoceptors)1994The Journal of pharmacology and experimental therapeutics, Dec, Volume: 271, Issue:3
The novel alpha-2 adrenergic radioligand [3H]-MK912 is alpha-2C selective among human alpha-2A, alpha-2B and alpha-2C adrenoceptors.
AID1346867Human 5-HT2B receptor (5-Hydroxytryptamine receptors)1998Naunyn-Schmiedeberg's archives of pharmacology, Jan, Volume: 357, Issue:1
[3H]Rauwolscine: an antagonist radioligand for the cloned human 5-hydroxytryptamine2b (5-HT2B) receptor.
AID1346528Human 5-HT1D receptor (5-Hydroxytryptamine receptors)1996Molecular pharmacology, Dec, Volume: 50, Issue:6
Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamin
AID624218Antagonists at Human 5-Hydroxytryptamine receptor 5-HT2B1999British journal of pharmacology, Jul, Volume: 127, Issue:5
RS-127445: a selective, high affinity, orally bioavailable 5-HT2B receptor antagonist.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID36181Compound was evaluated for inhibition of binding of [3H]yohimbine to Alpha-2 adrenergic receptor in hamster adipocyte1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification.
AID36188Inhibition of [3H]p-aminoclonidine (PAC) binding to alpha-2 adrenergic receptor of purified human platelet plasma membranes1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
Radioiodinated p-iodoclonidine: a high-affinity probe for the alpha 2-adrenergic receptor.
AID37079Binding affinity against alpha-2 adrenergic receptor was determined by the displacement of [3H]prazosin from rat brain cortical membranes1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Alpha 2-adrenergic agonists/antagonists: the synthesis and structure-activity relationships of a series of indolin-2-yl and tetrahydroquinolin-2-yl imidazolines.
AID36345Compound was evaluated for inhibition of binding of [3H]yohimbine to Alpha-2 adrenergic receptor in human platelet1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification.
AID503829Inverse agonist activity at adrenergic alpha2A receptor expressed in HEK293 cells coexpressing yellow fluorescent and cyan fluorescent protein assessed as effect on kinetics of receptor conformational change by FRET assay2005Nature chemical biology, Jun, Volume: 1, Issue:1
Molecular basis of inverse agonism in a G protein-coupled receptor.
AID238495In vitro binding affinity towards alpha-2a adrenergic receptor2005Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11
Synthesis and biological studies of yohimbine derivatives on human alpha2C-adrenergic receptors.
AID1546835Antagonist activity at human Gs-coupled PTGIR assessed as inhibition in beraprost-induced beta-arrestin 2 recruitment at 20 uM incubated for 30 mins followed by beraprost- addition and measured after 90 or 180 mins by pathhunter beta-arrestin assay relati2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Preventing Morphine-Seeking Behavior through the Re-Engineering of Vincamine's Biological Activity.
AID226401Ratio of pA2 value against alpha-2 to alpha1 adrenoceptor1983Journal of medicinal chemistry, Jun, Volume: 26, Issue:6
alpha-adrenoreceptor reagents. 1. Synthesis of some 1,4-benzodioxans as selective presynaptic alpha 2-adrenoreceptor antagonists and potential antidepressants.
AID1152690Displacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cells2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia.
AID35967Displacement of [3H]prazosin from calf cerebral cortex alpha-1 adrenergic receptor1984Journal of medicinal chemistry, Sep, Volume: 27, Issue:9
Adrenoceptor and tetrabenazine antagonism activities of some pyridinyltetrahydropyridines.
AID160059Inhibitory concentration of compound against primary aggregation of induced by R-81990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Synthesis and alpha 2-adrenoceptor effects of substituted catecholimidazoline and catecholimidazole analogues in human platelets.
AID223475In vivo antagonism of guanabenz-induced hypothermia in mice after peroral administration at a dose of 10 mg/kg2000Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
New substituted 1-(2,3-dihydrobenzo[1, 4]dioxin-2-ylmethyl)piperidin-4-yl derivatives with alpha(2)-adrenoceptor antagonist activity.
AID1720582Antagonist activity at human CXCR4 expressed in mouse C2C12 cells at 20 uM by PathHunter beta-arrestin assay relative to control2020Bioorganic & medicinal chemistry, 07-15, Volume: 28, Issue:14
Yohimbine as a Starting Point to Access Diverse Natural Product-Like Agents with Re-programmed Activities against Cancer-Relevant GPCR Targets.
AID35866Antagonistic potency of compound for Alpha-1 adrenergic receptor1981Journal of medicinal chemistry, Nov, Volume: 24, Issue:11
Synthesis and antihypertensive activity of a series of 8-substituted 1-oxa-3,8-diazaspiro[4.5]decan-2-ones.
AID179818Tested for reversal of clonidine-induced mydriasis in the rat administered intravenously1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
N-(1,3,4,6,7,12b-hexahydro-2H-benzo[b]furo[2,3-a]quinolizin -2-yl)-N- methyl-2-hydroxyethane-sulfonamide: a potent and selective alpha 2-adrenoceptor antagonist.
AID180484Reversal of clonidine-induced mydriasis in rat, after intravenous administration1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
(8a alpha,12a alpha,13a alpha)-5,8,8a,9,10,11,12,12a,13,13a-decahydro- 3-methoxy-12-(methylsulfonyl)-6H-isoquino[2,1-g][1,6]naphthyridi ne, a potent and highly selective alpha 2-adrenoceptor antagonist.
AID503655Inverse agonist activity at alpha2A adrenergic receptor T373K mutant expressed in HEK293 cells assessed as increase in resonance signal at 30 uM by FRET assay2005Nature chemical biology, Jun, Volume: 1, Issue:1
Molecular basis of inverse agonism in a G protein-coupled receptor.
AID752262Binding affinity to adrenergic alpha2 receptor (unknown origin) by radioligand displacement assay2013Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10
Synthesis and biological evaluation of 2-(5-methyl-4-phenyl-2-oxopyrrolidin-1-yl)-acetamide stereoisomers as novel positive allosteric modulators of sigma-1 receptor.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID141668Inhibition of [3H]quinuclidinyl benzilate (QNB) binding from rat forebrain membranes in the absence of Zn; Not tested1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeutic agents for Alzheimer's disease.
AID624626Ratio of apparent permeability from basolateral to apical side over apical to basolateral side determined in MDR1-MDCKII cells2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID624623Apparent permeability (Papp) from basolateral to apical side determined in MDR1-MDCKII cells2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID346399Displacement of radiolabeled yohimbine from adrenergic alpha2 receptor2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.
AID255287Percent inhibition against Alpha-2 adrenergic receptor at 1 uM2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID233670Selectivity ratio of compound towards alpha-2 adrenoceptor over alpha1 adrenoceptor of calf cerebral cortex1983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Pyridinylpiperazines, a new class of selective alpha 2-adrenoceptor antagonists.
AID125787Inhibition of 1'-hydroxybufuralol formation by human liver microsomes1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies.
AID196038Inhibitory activity against norepinephrine (NE) uptake in rat whole brain synaptosome preparation1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeutic agents for Alzheimer's disease.
AID36368Compound was evaluated for inhibition of binding of [3H]yohimbine to Alpha-2 adrenergic receptor in NG-108 cell1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification.
AID274932Antinociceptive activity in Swiss Albino mouse at 3 mg/kg, ip by abdominal constriction assay2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
Arylpiperazinylalkylpyridazinones and analogues as potent and orally active antinociceptive agents: synthesis and studies on mechanism of action.
AID35949Inhibition of [3H]- MK-912 binding against human recombinant Alpha-2A adrenergic receptor1999Journal of medicinal chemistry, Dec-16, Volume: 42, Issue:25
A series of 6- and 7-piperazinyl- and -piperidinylmethylbenzoxazinones with dopamine D4 antagonist activity: discovery of a potential atypical antipsychotic agent.
AID234642Selectivity for alpha-2a to that of alpha2b determined by their binding affinity ratios2000Bioorganic & medicinal chemistry letters, Apr-03, Volume: 10, Issue:7
Yohimbine dimers exhibiting binding selectivities for human alpha2a- versus alpha2b-adrenergic receptors.
AID219809Ability to reversal of inhibitory effects of UK-14304 on the contraction of guinea pig ileum as a measure of alpha-2-adrenoceptor antagonism1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
(8a alpha,12a alpha,13a alpha)-5,8,8a,9,10,11,12,12a,13,13a-decahydro- 3-methoxy-12-(methylsulfonyl)-6H-isoquino[2,1-g][1,6]naphthyridi ne, a potent and highly selective alpha 2-adrenoceptor antagonist.
AID1720607Agonist activity at human CCR8 expressed in CHO-K1 cells at 20 uM by PathHunter beta-arrestin assay relative to control2020Bioorganic & medicinal chemistry, 07-15, Volume: 28, Issue:14
Yohimbine as a Starting Point to Access Diverse Natural Product-Like Agents with Re-programmed Activities against Cancer-Relevant GPCR Targets.
AID132448Antagonistic activity against clonidine-induced antinociception in mouse after po administration1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Alpha 2-adrenergic agonists/antagonists: the synthesis and structure-activity relationships of a series of indolin-2-yl and tetrahydroquinolin-2-yl imidazolines.
AID36860In vitro inhibition of specific binding of [3H]- prazosin to alpha-1 adrenergic receptor site in rat brain membranes.2000Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
New substituted 1-(2,3-dihydrobenzo[1, 4]dioxin-2-ylmethyl)piperidin-4-yl derivatives with alpha(2)-adrenoceptor antagonist activity.
AID1720606Agonist activity at human CCR3 expressed in CHO-K1 cells at 20 uM by PathHunter beta-arrestin assay relative to control2020Bioorganic & medicinal chemistry, 07-15, Volume: 28, Issue:14
Yohimbine as a Starting Point to Access Diverse Natural Product-Like Agents with Re-programmed Activities against Cancer-Relevant GPCR Targets.
AID35775Binding affinity towards Alpha-2 adrenergic receptor1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Potent, selective tetrahydro-beta-carboline antagonists of the serotonin 2B (5HT2B) contractile receptor in the rat stomach fundus.
AID36013Binding affinity determined to alpha-1 adrenergic receptor of rat cerebral cortex using [3H]prazosin as radioligand1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Affinity of 2-(tetrahydroisoquinolin-2-ylmethyl)- and 2-(isoindolin-2-ylmethyl)imidazolines for alpha-adrenoceptors. Differential affinity of imidazolines for the [3H]idazoxan-labeled alpha 2-adrenoceptor vs the [3H]yohimbine-labeled site.
AID1720581Antagonist activity at human CX3CR1 expressed in CHO-K1 cells at 20 uM by PathHunter beta-arrestin assay relative to control2020Bioorganic & medicinal chemistry, 07-15, Volume: 28, Issue:14
Yohimbine as a Starting Point to Access Diverse Natural Product-Like Agents with Re-programmed Activities against Cancer-Relevant GPCR Targets.
AID37244Compound was evaluated for inhibition of binding of [3H]-yohimbine to Alpha-2 adrenergic receptor in alpha-2 C41995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification.
AID296764Antinociceptive activity in Swiss albino mouse assessed as number of writhing in presence of yohimbine at 3 mg/kg, po after 30 mins relative to control2007Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
4-amino-5-substituted-3(2H)-pyridazinones as orally active antinociceptive agents: synthesis and studies on the mechanism of action.
AID1720609Agonist activity at human CXCR4 expressed in mouse C2C12 cells at 20 uM by PathHunter beta-arrestin assay relative to control2020Bioorganic & medicinal chemistry, 07-15, Volume: 28, Issue:14
Yohimbine as a Starting Point to Access Diverse Natural Product-Like Agents with Re-programmed Activities against Cancer-Relevant GPCR Targets.
AID167198Inhibition of specific [3H]-prazosin binding (0.2 nM) to rat brain membranes alpha1 adrenoceptor.1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists.
AID35363Antagonistic potency of compound for Alpha-2 adrenergic receptor1981Journal of medicinal chemistry, Nov, Volume: 24, Issue:11
Synthesis and antihypertensive activity of a series of 8-substituted 1-oxa-3,8-diazaspiro[4.5]decan-2-ones.
AID1063790Displacement of [125I]Clonidine from adrenergic alpha2B receptor (unknown origin)2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
The synthesis and comparative receptor binding affinities of novel, isomeric pyridoindolobenzazepine scaffolds.
AID125784Inhibition of 1'-hydroxybufuralol formation by human liver microsomes1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies.
AID166793Blockade of the constrictor response to exogenously administered L-norepinephrine1983Journal of medicinal chemistry, Sep, Volume: 26, Issue:9
l-1,2,3,4-Tetrahydro-8-methoxy-5-(methylthio)-2-naphthalenamine: a potent and selective agonist at alpha 1-adrenoceptors.
AID36341Compound was evaluated for inhibition of binding of [3H]yohimbine to Alpha-2 adrenergic receptor in HT-29 cell1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification.
AID36503Compound was evaluated for inhibition of binding of [3H]yohimbine to Alpha-2 adrenergic receptor in porcine alpha2-clone1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification.
AID274929Antinociceptive activity in Swiss Albino mouse at 3 mg/kg, po by hot plate assay measured as licking latency2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
Arylpiperazinylalkylpyridazinones and analogues as potent and orally active antinociceptive agents: synthesis and studies on mechanism of action.
AID402038Inhibition of human recombinant DNA topoisomerase12005Journal of natural products, Jun, Volume: 68, Issue:6
Indole alkaloids and other constituents of Rauwolfia serpentina.
AID35603Binding affinity against Alpha-1D adrenergic receptor, from rat clones.1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification.
AID35362Antagonistic activity against clonidine-stimulated rat vas deferens presynaptic alpha-2 adrenergic receptor1984Journal of medicinal chemistry, Sep, Volume: 27, Issue:9
Adrenoceptor and tetrabenazine antagonism activities of some pyridinyltetrahydropyridines.
AID751901Binding affinity to adrenergic alpha2 receptor (unknown origin) by radioligand displacement assay2013European journal of medicinal chemistry, May, Volume: 63Synthesis and structure-activity relationship studies in serotonin 5-HT(1A) receptor agonists based on fused pyrrolidone scaffolds.
AID35860Antagonistic activity against Alpha-1 adrenergic receptor in the epidermal portion of the rat vas deferens1982Journal of medicinal chemistry, Jun, Volume: 25, Issue:6
Structure-activity relationships for 2-substituted imidazoles as alpha 2-adrenoceptor antagonists.
AID1546823Antagonist activity at human CCR8 expressed in CHOK1 cells assessed as inhibition in CCL1-induced beta-arrestin 2 recruitment at 20 uM incubated for 30 mins followed by CCL1 addition and measured after 90 or 180 mins by pathhunter beta-arrestin assay rela2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Preventing Morphine-Seeking Behavior through the Re-Engineering of Vincamine's Biological Activity.
AID36173Alpha-1 adrenergic receptor agonist activity in rat anococcygeus assay1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Alpha-adrenoreceptor reagents. 2. Effects of modification of the 1,4-benzodioxan ring system on alpha-adrenoreceptor activity.
AID35328Binding affinity against Alpha-1D adrenergic receptor, from human clones.1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification.
AID233671Selectivity ratio for alpha-2 adrenoceptor over alpha1 adrenoceptor of rat vas deferens1983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Pyridinylpiperazines, a new class of selective alpha 2-adrenoceptor antagonists.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID35864Antagonistic activity against postsynaptic Alpha-1 adrenergic receptor in isolated rat vas deferens using (-)-phenylephrine as agonist1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Berbanes: a new class of selective alpha 2-adrenoceptor antagonists.
AID5455Binding affinity analysed towards 5-HT 2A in rat jugular vein.1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Potent, selective tetrahydro-beta-carboline antagonists of the serotonin 2B (5HT2B) contractile receptor in the rat stomach fundus.
AID35359Antagonistic activity against Alpha-2 adrenergic receptor in the prostatic portion of the rat vas deferens1982Journal of medicinal chemistry, Jun, Volume: 25, Issue:6
Structure-activity relationships for 2-substituted imidazoles as alpha 2-adrenoceptor antagonists.
AID235865Index of alpha1/alpha2 adrenoceptor antagonist selectivity at pre and postsynaptic sites in vitro.1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists.
AID234759Selectivity expressed as Antilog (pA2 for clonidine - pA2 for methoxamine)1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
N-(1,3,4,6,7,12b-hexahydro-2H-benzo[b]furo[2,3-a]quinolizin -2-yl)-N- methyl-2-hydroxyethane-sulfonamide: a potent and selective alpha 2-adrenoceptor antagonist.
AID35916Compound was evaluated for inhibition of binding of [3H]yohimbine to Alpha-2 adrenergic receptor in bovine pineal1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification.
AID35360Antagonistic activity against alpha-2 adrenergic receptor in rat vas deferens1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Synthesis and structure-activity relationships of 2-sulfonamido-1,3,4,6,7,11b alpha-hexahydro-2H-benzo[a]quinolizines as alpha 2-adrenoceptor antagonists.
AID35482Alpha-2 adrenergic receptor antagonistic activity in rat vas deferens vs clonidine1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Alpha 2-adrenergic agonists/antagonists: the synthesis and structure-activity relationships of a series of indolin-2-yl and tetrahydroquinolin-2-yl imidazolines.
AID36226Inhibition of [3H]rauwolscine binding to CHO cells expressing the human Alpha-2B adrenergic receptor1995Journal of medicinal chemistry, Sep-15, Volume: 38, Issue:19
Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications.
AID37183Binding affinity against Alpha-1B adrenergic receptor from hamster clones.1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification.
AID503657Inverse agonist activity at alpha2A adrenergic receptor T373K mutant expressed in forskolin-stimulated HEK293 cells assessed as suppression of constitutive inhibition of cAMP synthesis at 0.3 uM2005Nature chemical biology, Jun, Volume: 1, Issue:1
Molecular basis of inverse agonism in a G protein-coupled receptor.
AID32094Inhibitory activity against acetylcholinesterase in rat striatal preparation1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeutic agents for Alzheimer's disease.
AID125786Inhibition of 1'-hydroxybufuralol formation by human liver microsomes1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies.
AID65625Tested for binding affinity against dopamine receptor D3 expressed in Sf9 cells.1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Synthesis of (R,S)-2'-trans-7-hydroxy-2-[N-n-propyl-N-(3'-iodo-2'- propenyl)-amino]tetralin (trans-7-OH-PIPAT): a new D3 dopamine receptor ligand.
AID36403Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor1995Journal of medicinal chemistry, Sep-15, Volume: 38, Issue:19
Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications.
AID79503In Vitro reversal of inhibitory effect of UK - 14304 on the contractile response of guinea pig ileum to field stimulation.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Structure-affinity relationships of 12-sulfonyl derivatives of 5,8,8a,9,10,11,12,12a,13,13a-decahydro-6H-isoquino[2,1-g][1 ,6] naphthyridines at alpha-adrenoceptors.
AID36774Alpha-2 adrenergic receptor activity was assessed from the ability to inhibit [3H]yohimbine binding to rat cerebral cortex preparation1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
New 1,4-dihydropyridine derivatives combining calcium antagonism and alpha-adrenolytic properties.
AID1720587Antagonist activity at NPSR1B in human U2OS cells at 20 uM by PathHunter beta-arrestin assay relative to control2020Bioorganic & medicinal chemistry, 07-15, Volume: 28, Issue:14
Yohimbine as a Starting Point to Access Diverse Natural Product-Like Agents with Re-programmed Activities against Cancer-Relevant GPCR Targets.
AID36010Binding affinity to alpha-1 adrenergic receptor determined by measurement of [3H]prazosin displacement from rat cortical membrane1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Structure-affinity relationships of 12-sulfonyl derivatives of 5,8,8a,9,10,11,12,12a,13,13a-decahydro-6H-isoquino[2,1-g][1 ,6] naphthyridines at alpha-adrenoceptors.
AID1720604Agonist activity at human ADRA2B expressed in CHO-K1 cells at 20 uM by PathHunter beta-arrestin assay relative to control2020Bioorganic & medicinal chemistry, 07-15, Volume: 28, Issue:14
Yohimbine as a Starting Point to Access Diverse Natural Product-Like Agents with Re-programmed Activities against Cancer-Relevant GPCR Targets.
AID1546832Antagonist activity at human Gq-coupled HRH1 expressed in CHOK1 cells assessed as inhibition in histamine-induced beta-arrestin 2 recruitment at 20 uM incubated for 30 mins followed by histamine addition and measured after 90 or 180 mins by pathhunter bet2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Preventing Morphine-Seeking Behavior through the Re-Engineering of Vincamine's Biological Activity.
AID36047Alpha-2 adrenergic receptor activity was assessed in vitro from the ability to inhibit norepinephrine binding to guinea pig vas deferens1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
New 1,4-dihydropyridine derivatives combining calcium antagonism and alpha-adrenolytic properties.
AID230520Ratio of reversal clonidine-induced mydriasis in rat, after oral administration to reversal of clonidine-induced mydriasis in rat, after intravenous administration1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
(8a alpha,12a alpha,13a alpha)-5,8,8a,9,10,11,12,12a,13,13a-decahydro- 3-methoxy-12-(methylsulfonyl)-6H-isoquino[2,1-g][1,6]naphthyridi ne, a potent and highly selective alpha 2-adrenoceptor antagonist.
AID1720576Antagonist activity at human ADRA1B expressed in CHO-K1 cells at 20 uM by PathHunter beta-arrestin assay relative to control2020Bioorganic & medicinal chemistry, 07-15, Volume: 28, Issue:14
Yohimbine as a Starting Point to Access Diverse Natural Product-Like Agents with Re-programmed Activities against Cancer-Relevant GPCR Targets.
AID229581Ratio of logKi of 5-HT-2B to 5-HT2C1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Potent, selective tetrahydro-beta-carboline antagonists of the serotonin 2B (5HT2B) contractile receptor in the rat stomach fundus.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID63016In vitro binding affinity to Dopamine receptors of rat striatal membranes by [3H]spiroperidol displacement.1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
4-Amino-6-chloro-2-piperazinopyrimidines with selective affinity for alpha 2-adrenoceptors.
AID64430In vitro inhibition of specific binding of [3H]-YM 09151-2 to Dopamine receptor D2 site in rat striatal tissue.2000Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
New substituted 1-(2,3-dihydrobenzo[1, 4]dioxin-2-ylmethyl)piperidin-4-yl derivatives with alpha(2)-adrenoceptor antagonist activity.
AID274924Antinociceptive activity in Swiss Albino mouse at 3 mg/kg, po by writhing test measured as number of writhes in presence of yohimbine2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
Arylpiperazinylalkylpyridazinones and analogues as potent and orally active antinociceptive agents: synthesis and studies on mechanism of action.
AID36918In vitro inhibition of binding of [3H]-RX-821002 to alpha-2 adrenergic receptor site in rat brain membranes.2000Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
New substituted 1-(2,3-dihydrobenzo[1, 4]dioxin-2-ylmethyl)piperidin-4-yl derivatives with alpha(2)-adrenoceptor antagonist activity.
AID238496In vitro binding affinity towards alpha-2b adrenergic receptor2005Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11
Synthesis and biological studies of yohimbine derivatives on human alpha2C-adrenergic receptors.
AID37382Inhibition of [3H]idazoxan binding to alpha-2 adrenergic receptor of rat cortical membranes1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
4-Amino-6-chloro-2-piperazinopyrimidines with selective affinity for alpha 2-adrenoceptors.
AID1546825Antagonist activity at human Gi/o-coupled CNR1 expressed in CHOK1 cells assessed as inhibition in CP55940-induced beta-arrestin 2 recruitment at 20 uM incubated for 30 mins followed by CP55940 addition and measured after 90 or 180 mins by pathhunter beta-2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Preventing Morphine-Seeking Behavior through the Re-Engineering of Vincamine's Biological Activity.
AID1720611Agonist activity at human FSHR expressed in CHO-K1 cells at 20 uM by PathHunter beta-arrestin assay relative to control2020Bioorganic & medicinal chemistry, 07-15, Volume: 28, Issue:14
Yohimbine as a Starting Point to Access Diverse Natural Product-Like Agents with Re-programmed Activities against Cancer-Relevant GPCR Targets.
AID239677In vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamine2005Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11
Synthesis and biological studies of yohimbine derivatives on human alpha2C-adrenergic receptors.
AID37242Compound was evaluated for inhibition of binding of [3H]yohimbine to Alpha-2 adrenergic receptor in RIN-m5F cell1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification.
AID229580Ratio of logKi of 5-HT-2B to 5-HT-2A1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Potent, selective tetrahydro-beta-carboline antagonists of the serotonin 2B (5HT2B) contractile receptor in the rat stomach fundus.
AID35412In vitro binding affinity was measured as the inhibition of [3H]WB-4101 binding to alpha-1 adrenergic receptor of rat cortical membranes1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
4-Amino-6-chloro-2-piperazinopyrimidines with selective affinity for alpha 2-adrenoceptors.
AID1720586Antagonist activity at HTR2C in human U2OS cells at 20 uM by PathHunter beta-arrestin assay relative to control2020Bioorganic & medicinal chemistry, 07-15, Volume: 28, Issue:14
Yohimbine as a Starting Point to Access Diverse Natural Product-Like Agents with Re-programmed Activities against Cancer-Relevant GPCR Targets.
AID37381In vitro binding affinity was measured as the inhibition of [3H]clonidine binding to alpha-2 adrenergic receptor of rat cortical membranes1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
4-Amino-6-chloro-2-piperazinopyrimidines with selective affinity for alpha 2-adrenoceptors.
AID503654Inverse agonist activity at alpha2A adrenergic receptor T373K mutant expressed in HEK293 cells assessed as increase in resonance signal at 0.3 uM by FRET assay2005Nature chemical biology, Jun, Volume: 1, Issue:1
Molecular basis of inverse agonism in a G protein-coupled receptor.
AID235864Index of alpha1/alpha2 adrenoceptor antagonist selectivity at post junctional vascular sites in vivo.1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists.
AID36343Compound was evaluated for inhibition of binding of [3H]yohimbine to Alpha-2 adrenergic receptor in alpha2C21995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification.
AID1581728Displacement of [3H]prazosin from human recombinant adrenergic alpha-1A receptor expressed in CHO cell membranes incubated for 60 mins2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
AID179415In vivo inhibition of clonidine induced mydriasis in the rat following p.o. administration.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Structure-affinity relationships of 12-sulfonyl derivatives of 5,8,8a,9,10,11,12,12a,13,13a-decahydro-6H-isoquino[2,1-g][1 ,6] naphthyridines at alpha-adrenoceptors.
AID36499Compound was evaluated for inhibition of binding of [3H]yohimbine to Alpha-2 adrenergic receptor in opossum kidney1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification.
AID1546831Antagonist activity at human Gq-coupled HCRTR2 expressed in CHOK1 cells assessed as inhibition in Orexin A-induced beta-arrestin 2 recruitment at 20 uM incubated for 30 mins followed by Orexin A addition and measured after 90 or 180 mins by pathhunter bet2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Preventing Morphine-Seeking Behavior through the Re-Engineering of Vincamine's Biological Activity.
AID166854Antagonist activity against norepinephrine-induced alpha-2-adrenoceptor-mediated vasoconstriction of rabbit isolated pulmonary artery.1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists.
AID35484The compound was evaluated for the alpha-2 adrenergic receptor antagonistic activity in rat vas deferens vs methoxamine alpha1 adrenoceptor antagonism1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Alpha 2-adrenergic agonists/antagonists: the synthesis and structure-activity relationships of a series of indolin-2-yl and tetrahydroquinolin-2-yl imidazolines.
AID36058Antagonistic activity against longitudinal muscle strip of the guinea pig ileum using xylazine as agonist1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Berbanes: a new class of selective alpha 2-adrenoceptor antagonists.
AID221207Binding affinity against alpha-2 adrenergic receptor was determined by the displacement of [3H]clonidine from rat brain cortical membranes1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Alpha 2-adrenergic agonists/antagonists: the synthesis and structure-activity relationships of a series of indolin-2-yl and tetrahydroquinolin-2-yl imidazolines.
AID234739Selectivity as the ratio of Ki [3H]prazosin to that of Ki [3H]rauwolscine.1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
N-(1,3,4,6,7,12b-hexahydro-2H-benzo[b]furo[2,3-a]quinolizin -2-yl)-N- methyl-2-hydroxyethane-sulfonamide: a potent and selective alpha 2-adrenoceptor antagonist.
AID233915selectivity ratio is the ratio between pA2 values of alfa2 and alfa1 adrenoceptors1982Journal of medicinal chemistry, Jun, Volume: 25, Issue:6
Structure-activity relationships for 2-substituted imidazoles as alpha 2-adrenoceptor antagonists.
AID19006Calculated membrane partition coefficient (Kmemb)2004Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7
Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.
AID223466In vivo antagonism of guanabenz-induced hypothermia in mice after intraperitoneal administration at a dose of 1 mg/kg2000Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
New substituted 1-(2,3-dihydrobenzo[1, 4]dioxin-2-ylmethyl)piperidin-4-yl derivatives with alpha(2)-adrenoceptor antagonist activity.
AID503659Inverse agonist activity at alpha2A adrenergic receptor T373K mutant expressed in forskolin-stimulated HEK293 cells assessed as suppression of constitutive inhibition of cAMP synthesis at 300 uM2005Nature chemical biology, Jun, Volume: 1, Issue:1
Molecular basis of inverse agonism in a G protein-coupled receptor.
AID36342Compound was evaluated for inhibition of binding of [3H]yohimbine to Alpha-2 adrenergic receptor in alpha2C101995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification.
AID218806Ability to displace [3H]clonidine from alpha-2 adrenergic receptor in rat brain homogenates in vitro1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Synthesis and antidepressant properties of novel 2-substituted 4,5-dihydro-1H-imidazole derivatives.
AID218809In vitro antagonistic activity against alpha-2 adrenergic receptor in isolated electrically stimulated rat vas deferens (clonidine-induced decrease in twitch height)1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Synthesis and antidepressant properties of novel 2-substituted 4,5-dihydro-1H-imidazole derivatives.
AID1720614Agonist activity at NPSR1B in human U2OS cells at 20 uM by PathHunter beta-arrestin assay relative to control2020Bioorganic & medicinal chemistry, 07-15, Volume: 28, Issue:14
Yohimbine as a Starting Point to Access Diverse Natural Product-Like Agents with Re-programmed Activities against Cancer-Relevant GPCR Targets.
AID611926Displacement of [3H]RX821002 from adrenergic alpha2 receptor2011Journal of medicinal chemistry, Aug-11, Volume: 54, Issue:15
Tryptophan 2,3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential anticancer immunomodulators.
AID36367Compound was evaluated for inhibition of binding of [3H]yohimbine to Alpha-2 adrenergic receptor in Malpha2-4H (mouse)1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification.
AID167201Inhibition of specific [3H]clonidine binding (0.4 nM) to rat brain membranes alpha2 adrenoceptor1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists.
AID751697Displacement of [3H]MK912 from human recombinant alpha2A adrenergic receptor expressed in Sf9 cells after 60 mins2013Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells.
AID1336304Displacement of [3H]RX 821002 from rat cerebral cortex alpha-2 adrenergic receptor measured after 60 mins by scintillation counting method2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH
AID36277Relative potency was determined with respect to Yohimbine against alpha-1 adrenergic receptor1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Berbanes: a new class of selective alpha 2-adrenoceptor antagonists.
AID125789Inhibitory effect on Bufuralol 1'-hydroxylation by human liver microsomes (Ki = apparent inhibition constant)1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies.
AID36425Inhibition of phenylephrine-induced contraction of the rabbit aorta as a measure of functional alpha-1-adrenoceptor antagonism1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
(8a alpha,12a alpha,13a alpha)-5,8,8a,9,10,11,12,12a,13,13a-decahydro- 3-methoxy-12-(methylsulfonyl)-6H-isoquino[2,1-g][1,6]naphthyridi ne, a potent and highly selective alpha 2-adrenoceptor antagonist.
AID1546829Antagonist activity at human Gi/o-coupled FPR1 expressed in CHOK1 cells assessed as inhibition in WKYMVm-NH2-induced beta-arrestin 2 recruitment at 20 uM incubated for 30 mins followed by WKYMVm-NH2 addition and measured after 90 or 180 mins by pathhunter2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Preventing Morphine-Seeking Behavior through the Re-Engineering of Vincamine's Biological Activity.
AID36639Alpha-2 adrenergic receptor pA2 value against clonidine in vitro experiment in rat vas deferens1983Journal of medicinal chemistry, Jun, Volume: 26, Issue:6
alpha-adrenoreceptor reagents. 1. Synthesis of some 1,4-benzodioxans as selective presynaptic alpha 2-adrenoreceptor antagonists and potential antidepressants.
AID235866Index of alpha1/alpha2 adrenoceptor binding selectivity.1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists.
AID1581731Displacement of [3H]RX 821002 from human recombinant adrenergic alpha-2A receptor expressed in CHO cell membranes incubated for 60 mins2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
AID503656Inverse agonist activity at alpha2A adrenergic receptor T373K mutant expressed in HEK293 cells assessed as increase in resonance signal at 300 uM by FRET assay2005Nature chemical biology, Jun, Volume: 1, Issue:1
Molecular basis of inverse agonism in a G protein-coupled receptor.
AID1546834Antagonist activity at human Gq-coupled PRLHR expressed in CHOK1 cells assessed as inhibition in prolactin releasing peptide (1 to 31)-induced beta-arrestin 2 recruitment at 20 uM incubated for 30 mins followed by prolactin releasing peptide (1 to 31) add2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Preventing Morphine-Seeking Behavior through the Re-Engineering of Vincamine's Biological Activity.
AID179414In vivo inhibition of clonidine induced mydriasis in the rat following i.v. administration.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Structure-affinity relationships of 12-sulfonyl derivatives of 5,8,8a,9,10,11,12,12a,13,13a-decahydro-6H-isoquino[2,1-g][1 ,6] naphthyridines at alpha-adrenoceptors.
AID226638Hill coefficient value.1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Synthesis of (R,S)-2'-trans-7-hydroxy-2-[N-n-propyl-N-(3'-iodo-2'- propenyl)-amino]tetralin (trans-7-OH-PIPAT): a new D3 dopamine receptor ligand.
AID1846869Antimalarial activity against Plasmodium falciparum incubated for 72 hrs by SYBR green I-based assay2021European journal of medicinal chemistry, Oct-05, Volume: 221Structure activity relationship in β-carboline derived anti-malarial agents.
AID1546828Antagonist activity at human Gi/o-coupled DRD2L expressed in CHOK1 cells assessed as inhibition in dopamine-induced beta-arrestin 2 recruitment at 20 uM incubated for 30 mins followed by dopamine addition and measured after 90 or 180 mins by pathhunter be2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Preventing Morphine-Seeking Behavior through the Re-Engineering of Vincamine's Biological Activity.
AID37335Binding affinity against Alpha-1B adrenergic receptor from human clone1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification.
AID1546824Antagonist activity at human Gs/Gi/o-coupled CHRM4 expressed in CHOK1 cells assessed as inhibition in acetylcholine-induced beta-arrestin 2 recruitment at 20 uM incubated for 30 mins followed by acetylcholine addition and measured after 90 or 180 mins by 2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Preventing Morphine-Seeking Behavior through the Re-Engineering of Vincamine's Biological Activity.
AID36004Binding affinity against Alpha-1 adrenergic receptor in rat cerebral cortical membrane, determined using [3H]-prazosin as the radioligand1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
(8a alpha,12a alpha,13a alpha)-5,8,8a,9,10,11,12,12a,13,13a-decahydro- 3-methoxy-12-(methylsulfonyl)-6H-isoquino[2,1-g][1,6]naphthyridi ne, a potent and highly selective alpha 2-adrenoceptor antagonist.
AID232492Selectivity between alpha2 and alpha-1 adrenoceptors.1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Alpha-adrenoreceptor reagents. 2. Effects of modification of the 1,4-benzodioxan ring system on alpha-adrenoreceptor activity.
AID35935Binding affinity against human Alpha-2A adrenergic receptor expressed stably in CHO cells using [3H]rauwolscine as radioligand2000Bioorganic & medicinal chemistry letters, Apr-03, Volume: 10, Issue:7
Yohimbine dimers exhibiting binding selectivities for human alpha2a- versus alpha2b-adrenergic receptors.
AID235334Selectivity ratio (Alpha-1: Alpha-2)1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Berbanes: a new class of selective alpha 2-adrenoceptor antagonists.
AID1720612Agonist activity at HTR1B in human U2OS cells at 20 uM by PathHunter beta-arrestin assay relative to control2020Bioorganic & medicinal chemistry, 07-15, Volume: 28, Issue:14
Yohimbine as a Starting Point to Access Diverse Natural Product-Like Agents with Re-programmed Activities against Cancer-Relevant GPCR Targets.
AID240619Inhibitory concentration against cytochrome P450 2D62004Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22
Validation of model of cytochrome P450 2D6: an in silico tool for predicting metabolism and inhibition.
AID35314Inhibition of [3H]prazosin binding to human Alpha-1D adrenergic receptor expressed in CHO cells1995Journal of medicinal chemistry, Sep-15, Volume: 38, Issue:19
Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications.
AID233447Selectivity ratio measured as the pKi (alpha-2) /pKi(alpha-1) receptor values.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Structure-affinity relationships of 12-sulfonyl derivatives of 5,8,8a,9,10,11,12,12a,13,13a-decahydro-6H-isoquino[2,1-g][1 ,6] naphthyridines at alpha-adrenoceptors.
AID36344Compound was evaluated for inhibition of binding of [3H]yohimbine to Alpha-2 adrenergic receptor in human adipocyte1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification.
AID402037Inhibition of human recombinant DNA topoisomerase-22005Journal of natural products, Jun, Volume: 68, Issue:6
Indole alkaloids and other constituents of Rauwolfia serpentina.
AID197111Tested for antagonism of clonidine in the field-stimulated rat vas deferens.1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
N-(1,3,4,6,7,12b-hexahydro-2H-benzo[b]furo[2,3-a]quinolizin -2-yl)-N- methyl-2-hydroxyethane-sulfonamide: a potent and selective alpha 2-adrenoceptor antagonist.
AID233431Selectivity ratio for alpha 2 adrenergic receptor subpopulation, [3H]yohimbine pKi minus [3H]-prazosin pKi1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Affinity of 2-(tetrahydroisoquinolin-2-ylmethyl)- and 2-(isoindolin-2-ylmethyl)imidazolines for alpha-adrenoceptors. Differential affinity of imidazolines for the [3H]idazoxan-labeled alpha 2-adrenoceptor vs the [3H]yohimbine-labeled site.
AID36346Compound was evaluated for inhibition of binding of [3H]yohimbine to Alpha-2 adrenergic receptor in rat adipocyte1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification.
AID37243Compound was evaluated for inhibition of binding of [3H]yohimbine to Alpha-2 adrenergic receptor in RNG (rat)1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification.
AID340235Inhibition of alpha 2 adrenergic receptor2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity.
AID1720584Antagonist activity at human FSHR expressed in CHO-K1 cells at 20 uM by PathHunter beta-arrestin assay relative to control2020Bioorganic & medicinal chemistry, 07-15, Volume: 28, Issue:14
Yohimbine as a Starting Point to Access Diverse Natural Product-Like Agents with Re-programmed Activities against Cancer-Relevant GPCR Targets.
AID1720585Antagonist activity at HTR1B in human U2OS cells at 20 uM by PathHunter beta-arrestin assay relative to control2020Bioorganic & medicinal chemistry, 07-15, Volume: 28, Issue:14
Yohimbine as a Starting Point to Access Diverse Natural Product-Like Agents with Re-programmed Activities against Cancer-Relevant GPCR Targets.
AID382239Binding affinity to adrenergic alpha1H receptor2008Bioorganic & medicinal chemistry, May-01, Volume: 16, Issue:9
Recent advances in selective alpha1-adrenoreceptor antagonists as antihypertensive agents.
AID35872Presynaptic antagonistic activity against alpha-1 adrenergic receptor from rat, isolated, field-stimulated vas deferens, using methoxamine as the agonist1983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Pyridinylpiperazines, a new class of selective alpha 2-adrenoceptor antagonists.
AID402039Cytotoxicity against human HL60 cells by MTT assay2005Journal of natural products, Jun, Volume: 68, Issue:6
Indole alkaloids and other constituents of Rauwolfia serpentina.
AID36781Binding affinity towards rat Alpha-2 adrenergic receptor was evaluated using [3H]- yohimbine as radioligand1996Journal of medicinal chemistry, Dec-06, Volume: 39, Issue:25
Structure-activity relationship studies on the 5-HT(1A) receptor affinity of 1-phenyl-4-[omega-(alpha- or beta-tetralinyl)alkyl]piperazines. 4.
AID180483Reversal clonidine-induced mydriasis in rat, after oral administration1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
(8a alpha,12a alpha,13a alpha)-5,8,8a,9,10,11,12,12a,13,13a-decahydro- 3-methoxy-12-(methylsulfonyl)-6H-isoquino[2,1-g][1,6]naphthyridi ne, a potent and highly selective alpha 2-adrenoceptor antagonist.
AID503831Inverse agonist activity at alpha2A adrenergic receptor T373K mutant expressed in HEK293 cells assessed as change in resonance signal at 100 uM by FRET assay2005Nature chemical biology, Jun, Volume: 1, Issue:1
Molecular basis of inverse agonism in a G protein-coupled receptor.
AID1720589Antagonist activity at human PRLHR expressed in CHO-K1 cells at 20 uM by PathHunter beta-arrestin assay relative to control2020Bioorganic & medicinal chemistry, 07-15, Volume: 28, Issue:14
Yohimbine as a Starting Point to Access Diverse Natural Product-Like Agents with Re-programmed Activities against Cancer-Relevant GPCR Targets.
AID1720617Agonist activity at human ADRA2A expressed in CHO-K1 cells at 20 uM by PathHunter beta-arrestin assay relative to control2020Bioorganic & medicinal chemistry, 07-15, Volume: 28, Issue:14
Yohimbine as a Starting Point to Access Diverse Natural Product-Like Agents with Re-programmed Activities against Cancer-Relevant GPCR Targets.
AID1581730Displacement of [3H]prazosin from human recombinant adrenergic alpha-1D receptor expressed in CHO cell membranes incubated for 60 mins2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
AID503828Inverse agonist activity at adrenergic alpha2A receptor expressed in HEK293 cells coexpressing yellow fluorescent and cyan fluorescent protein assessed as induction of receptor conformational change at 250 to 1000 uM by FRET assay2005Nature chemical biology, Jun, Volume: 1, Issue:1
Molecular basis of inverse agonism in a G protein-coupled receptor.
AID150607Inhibition of partially purified cytochrome P450 2D6 1'-hydroxybufuralol formation1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies.
AID1720616Agonist activity at human PRLHR expressed in CHO-K1 cells at 20 uM by PathHunter beta-arrestin assay relative to control2020Bioorganic & medicinal chemistry, 07-15, Volume: 28, Issue:14
Yohimbine as a Starting Point to Access Diverse Natural Product-Like Agents with Re-programmed Activities against Cancer-Relevant GPCR Targets.
AID234972Selectivity as antilog of pA2 (UK-14304) minus pA2 (phenylephrine).1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
(8a alpha,12a alpha,13a alpha)-5,8,8a,9,10,11,12,12a,13,13a-decahydro- 3-methoxy-12-(methylsulfonyl)-6H-isoquino[2,1-g][1,6]naphthyridi ne, a potent and highly selective alpha 2-adrenoceptor antagonist.
AID205268Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 10 uM1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID36600Inhibition of [3H]prazosin binding to human Alpha-1A adrenergic receptor expressed in CHO cells1995Journal of medicinal chemistry, Sep-15, Volume: 38, Issue:19
Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications.
AID1720588Antagonist activity at human OXTR expressed in CHO-K1 cells at 20 uM by PathHunter beta-arrestin assay relative to control2020Bioorganic & medicinal chemistry, 07-15, Volume: 28, Issue:14
Yohimbine as a Starting Point to Access Diverse Natural Product-Like Agents with Re-programmed Activities against Cancer-Relevant GPCR Targets.
AID35970Evaluated for its ability to displace [3H]prazosin from alpha-1-Adrenoceptor of calf cerebral cortex1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
N-(1,3,4,6,7,12b-hexahydro-2H-benzo[b]furo[2,3-a]quinolizin -2-yl)-N- methyl-2-hydroxyethane-sulfonamide: a potent and selective alpha 2-adrenoceptor antagonist.
AID1720579Antagonist activity at human CCR3 expressed in CHO-K1 cells at 20 uM by PathHunter beta-arrestin assay relative to control2020Bioorganic & medicinal chemistry, 07-15, Volume: 28, Issue:14
Yohimbine as a Starting Point to Access Diverse Natural Product-Like Agents with Re-programmed Activities against Cancer-Relevant GPCR Targets.
AID5796Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Potent, selective tetrahydro-beta-carboline antagonists of the serotonin 2B (5HT2B) contractile receptor in the rat stomach fundus.
AID380498Displacement of [3H]MK912 from human recombinant adrenergic alpha2A receptor expressed in Sf9 cells2006Journal of natural products, Mar, Volume: 69, Issue:3
Alkaloids from Eschscholzia californica and their capacity to inhibit binding of [3H]8-Hydroxy-2-(di-N-propylamino)tetralin to 5-HT1A receptors in Vitro.
AID1720577Antagonist activity at human ADRA2B expressed in CHO-K1 cells at 20 uM by PathHunter beta-arrestin assay relative to control2020Bioorganic & medicinal chemistry, 07-15, Volume: 28, Issue:14
Yohimbine as a Starting Point to Access Diverse Natural Product-Like Agents with Re-programmed Activities against Cancer-Relevant GPCR Targets.
AID1720603Agonist activity at human ADRA1B expressed in CHO-K1 cells at 20 uM by PathHunter beta-arrestin assay relative to control2020Bioorganic & medicinal chemistry, 07-15, Volume: 28, Issue:14
Yohimbine as a Starting Point to Access Diverse Natural Product-Like Agents with Re-programmed Activities against Cancer-Relevant GPCR Targets.
AID35861Antagonistic activity against alpha-1 adrenergic receptor in isolated rat anococcygeus muscle1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Synthesis and structure-activity relationships of 2-sulfonamido-1,3,4,6,7,11b alpha-hexahydro-2H-benzo[a]quinolizines as alpha 2-adrenoceptor antagonists.
AID36707Alpha-1-adrenolytic activity was assessed in vitro from the ability to inhibit clonidine binding to rat aorta preparation1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
New 1,4-dihydropyridine derivatives combining calcium antagonism and alpha-adrenolytic properties.
AID1720580Antagonist activity at human CCR8 expressed in CHO-K1 cells at 20 uM by PathHunter beta-arrestin assay relative to control2020Bioorganic & medicinal chemistry, 07-15, Volume: 28, Issue:14
Yohimbine as a Starting Point to Access Diverse Natural Product-Like Agents with Re-programmed Activities against Cancer-Relevant GPCR Targets.
AID35945Inhibition of [3H]rauwolscine binding to CHO cells expressing the human Alpha-2A adrenergic receptor1995Journal of medicinal chemistry, Sep-15, Volume: 38, Issue:19
Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID382494Binding affinity to adrenergic alpha1N receptor2008Bioorganic & medicinal chemistry, May-01, Volume: 16, Issue:9
Recent advances in selective alpha1-adrenoreceptor antagonists as antihypertensive agents.
AID231408Antilog of [3H]idazoxan pKi minus [3H]-yohimbine pKi1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Affinity of 2-(tetrahydroisoquinolin-2-ylmethyl)- and 2-(isoindolin-2-ylmethyl)imidazolines for alpha-adrenoceptors. Differential affinity of imidazolines for the [3H]idazoxan-labeled alpha 2-adrenoceptor vs the [3H]yohimbine-labeled site.
AID1720615Agonist activity at human OXTR expressed in CHO-K1 cells at 20 uM by PathHunter beta-arrestin assay relative to control2020Bioorganic & medicinal chemistry, 07-15, Volume: 28, Issue:14
Yohimbine as a Starting Point to Access Diverse Natural Product-Like Agents with Re-programmed Activities against Cancer-Relevant GPCR Targets.
AID5675Binding affinity analysed towards 5-HT 2C in rat stomach fundus1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Potent, selective tetrahydro-beta-carboline antagonists of the serotonin 2B (5HT2B) contractile receptor in the rat stomach fundus.
AID36706Alpha-1-adrenolytic activity was assessed from the ability to inhibit [3H]prazosin binding to rat cerebral cortex preparation1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
New 1,4-dihydropyridine derivatives combining calcium antagonism and alpha-adrenolytic properties.
AID37369Evaluated for its ability to displace [3H]rauwolscine from alpha-2 adrenergic receptor of rat cerebral cortex1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
N-(1,3,4,6,7,12b-hexahydro-2H-benzo[b]furo[2,3-a]quinolizin -2-yl)-N- methyl-2-hydroxyethane-sulfonamide: a potent and selective alpha 2-adrenoceptor antagonist.
AID35626Binding affinity to alpha-2 adrenergic receptor of rat cerebral cortex assayed using [3H]yohimbine as radioligand1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Affinity of 2-(tetrahydroisoquinolin-2-ylmethyl)- and 2-(isoindolin-2-ylmethyl)imidazolines for alpha-adrenoceptors. Differential affinity of imidazolines for the [3H]idazoxan-labeled alpha 2-adrenoceptor vs the [3H]yohimbine-labeled site.
AID35963Binding activity against alpha-1 adrenergic receptor from calf cerebral cortex, using [3H]-prazosin as the radioligand1983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Pyridinylpiperazines, a new class of selective alpha 2-adrenoceptor antagonists.
AID197112Tested for antagonism of methoxamine in the field-stimulated rat vas deferens.1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
N-(1,3,4,6,7,12b-hexahydro-2H-benzo[b]furo[2,3-a]quinolizin -2-yl)-N- methyl-2-hydroxyethane-sulfonamide: a potent and selective alpha 2-adrenoceptor antagonist.
AID229627Selectivity ratio represented as antilog (alpha-2 pA2 - alpha-1 pA2)1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Synthesis and structure-activity relationships of 2-sulfonamido-1,3,4,6,7,11b alpha-hexahydro-2H-benzo[a]quinolizines as alpha 2-adrenoceptor antagonists.
AID1720578Antagonist activity at human AVPR2 at 20 uM by PathHunter beta-arrestin assay relative to control2020Bioorganic & medicinal chemistry, 07-15, Volume: 28, Issue:14
Yohimbine as a Starting Point to Access Diverse Natural Product-Like Agents with Re-programmed Activities against Cancer-Relevant GPCR Targets.
AID1720608Agonist activity at human CX3CR1 expressed in CHO-K1 cells at 20 uM by PathHunter beta-arrestin assay relative to control2020Bioorganic & medicinal chemistry, 07-15, Volume: 28, Issue:14
Yohimbine as a Starting Point to Access Diverse Natural Product-Like Agents with Re-programmed Activities against Cancer-Relevant GPCR Targets.
AID1546826Antagonist activity at human Gi/o-coupled CNR2 expressed in CHOK1 cells assessed as inhibition in CP55940-induced beta-arrestin 2 recruitment at 20 uM incubated for 30 mins followed by CP55940 addition and measured after 90 or 180 mins by pathhunter beta-2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Preventing Morphine-Seeking Behavior through the Re-Engineering of Vincamine's Biological Activity.
AID233275Selectivity ratio expressed as the ratio of -log methoxamine pA2 to -log clonidine pA21984Journal of medicinal chemistry, Sep, Volume: 27, Issue:9
Adrenoceptor and tetrabenazine antagonism activities of some pyridinyltetrahydropyridines.
AID1285612Displacement of [3H]RX 821002 from rat cerebral cortex Alpha-2 adrenergic receptor2016Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8
Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.
AID683025Antidepressant activity in CD1 mouse assessed as decrease in immobility time at 0.1 mg/kg, sc measured after 15 mins by forced swim test relative to vehicle-treated control2012ACS medicinal chemistry letters, Jul-12, Volume: 3, Issue:7
Low Doses of Allyphenyline and Cyclomethyline, Effective against Morphine Dependence, Elicit an Antidepressant-like Effect.
AID35361Antagonistic activity against presynaptic alpha-2 adrenergic receptor in isolated rat vas deferens using xylazine as agonist1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Berbanes: a new class of selective alpha 2-adrenoceptor antagonists.
AID1196335Displacement of [3H]RX-821002 from human adrenergic alpha2C receptor expressed in CHO cells2015European journal of medicinal chemistry, Mar-06, Volume: 92Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia.
AID36422Inhibition of specific [3H]prazosin binding (0.2 nM) to rat brain membranes alpha-1 adrenergic receptor1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists.
AID217461Inhibition of [3H]nitrendipine binding to membrane homogenates of rat cardiac muscle.1995Journal of medicinal chemistry, Sep-15, Volume: 38, Issue:19
Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications.
AID36057Antagonistic activity against adrenergic alpha-2 receptor in longitudinal muscle strip of the guinea pig ileum using l-norepinephrine as agonist1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Berbanes: a new class of selective alpha 2-adrenoceptor antagonists.
AID1720605Agonist activity at human AVPR2 at 20 uM by PathHunter beta-arrestin assay relative to control2020Bioorganic & medicinal chemistry, 07-15, Volume: 28, Issue:14
Yohimbine as a Starting Point to Access Diverse Natural Product-Like Agents with Re-programmed Activities against Cancer-Relevant GPCR Targets.
AID624629Inhibition of Pgp expressed in MDR1-MDCKII cells measured by calcein-AM assay2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID35574Ratio of alpha1, alpha2 adrenoceptor antagonistic activity was expressed as slelctivity ratio1981Journal of medicinal chemistry, Nov, Volume: 24, Issue:11
Synthesis and antihypertensive activity of a series of 8-substituted 1-oxa-3,8-diazaspiro[4.5]decan-2-ones.
AID196436Inhibition constant on radiolabeled [125 I] FIDA2 binding to rat striatal membranes1993Journal of medicinal chemistry, Jan-22, Volume: 36, Issue:2
Fluorinated and iodinated dopamine agents: D2 imaging agents for PET and SPECT.
AID125788Inhibition of 1'-hydroxybufuralol formation by human liver microsomes1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies.
AID35476Presynaptic antagonistic activity against alpha-2 adrenergic receptor from rat, isolated, field-stimulated vas deferens, using clonidine as the agonist1983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Pyridinylpiperazines, a new class of selective alpha 2-adrenoceptor antagonists.
AID691261Inhibition of His-tagged Cdc25A expressed in the Escherichia coli BL21(DE3) using p-nitrophenyl phosphate as substrate for 80 mins by spectrophotometry2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Charting, navigating, and populating natural product chemical space for drug discovery.
AID196985In vivo antagonist activity against B-HT 933-induced Alpha-2 adrenergic receptor-mediated vasoconstriction in pithed normotensive rats1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists.
AID35624Binding affinity to alpha-2 adrenergic receptor determined by measurement of [3H]yohimbine displacement from rat cortical membrane1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Structure-affinity relationships of 12-sulfonyl derivatives of 5,8,8a,9,10,11,12,12a,13,13a-decahydro-6H-isoquino[2,1-g][1 ,6] naphthyridines at alpha-adrenoceptors.
AID238250Binding affinity for cytochrome P450 2D62004Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22
Validation of model of cytochrome P450 2D6: an in silico tool for predicting metabolism and inhibition.
AID503658Inverse agonist activity at alpha2A adrenergic receptor T373K mutant expressed in forskolin-stimulated HEK293 cells assessed as suppression of constitutive inhibition of cAMP synthesis at 30 uM2005Nature chemical biology, Jun, Volume: 1, Issue:1
Molecular basis of inverse agonism in a G protein-coupled receptor.
AID35911Evaluated for its ability to displace [3H]clonidine from alpha-2 adrenergic receptor of calf cerebral cortex1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
N-(1,3,4,6,7,12b-hexahydro-2H-benzo[b]furo[2,3-a]quinolizin -2-yl)-N- methyl-2-hydroxyethane-sulfonamide: a potent and selective alpha 2-adrenoceptor antagonist.
AID36498Compound was evaluated for inhibition of binding of [3H]yohimbine to Alpha-2 adrenergic receptor in OK cell1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification.
AID36515Compound was evaluated for inhibition of binding of [3H]-yohimbine to Alpha-2 adrenergic receptor in rabbit adipocyte1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification.
AID624628Drug-stimulated Pgp ATPase activity ratio determined in MDR1-Sf9 cell membranes with test compound at a concentration of 20uM2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID227718Binding energy by using the equation deltaG obsd = -RT ln KD1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Functional group contributions to drug-receptor interactions.
AID141670Inhibition of [3H]quinuclidinyl benzilate (QNB) binding from rat forebrain membranes in the presence of Zn; Not tested1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeutic agents for Alzheimer's disease.
AID35902Binding activity against alpha-2 adrenergic receptor from calf cerebral cortex, using [3H]clonidine as the radioligand1983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Pyridinylpiperazines, a new class of selective alpha 2-adrenoceptor antagonists.
AID114183Effective dose against administration in mice1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeutic agents for Alzheimer's disease.
AID36281Antagonistic activity against postsynaptic alpha-1 adrenergic receptor in rabbit pulmonary artery using l-norepinephrine as agonist1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Berbanes: a new class of selective alpha 2-adrenoceptor antagonists.
AID37247Compound was evaluated for inhibition of binding of [3H]yohimbine to Alpha-2 adrenergic receptor in rat kidney1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification.
AID35849Alpha-1 adrenergic receptor pA2 value against norepinephrine in vitro experiment in rat anococcygeus.1983Journal of medicinal chemistry, Jun, Volume: 26, Issue:6
alpha-adrenoreceptor reagents. 1. Synthesis of some 1,4-benzodioxans as selective presynaptic alpha 2-adrenoreceptor antagonists and potential antidepressants.
AID196984Antagonist activity against phenylephrine-induced alpha1- adrenoceptor mediated vasoconstriction in pithed normotensive rats. 1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists.
AID751762Displacement of [3H]MK912 from human recombinant alpha2A adrenergic receptor expressed in Sf9 cells at 10 uM after 60 mins relative to control2013Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells.
AID1581733Displacement of [3H]RX 821002 from human recombinant adrenergic alpha-2C receptor expressed in CHO cell membranes incubated for 60 mins2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
AID1581729Displacement of [3H]prazosin from human recombinant adrenergic alpha-1B receptor expressed in CHO cell membranes incubated for 60 mins2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
AID36220Binding affinity against human alpha 2b-adrenergic receptor expressed stably in CHO cells using [3H]rauwolscine as radioligand2000Bioorganic & medicinal chemistry letters, Apr-03, Volume: 10, Issue:7
Yohimbine dimers exhibiting binding selectivities for human alpha2a- versus alpha2b-adrenergic receptors.
AID650485Potentiation of morphine-induced analgesic activity in CD1 mouse assessed as latency in radiant heat-induced tail flick at 1.250 mg/kg, ip administered 15 mins prior to morphine measured up to 120 mins2012Bioorganic & medicinal chemistry, Apr-01, Volume: 20, Issue:7
Favourable involvement of α2A-adrenoreceptor antagonism in the I₂-imidazoline binding sites-mediated morphine analgesia enhancement.
AID37241Compound was evaluated for inhibition of binding of [3H]yohimbine to Alpha-2 adrenergic receptor in RGlO (rat)1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification.
AID36353Compound was evaluated for inhibition of binding of [3H]yohimbine to Alpha-2 adrenergic receptor in Malpha-10H (mouse)1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification.
AID233276Relative binding to alpha-1a and alpha-2 adrenergic receptors (ratio of Ki-prazosin and Ki-clonidine)1984Journal of medicinal chemistry, Sep, Volume: 27, Issue:9
Adrenoceptor and tetrabenazine antagonism activities of some pyridinyltetrahydropyridines.
AID1546830Antagonist activity at human GPR119 assessed as inhibition in oleoylethanolamide-induced beta-arrestin 2 recruitment at 20 uM incubated for 30 mins followed by oleoylethanolamide addition and measured after 90 or 180 mins by pathhunter beta-arrestin assay2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Preventing Morphine-Seeking Behavior through the Re-Engineering of Vincamine's Biological Activity.
AID1546833Antagonist activity at human Gq-coupled NPSR1b expressed in human U2OS cells assessed as inhibition in neuropeptide S-induced beta-arrestin 2 recruitment at 20 uM incubated for 30 mins followed by neuropeptide S addition and measured after 90 or 180 mins 2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Preventing Morphine-Seeking Behavior through the Re-Engineering of Vincamine's Biological Activity.
AID234973Selectivity as antilog of pKi [3H]yohimbine minus pKi [3H]-prazosin.1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
(8a alpha,12a alpha,13a alpha)-5,8,8a,9,10,11,12,12a,13,13a-decahydro- 3-methoxy-12-(methylsulfonyl)-6H-isoquino[2,1-g][1,6]naphthyridi ne, a potent and highly selective alpha 2-adrenoceptor antagonist.
AID640615Clearance in human liver microsomes at 1 uM measured after 60 mins by HPLC analysis2012Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
Capture hydrolysis signals in the microsomal stability assay: molecular mechanisms of the alkyl ester drug and prodrug metabolism.
AID35907Displacement of [3H]clonidine from calf cerebral cortex alpha-2 adrenergic receptor1984Journal of medicinal chemistry, Sep, Volume: 27, Issue:9
Adrenoceptor and tetrabenazine antagonism activities of some pyridinyltetrahydropyridines.
AID36040Compound was evaluated for inhibition of binding of [3H]yohimbine to Alpha-2 adrenergic receptor in canine adipocyte1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification.
AID566240Inhibition of rat alpha2 adrenoceptor2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: de
AID1720610Agonist activity at human DRD2L expressed in CHO-K1 cells at 20 uM by PathHunter beta-arrestin assay relative to control2020Bioorganic & medicinal chemistry, 07-15, Volume: 28, Issue:14
Yohimbine as a Starting Point to Access Diverse Natural Product-Like Agents with Re-programmed Activities against Cancer-Relevant GPCR Targets.
AID37246Compound was evaluated for inhibition of binding of [3H]yohimbine to Alpha-2 adrenergic receptor in rat enterocyte1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification.
AID624622Apparent permeability (Papp) from apical to basolateral side determined in MDR1-MDCKII cells2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID36648Antagonistic activity against central alpha-2 adrenergic receptor, in anesthetized rats (reversal of clonidine-induced mydriasis)1983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Pyridinylpiperazines, a new class of selective alpha 2-adrenoceptor antagonists.
AID1720583Antagonist activity at human DRD2L expressed in CHO-K1 cells at 20 uM by PathHunter beta-arrestin assay relative to control2020Bioorganic & medicinal chemistry, 07-15, Volume: 28, Issue:14
Yohimbine as a Starting Point to Access Diverse Natural Product-Like Agents with Re-programmed Activities against Cancer-Relevant GPCR Targets.
AID1720613Agonist activity at HTR2C in human U2OS cells at 20 uM by PathHunter beta-arrestin assay relative to control2020Bioorganic & medicinal chemistry, 07-15, Volume: 28, Issue:14
Yohimbine as a Starting Point to Access Diverse Natural Product-Like Agents with Re-programmed Activities against Cancer-Relevant GPCR Targets.
AID503652Displacement of [3H]RX821002 from adrenergic alpha2A receptor T373K mutant expressed in human HEK293 cells2005Nature chemical biology, Jun, Volume: 1, Issue:1
Molecular basis of inverse agonism in a G protein-coupled receptor.
AID35187Displacement of [3H]clonidine from Alpha-2 adrenergic receptor of rat brain membranes1982Journal of medicinal chemistry, Dec, Volume: 25, Issue:12
alpha 2 adrenoceptors: classification, localization, mechanisms, and targets for drugs.
AID503660Inverse agonist activity at adrenergic alpha2A receptor expressed in HEK293 cells coexpressing yellow fluorescent and cyan fluorescent protein assessed as reversal of norepinephrine-induced resonance signal at 100 uM by FRET assay2005Nature chemical biology, Jun, Volume: 1, Issue:1
Molecular basis of inverse agonism in a G protein-coupled receptor.
AID5457Binding affinity for 5-HT 2A in rat stomach fundus1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Potent, selective tetrahydro-beta-carboline antagonists of the serotonin 2B (5HT2B) contractile receptor in the rat stomach fundus.
AID36782Binding affinity against Alpha-2 adrenergic receptor in rat brain membrane using [3H]yohimbine as radioligand1996Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16
1-aryl-4-[(1-tetralinyl)alkyl]piperazines: alkylamido and alkylamino derivatives. Synthesis, 5-HT1A receptor affinity, and selectivity. 3.
AID35625Binding affinity to the alpha-2 adrenergic receptor of rat cerebral cortex assayed using [3H]idazoxan as radioligand1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Affinity of 2-(tetrahydroisoquinolin-2-ylmethyl)- and 2-(isoindolin-2-ylmethyl)imidazolines for alpha-adrenoceptors. Differential affinity of imidazolines for the [3H]idazoxan-labeled alpha 2-adrenoceptor vs the [3H]yohimbine-labeled site.
AID36496Alpha-2 adrenergic receptor agonist activity in mouse vas deferens relative to clonidine1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Alpha-adrenoreceptor reagents. 2. Effects of modification of the 1,4-benzodioxan ring system on alpha-adrenoreceptor activity.
AID37245Compound was evaluated for inhibition of binding of [3H]yohimbine to Alpha-2 adrenergic receptor in neonatal rat lung1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification.
AID1720590Antagonist activity at human ADRA2A expressed in CHO-K1 cells at 20 uM by PathHunter beta-arrestin assay relative to control2020Bioorganic & medicinal chemistry, 07-15, Volume: 28, Issue:14
Yohimbine as a Starting Point to Access Diverse Natural Product-Like Agents with Re-programmed Activities against Cancer-Relevant GPCR Targets.
AID35504Binding affinity against Alpha-2 adrenergic receptor in rat cerebral cortical membrane, determined using [3H]- yohimbine as the radioligand1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
(8a alpha,12a alpha,13a alpha)-5,8,8a,9,10,11,12,12a,13,13a-decahydro- 3-methoxy-12-(methylsulfonyl)-6H-isoquino[2,1-g][1,6]naphthyridi ne, a potent and highly selective alpha 2-adrenoceptor antagonist.
AID118336Antagonistic activity against Scopolamine induced behavioral deficits in mice at dose 0.31 mg/kg sc; Not tested1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeutic agents for Alzheimer's disease.
AID205267Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID1581732Displacement of [3H]RX 821002 from human recombinant adrenergic alpha-2B receptor expressed in CHO cell membranes incubated for 60 mins2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
AID36374Inhibition of [3H]- Yohimbine binding against rat kidney cortex Alpha-2B adrenergic receptor1999Journal of medicinal chemistry, Dec-16, Volume: 42, Issue:25
A series of 6- and 7-piperazinyl- and -piperidinylmethylbenzoxazinones with dopamine D4 antagonist activity: discovery of a potential atypical antipsychotic agent.
AID274935Antagonist effect on compound A-induced antinociception in Swiss Albino mouse at 3 mg/kg, ip2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
Arylpiperazinylalkylpyridazinones and analogues as potent and orally active antinociceptive agents: synthesis and studies on mechanism of action.
AID37213Inhibition of [3H]prazosin binding to human Alpha-1B adrenergic receptor expressed in CHO cells1995Journal of medicinal chemistry, Sep-15, Volume: 38, Issue:19
Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications.
AID37240Compound was evaluated for inhibition of binding of [3H]yohimbine to Alpha-2 adrenergic receptor in RG20 (rat)1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification.
AID35865Antagonistic activity upon postsynaptic alpha-1 adrenergic receptor was determined in the rat isolated, field stimulated vas deferens using methoxamine1984Journal of medicinal chemistry, Sep, Volume: 27, Issue:9
Adrenoceptor and tetrabenazine antagonism activities of some pyridinyltetrahydropyridines.
AID683026Antidepressant activity in CD1 mouse assessed as decrease in immobility time at 1.25 mg/kg, sc measured after 15 mins by forced swim test relative to vehicle-treated control2012ACS medicinal chemistry letters, Jul-12, Volume: 3, Issue:7
Low Doses of Allyphenyline and Cyclomethyline, Effective against Morphine Dependence, Elicit an Antidepressant-like Effect.
AID503650Inverse agonist activity at adrenergic alpha2A receptor expressed in HEK293 cells coexpressing yellow fluorescent and cyan fluorescent protein assessed as increase in resonance signal at 300 uM by FRET assay2005Nature chemical biology, Jun, Volume: 1, Issue:1
Molecular basis of inverse agonism in a G protein-coupled receptor.
AID1546827Antagonist activity at human Gi/o-coupled CXCR4 expressed in mouse C2C12 cells assessed as inhibition in CXCL12-induced beta-arrestin 2 recruitment at 20 uM incubated for 30 mins followed by CXCL12 addition and measured after 90 or 180 mins by pathhunter 2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Preventing Morphine-Seeking Behavior through the Re-Engineering of Vincamine's Biological Activity.
AID1347391qHTS for activators of Nrf2/ARE signaling pathway screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347365SDT Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347358HPAF-II 12hr Apoptosis Induction qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347347UWB1.289 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347348OV-SAHO Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID134737610-beta competent E. coli microbial cell viability qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347402qHTS for inhibitors of Rabies Virus screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347346HPAF-II Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347370qHTS for ATAD5 Antagonist screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347377DH5-alpha competent E. coli microbial cell viability qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347378qHTS for H2AX Agonists against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347401Redox Reaction Profiling qHTS: Assay Interference Panel against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347375qHTS for Hypoxia signaling pathway (HIF-1) agonists against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347374qHTS for Hypoxia signaling pathway (HIF-1) antagonists against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347356HPAF-II 24hr Apoptosis Induction qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347380qHTS for Antimalaria activity screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347350SW1088 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347390Secretion counterscreen for inhibitors of the SERCaMP assay screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347394Vero-766 cells viability qHTS against the NCATS CANVASS Library: Counterscreen for Zika virus inhibition assay2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347349Panc-1005 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347354UWB1.289-WTBRCA1 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347379qHTS for Inflammasome Signaling Inhibitors: IL-1-beta AlphaLISA screen against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347362Diaphorse counterscreen qHTS: Assay Interference Panel against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347372qHTS for Constitutive Androstane Receptor (CAR) Antagonist screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347392qHTS for activators of dead-cell proteases activity screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347388qHTS for Activators of p53 Stress Response Pathway screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347351U-118MG Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347400Viability qHTS for inhibitors of the SERCaMP assay screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347373qHTS for Constitutive Androstane Receptor (CAR) Agonist screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347353A2780 Cisplatin Sensitive Ovarian Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347361HEK293 12hr Apoptosis Induction qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347360HPAF-II 18hr Apoptosis Induction qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347369MCF7 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347359HEK293 24hr Apoptosis Induction qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347366KB-3-1 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347387Cytotoxicity qHTS for assessment of Hepg2 cells membrane integrity screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347396qHTS for inhibitors of Wild type Zika virus screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347393qHTS for inhibitors of ER calcium dysfunction: SERCaMP assay screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347364KB-8-5-11 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347389qHTS assay for small molecule disruptors of mitochondrial membrane potential screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347367qHTS for ATAD5 Agonist screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347368G06 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347371J3T Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347363Firefly luciferase counterscreen qHTS: Assay Interference Panel against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347357HEK293 18hr Apoptosis Induction qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347352COV-362 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347355HEK-293 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347381Inflammasome Signaling qHTS Counterscreen: IL-1-beta AlphaLISA counterscreen against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347345OV-KATE Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5,638)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902643 (46.88)18.7374
1990's1611 (28.57)18.2507
2000's802 (14.22)29.6817
2010's487 (8.64)24.3611
2020's95 (1.68)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 55.00

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index55.00 (24.57)
Research Supply Index8.72 (2.92)
Research Growth Index4.28 (4.65)
Search Engine Demand Index192.34 (26.88)
Search Engine Supply Index3.92 (0.95)

This Compound (55.00)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials253 (4.29%)5.53%
Reviews135 (2.29%)6.00%
Case Studies61 (1.04%)4.05%
Observational0 (0.00%)0.25%
Other5,444 (92.38%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (27)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Role of the Noradrenergic System in the Nonmotor Symptoms of Parkinson's Disease: Orthostatic Hypotension and Other Nonmotor Symptoms [NCT04346394]Early Phase 10 participants (Actual)Interventional2021-05-11Withdrawn(stopped due to COVID-19)
The Role of Stress Neuromodulators in Decision Making Under Risk [NCT04359147]167 participants (Actual)Interventional2019-11-01Completed
Neuropharmacological Investigation of Frontostriatal Network Function and Nicotine Seeking Behavior in Current Smokers [NCT03670212]Phase 121 participants (Actual)Interventional2016-01-07Completed
Using Repetitive Transcranial Magnetic Stimulation (rTMS) to Explore Neural Mechanisms of Stress-Induced Opioid Use [NCT04181515]Phase 20 participants (Actual)Interventional2023-04-10Withdrawn(stopped due to Lack of funding)
Impact of Repetitive Transcranial Magnetic Stimulation (rTMS) of Limbic Brain Circuitry in Stress Modulation in a Healthy Population [NCT04180969]Phase 20 participants (Actual)Interventional2023-04-10Withdrawn(stopped due to Lack of funding)
The Pathophysiology of Orthostatic Hypotension [NCT00748059]Phase 110 participants (Actual)Interventional1996-12-31Completed
Placebo-Controlled Evaluation of the Efficacy of Yohimbine Hydrochloride for Enhancing the Effects of CBT for Social Phobia [NCT00958880]Phase 340 participants (Actual)Interventional2009-03-31Completed
Characterisation of Relative Bioavailability and Assessment of Bioequivalence of Two Generic Yohimbine Formulations in Comparison With a Marketed Reference Product - an Open, Randomised, Single Dose, 3-period Change-over Study [NCT00975325]Phase 442 participants (Actual)Interventional2009-10-31Completed
Influence of the Noradrenergic System on the Formation of Intrusive Memories: An Experimental Approach With a Trauma Film Paradigm [NCT02541071]118 participants (Actual)Interventional2013-11-30Completed
Psychophysiology of Prolonged Exposure for PTSD With/Without Yohimbine [NCT01031979]Phase 226 participants (Actual)Interventional2010-12-01Completed
Effects of Pharmacological Stress and Repetitive Transcranial Magnetic Stimulation Interventions on Executive Function in Opioid Use Disorder [NCT04231708]Phase 220 participants (Anticipated)Interventional2023-10-31Not yet recruiting
The Effect of an α2-Adrenoceptor Antagonist (Yohimbine) on Dynamic Autoregulation in the Human Middle Cerebral Artery and Ophthalmic Artery [NCT00814047]Phase 418 participants InterventionalCompleted
Alpha(2)-Adrenoreceptor (AR) Subtype Polymorphisms and Physiological Responses to Alpha(2)-AR Agonist and Antagonist Drugs [NCT00029627]200 participants Observational2002-01-31Completed
Identifying the Pathophysiology of Neurogenic Orthostatic Hypotension and the Effects of Melatonin on Reducing Supine Hypertension in Peripherally Intact Versus Denervated Post-ganglionic Sympathetic Nerves [NCT02963181]Early Phase 110 participants (Actual)Interventional2018-03-01Terminated(stopped due to PI leaving)
Evaluation and Treatment of Autonomic Failure. [NCT00223691]Phase 1389 participants (Actual)Interventional2002-03-31Completed
Role Of Sensitivity to neuroEndocrine Systems in Social Decisions [NCT06018727]Phase 4104 participants (Anticipated)Interventional2024-03-31Not yet recruiting
SCOR on Sex and Gender Factors Affecting Women's Health [NCT00535002]Phase 2112 participants (Actual)Interventional2007-09-30Completed
Modulation of Pharmacologically Induced Alcohol Craving in Recently Detoxified Alcoholics [NCT00605904]Phase 237 participants (Actual)Interventional2008-01-31Completed
An Investigation of a Pharmacologic Strategy to Bring About Rapid (Next Day) Antidepressant Effects [NCT00078715]Phase 211 participants (Actual)Interventional2004-03-31Completed
The Effects of Cortisol and Norepinephrine Modulation on Emotional and Nonemotional Processing [NCT00032838]170 participants Observational2002-03-31Completed
Effect of Oral Yohimbine on Colonic Transit: Randomized, Placebo-Controlled Trial [NCT00217048]Phase 1/Phase 230 participants (Anticipated)Interventional2005-06-30Completed
Effects of Alpha-2 Adrenergic and Opiate Receptor Blockade on Sexual Function in Healthy Male Volunteers [NCT00042536]40 participants Observational2002-07-31Completed
The Role of Sympatho-vagal Balance on Different Limbs of Pain Perception in Healthy Subjects [NCT01621620]20 participants (Anticipated)Interventional2012-08-31Not yet recruiting
Randomized Study of Yohimbine Treatment for Type 2 Diabetes Patients Carrying a Specific Genetic Risk Variant [NCT01593215]Phase 250 participants (Actual)Interventional2012-05-31Completed
Influences on Noradrenergic Activity for Cognition in Patients With Major Depressive Disorder [NCT02470026]131 participants (Actual)Interventional2014-06-30Completed
Positron Emission Tomography Study of alpha2-adrenergic Receptors With [11C]Yohimbine [NCT03520543]Phase 116 participants (Actual)Interventional2018-05-21Completed
Effects of Stress and Drug-cue Exposure on Craving and Marijuana Seeking Behavior in Regular Cannabis Smokers [NCT03154567]Phase 120 participants (Anticipated)Interventional2017-11-01Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00078715 (1) [back to overview]Hamilton Depression Rating Scale (6 Items)
NCT00535002 (1) [back to overview]Cocaine Craving
NCT00605904 (3) [back to overview]Alcohol Craving Rating in Response to Meta-Chlorophenylpiperazine
NCT00605904 (3) [back to overview]Alcohol Craving Rating in Response to Saline Infusion
NCT00605904 (3) [back to overview]Alcohol Craving Rating in Response to Yohimbine Infusion
NCT00958880 (2) [back to overview]Social Phobic Disorders Severity and Change Form
NCT00958880 (2) [back to overview]The Liebowitz Social Anxiety Scale (LSAS)
NCT01031979 (4) [back to overview]Trauma-Cued Heart Rate Reactivity
NCT01031979 (4) [back to overview]Change in Becks Depression Inventory (BDI-II) Score
NCT01031979 (4) [back to overview]Change in Clinician Administered PTSD Scale (CAPS) Score
NCT01031979 (4) [back to overview]Change in Post Traumatic Stress Disorder Checklist (PCL) Score
NCT01593215 (1) [back to overview]Insulin Secretion

Hamilton Depression Rating Scale (6 Items)

The 6 item Hamilton Depression Rating Scale is a measurement of the severity of depression with a range of scores from 0 to 24, where 24 indicates the most severe depression. (NCT00078715)
Timeframe: Once per day, where the primary comparison involves an average over the full study after controlling for baseline

InterventionUnits on a scale (Mean)
Placebo8.776
Yohimbine9.780

[back to top]

Cocaine Craving

"Cocaine-dependent participants were pre-treated with either yohimbine or placebo provided subjective ratings of cocaine craving immediately following cocaine cue exposure.~The scale used was the Within Sessions Ratings Scales (Childress AR, McLellan AT, O'Brien CP (1986) Conditioned responses in a methadone population. A comparison of laboratory, clinic, and natural settings. Journal of Substance Abuse Treatment 3:173-179.) Craving was rated on a scale of 0-10 with 0 being Not At All and 10 being Extremely." (NCT00535002)
Timeframe: Post cocaine cue exposure

Interventionunits on a scale (Mean)
Cocaine Females Yohimbine4.8
Cocaine Females Placebo3.4
Cocaine Males Yohimbine3.0
Cocaine Males Placebo2.7
Control Females Yohimbine0
Control Females Placebo0
Control Males Yohimbine0
Control Males Placebo0

[back to top]

Alcohol Craving Rating in Response to Meta-Chlorophenylpiperazine

Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). It is a 5-item self-administered instrument that measures frequency, intensity, and duration of thoughts about drinking, along with ability to resist drinking. There is a single outcome score than ranges from 0 to 30, with 30 being the maximum amount of alcohol craving. (NCT00605904)
Timeframe: 180 minutes after the start of the infusion

InterventionUnits on a scale (Mean)
Acamprosate3.460
Placebo5.416

[back to top]

Alcohol Craving Rating in Response to Saline Infusion

Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). It is a 5-item self-administered instrument that measures frequency, intensity, and duration of thoughts about drinking, along with ability to resist drinking. There is a single outcome score than ranges from 0 to 30, with 30 being the maximum amount of alcohol craving. (NCT00605904)
Timeframe: 180 minutes after the start of the infusion

InterventionUnits on a scale (Mean)
Acamprosate1.704
Placebo1.766

[back to top]

Alcohol Craving Rating in Response to Yohimbine Infusion

Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). It is a 5-item self-administered instrument that measures frequency, intensity, and duration of thoughts about drinking, along with ability to resist drinking. There is a single outcome score than ranges from 0 to 30, with 30 being the maximum amount of alcohol craving. (NCT00605904)
Timeframe: 180 minutes after the start of the infusion

InterventionUnits on a scale (Mean)
Acamprosate3.613
Placebo3.606

[back to top]

Social Phobic Disorders Severity and Change Form

Social Phobic Disorders Severity and Change (SPDSC) Form is a version of the Clinical Global Improvement-Severity scale adapted specifically for clinician ratings of social anxiety disorder symptom severity. The scale ranges from 0 to 5, with higher scores indicating more social anxiety symptoms severity (i.e., worse outcomes). We examined the change in SPDSC scores from baseline to a 1 month follow-up. (NCT00958880)
Timeframe: CGI change scores from baseline to 1 month follow-up

Interventionunits on a scale (Mean)
Sugar Pill2.0
Yohimbine Hydrochloride2.0

[back to top]

The Liebowitz Social Anxiety Scale (LSAS)

The Liebowitz Social Anxiety Scale (LSAS) is a self-report measure of social anxiety symptom severity. Scores range from 0 to 144, with higher scores indicating more social anxiety symptoms severity (i.e., a worse outcome). (NCT00958880)
Timeframe: LSAS means at 1 month follow-up

Interventionunits on a scale (Mean)
Sugar Pill41.0
Yohimbine Hydrochloride33.3

[back to top]

Trauma-Cued Heart Rate Reactivity

The primary outcome was trauma-cued heart rate reactivity a week after the drug visit as measured by the PTSD Brief Reactivity (PBR) task. For each patient, a 3-minute trauma script was constructed containing vivid details of the target trauma and used in tandem with a standard neutral script for baseline measurement. Heart rate reactivity for each time point was the beats per minute (BPM) difference between the neutral and trauma scripts represented as a slope. (NCT01031979)
Timeframe: One week after drug visit

Interventionbeats per minute (Mean)
Yohimbine Group71.01
Placebo Group75.08

[back to top]

Change in Becks Depression Inventory (BDI-II) Score

The BDI-II is a 21-item self-report measure that assesses depressive behavioral symptoms. It has demonstrated adequate psychometric validity, and external validity and is used widely as the dependent variable in treatment outcomes research. The BDI-II produces score ranges from 0-63, with higher scores indicating more severe depression symptom severity. A 5-point decrease on the BDI-II is considered clinically significant. (NCT01031979)
Timeframe: 0 weeks, 15 weeks

,
Interventionunits on a scale (Mean)
Baseline BDI-IIWeek 15 BDI-II (post-treatment)
Placebo Group22.627.87
Yohimbine Group30.567.00

[back to top]

Change in Clinician Administered PTSD Scale (CAPS) Score

The CAPS is a structured interview for diagnosis of PTSD and is widely considered the gold-standard assessment. The CAPS produces a total score ranging from 0-136, with higher scores indicating more severe PTSD symptom severity. A 15-point decrease is considered clinically significant. (NCT01031979)
Timeframe: 0 Weeks, 15 weeks

,
Interventionunits on a scale (Mean)
Baseline CAPSWeek 15 CAPS (post-treatment)
Placebo Group65.0020.62
Yohimbine Group67.3325.13

[back to top]

Change in Post Traumatic Stress Disorder Checklist (PCL) Score

The PCL is a 17-item self-report measure of PTSD symptom severity based on the DSM-IV and has adequate psychometric properties. The PCL produces a score range between 17-85, with higher scores indicating more distress related to PTSD symptoms. A 10-point decrease on the PCL is considered clinically significant. (NCT01031979)
Timeframe: 0 weeks, 15 weeks

,
Interventionunits on a scale (Mean)
Baseline PCLWeek 15 PCL (post-treatment)
Placebo Group60.2528.50
Yohimbine Group64.0027.37

[back to top]

Insulin Secretion

insulin secretion will be measured (nMole) in response to an oral glucose tolerance test. Patients will receive the capsules 1 h before the glucose test, and the insulin levels 30 minutes after the oral glucose will be used as a primary outcome measure. The insulin levels at the highest tolerated dose of yohimbine will be used. (NCT01593215)
Timeframe: 30 minutes after oral glucose

Intervention% increase of Ins30 (Mean)
Placebo5
Yohimbine29

[back to top]